<!DOCTYPE html>
<html lang="en">

  <head>
    <meta charset="utf-8">
    </meta>
    <title>Metadata reference</title>
  </head>

  <body>
    <h1>Metadata reference</h1>
    <div id="tocContainer">
      <ul>
        <li><a href="#package">Package ID</a></li>
        <li><a href="#trackedEntityTypes">Tracked Entity Types</a></li>
        <li><a href="#trackedEntityAttributes">Tracked Entity Attributes</a></li>
        <li><a href="#programs">Programs</a></li>
        <li><a href="#programRules">Program Rules</a></li>
        <li><a href="#programIndicators">Program Indicators</a></li>
        <li><a href="#constants">Constants</a></li>
        <li><a href="#dataElements">Data Elements</a></li>
        <li><a href="#dataElementGroups">Data Element Groups</a></li>
        <li><a href="#categoryCombos">Category Combos</a></li>
        <li><a href="#categories">Categories</a></li>
        <li><a href="#categoryOptions">Category Options</a></li>
        <li><a href="#categoryOptionCombos">Category Option Combos</a></li>
        <li><a href="#optionSets">Option Sets</a></li>
        <li><a href="#options">Options</a></li>
        <li><a href="#indicatorGroups">Indicator Groups</a></li>
        <li><a href="#indicators">Indicators</a></li>
        <li><a href="#indicatorTypes">Indicator Types</a></li>
        <li><a href="#programIndicatorGroups">Program Indicator Groups</a></li>
        <li><a href="#dashboards">Dashboards</a></li>
        <li><a href="#charts">Charts</a></li>
        <li><a href="#maps">Maps</a></li>
        <li><a href="#eventReports">Event Reports</a></li>
        <li><a href="#trackedEntityInstanceFilters">Tracked Entity Instance Filters</a></li>
        <li><a href="#userGroups">User Groups</a></li>
      </ul>
    </div>
    <h2>Package info</h2>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Code</th>
        <td>TB-REG</td>
      </tr>
      <tr>
        <th>Type</th>
        <td>TRACKER</td>
      </tr>
      <tr>
        <th>Version</th>
        <td>V1.1.0</td>
      </tr>
      <tr>
        <th>DHIS2 version</th>
        <td>DHIS2.33</td>
      </tr>
      <tr>
        <th>Created</th>
        <td>2020-12-10T14:11</td>
      </tr>
      <tr>
        <th>Identifier</th>
        <td>TB-REG_TRACKER_V1.1.0_DHIS2.33_2020-12-10T14:11</td>
      </tr>
    </table>
    <h2 id="trackedEntityTypes">Tracked entity types</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Person</td>
        <td>2020-12-10</td>
        <td>MCPQUTHX1Ze</td>
      </tr>
    </table>
    <h3>Tracked Entity Type - Tracked Entity Type Attributes</h3>
    <table>
      <tr>
        <th>Tracked Entity Type</th>
        <th>Tracked Entity Type Attribute</th>
      </tr>
      <tr>
        <td>Person</td>
        <td>gqLw62UZlrD</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>hKZ9AJpnVcG</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>loHxNJH4IvV</td>
      </tr>
      <tr>
        <td>Person</td>
        <td>qb8PkSObwqh</td>
      </tr>
    </table>
    <h2 id="trackedEntityAttributes">Tracked entity attributes</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Code</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Family name</td>
        <td></td>
        <td>Family name of the patient</td>
        <td>2020-10-16</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Mobile phone number</td>
        <td></td>
        <td></td>
        <td>2020-10-10</td>
        <td>ciCR6BBvIT4</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td></td>
        <td>Sex of Person</td>
        <td>2020-10-16</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>National ID</td>
        <td></td>
        <td></td>
        <td>2020-08-04</td>
        <td>Ewi7FUfcHAD</td>
      </tr>
      <tr>
        <td>Administrative area of residence</td>
        <td></td>
        <td></td>
        <td>2020-11-05</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td></td>
        <td>Date of birth plus calculated age</td>
        <td>2020-11-05</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td></td>
        <td></td>
        <td>2020-11-06</td>
        <td>ntelZthDPpR</td>
      </tr>
      <tr>
        <td>Given name</td>
        <td></td>
        <td>The name of the patient or initials</td>
        <td>2020-10-16</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Address (current)</td>
        <td></td>
        <td>Current home address of the patient/case </td>
        <td>2020-11-30</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Foreign-born</td>
        <td></td>
        <td></td>
        <td>2020-06-29</td>
        <td>xdRQzKcARGt</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td></td>
        <td></td>
        <td>2020-11-05</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
    </table>
    <h2 id="programs">Programs</h2>
    <h3>TB Case Surveillance</h3>
    <table>
      <tr>
        <th>Property</th>
        <td>Value</td>
      </tr>
      <tr>
        <th>Name</th>
        <td>TB Case Surveillance</td>
      </tr>
      <tr>
        <th>Tracked Entity Type:</th>
        <td>Person</td>
      </tr>
      <tr>
        <th>Last updated:</th>
        <td>2020-10-16</td>
      </tr>
      <tr>
        <th>UID:</th>
        <td>Lt6P15ps7f6</td>
      </tr>
    </table>
    <h4>Program Stages</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>2020-12-08</td>
        <td>mPdMZNWVrOQ</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>2020-12-08</td>
        <td>ODD4lMPm0JX</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>2020-12-08</td>
        <td>RB3a5MXMe8g</td>
      </tr>
      <tr>
        <td>Outcome</td>
        <td>2020-12-08</td>
        <td>UZn8sMwz7Nm</td>
      </tr>
    </table>
    <h4>Program Stage - Program Stage Section - Data Element</h4>
    <table>
      <tr>
        <th>Program Stage</th>
        <th>Program Stage Section</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Baseline information</td>
        <td>TB: Site of disease</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Baseline information</td>
        <td>TB Registration: Previous treatment history</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>HIV</td>
        <td>HIV Infection</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>HIV</td>
        <td>TB: ART started</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>HIV</td>
        <td>ART start date</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Risk Factors</td>
        <td>TB: risk factor - undernourishment</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Baseline information</td>
        <td>TB Registration: Second-line drugs</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Baseline information</td>
        <td>Current Address - Coordinates</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>HIV</td>
        <td>TB: ART Patient ID</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>HIV</td>
        <td>HIV status date</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Risk Factors</td>
        <td>TB: risk factor - alcohol</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Risk Factors</td>
        <td>TB: risk factor - diabetes</td>
      </tr>
      <tr>
        <td>TB Registration</td>
        <td>Risk Factors</td>
        <td>TB: risk factor - smoking</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Laboratory status</td>
        <td>TB Lab: Date RIF resistance detected</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Solid culture lab result date</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF</td>
        <td>TB Lab: Xpert results - MTB</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF</td>
        <td>TB Lab: Xpert results - RIF</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Solid culture specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Sputum Smear Microscopy</td>
        <td>TB Lab: Smear specimen result</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Solid culture specimen test result</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Sputum Smear Microscopy</td>
        <td>TB Lab: Smear specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF</td>
        <td>TB Lab: Xpert specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF</td>
        <td>TB Lab: Xpert Result Date</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Sputum Smear Microscopy</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Rifampicin/Isoniazid)</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Rifampicin/Isoniazid)</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Rifampicin/Isoniazid)</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Rifampicin/Isoniazid)</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Rifampicin/Isoniazid)</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Rifampicin/Isoniazid)</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert Ultra specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert Ultra Result Date</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert Ultra results - MTB</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>TB Lab: Xpert Ultra results - RIF</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Liquid culture lab result date</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Liquid culture specimen test result</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Culture in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Liquid culture specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Laboratory status</td>
        <td>TB Lab: Date RIF resistance first detected</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT) - Final Results</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Initial DST Liquid Media Specimen Number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Initial Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Initial DST Solid Media Specimen Number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Fluoroquinolones/Second-line Injectables)</td>
        <td>TB Lab: LPA FQ/2LI Specimen Number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LPA (Rifampicin/Isoniazid)</td>
        <td>TB Lab: LPA RIF/INH Specimen Number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Liquid Media (e.g. MGIT)</td>
        <td>TB Lab: Subsequent DST Specimen Number (liquid nedia) </td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ)</td>
        <td>TB Lab: Subsequent DST Specimen Number (solid media)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>TB-LAMP</td>
        <td>TB Lab: TB-LAMP</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>TB-LAMP</td>
        <td>TB Lab: TB-LAMP Date</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>TB-LAMP</td>
        <td>TB Lab: TB-LAMP MTB</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>TB-LAMP</td>
        <td>TB Lab: TB-LAMP specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LF-LAM</td>
        <td>TB Lab: LF-LAM</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LF-LAM</td>
        <td>TB Lab: LF-LAM Date</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LF-LAM</td>
        <td>TB Lab: LF-LAM MTB</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>LF-LAM</td>
        <td>TB Lab: LF-LAM specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Truenat</td>
        <td>TB Lab: Truenat</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Truenat</td>
        <td>TB Lab: Truenat MTB</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Truenat</td>
        <td>TB Lab: Truenat Result Date</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Truenat</td>
        <td>TB Lab: Truenat RIF</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Truenat</td>
        <td>TB Lab: Truenat specimen number</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Sputum Smear Microscopy</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>Laboratory Results</td>
        <td>Subsequent Phenotypic DST in Solid Media (e.g. LJ) - Final Results</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Treatment Regimen</td>
        <td>Treatment regimen</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group A)</td>
        <td>Treatment Second-line - Lfx</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group A)</td>
        <td>Treatment Second-line - Mfx</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Amk</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Stm</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group B)</td>
        <td>Treatment Second-line - Cfz</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group B)</td>
        <td>Treatment Second-line - Cs</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Eto</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group A)</td>
        <td>Treatment Second-line - Lzd</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Pto</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group B)</td>
        <td>Treatment Second-line - Trd</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>First-line</td>
        <td>Treatment First-line - Emb</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>First-line</td>
        <td>Treatment First-line - Pza</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group A)</td>
        <td>Treatment Second-line - Bdq</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Dlm</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Ipm</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Mpm</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - PAS</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Other)</td>
        <td>Treatment Second-line - Other</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>First-line</td>
        <td>Treatment First-line - Inh</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Treatment status</td>
        <td>TB first-line treatment start date</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>First-line</td>
        <td>Treatment First-line - Rif</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Other)</td>
        <td>Treatment Second-line - Other drug - specify</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Treatment status</td>
        <td>TB: second-line treatment start date</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Other)</td>
        <td>Treatment Second-line - Amx/Clv</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Other)</td>
        <td>Treatment Second-line - Cap</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Emb</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Other)</td>
        <td>Treatment Second-line - Kan</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Other)</td>
        <td>Treatment Second-line - Pa</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Second-line (Group C)</td>
        <td>Treatment Second-line - Pza</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>TB Drug Resistance Type Classification</td>
        <td>TB: Reassign Resistance Classification</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>TB Drug Resistance Type Classification</td>
        <td>TB Resistance Classification</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>TB Drug Resistance Type Classification</td>
        <td>TB Manually Assigned Resistance Classification</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Treatment status</td>
        <td>TB: Treatment Initiation delay (days)</td>
      </tr>
      <tr>
        <td>Treatment</td>
        <td>Treatment status</td>
        <td>TB outcome due date</td>
      </tr>
      <tr>
        <td>Outcome</td>
        <td>Outcome</td>
        <td>TB: Treatment outcome</td>
      </tr>
      <tr>
        <td>Outcome</td>
        <td>Outcome</td>
        <td>TB Outcome - Reason for case denotification</td>
      </tr>
      <tr>
        <td>Outcome</td>
        <td>Outcome</td>
        <td>TB Outcome - Duplicate's record number</td>
      </tr>
      <tr>
        <td>Outcome</td>
        <td>Outcome status</td>
        <td>TB: Treatment Outcome delay (weeks)</td>
      </tr>
      <tr>
        <td>Outcome</td>
        <td>Outcome</td>
        <td>TB Outcome - Not TB case (Explanation)</td>
      </tr>
      <tr>
        <td>Outcome</td>
        <td>Outcome</td>
        <td>TB Outcome - Case denotification</td>
      </tr>
    </table>
    <h2 id="programIndicators">Program Indicators</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Analytics Type</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>2.28.05(iii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - New</td>
        <td>TB - new - pulmonary - bact - R&H tested</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>a2ISgtLxvUD</td>
      </tr>
      <tr>
        <td>2.29.05(b) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - HIV unknown</td>
        <td>TB - pulm - bact - R tested - R sus - HIV unknown</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>A3jU0towQsO</td>
      </tr>
      <tr>
        <td>TB smear negative cases confirmed by Xpert/Xpert Ultra</td>
        <td>Smear negative cases confirmed by Xpert/Ultra</td>
        <td></td>
        <td>TB cases that are smear negative, but confirmed by positive Xpert/Xpert Ultra MTB result.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>A6QW5Se4bN1</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: not evaluated - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>Not evaluated RR and MDR cases on 2nd line</td>
        <td>TB_MDR_NEVAL</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases, that are not evaluated.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>AMBYD2z0chD</td>
      </tr>
      <tr>
        <td>2.28.11(vi) - TB test - Pulmonary TB cases, bacteriologically confirmed, MDR - New</td>
        <td>TB - new - pulmonary - bact - MDR</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>AQUPGk2RiyX</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: lost to follow-up - confirmed XDR cases on second line regimen</td>
        <td>Lost to follow-up XDR-TB cases on 2nd line</td>
        <td>TB_XDR_LOST</td>
        <td>XDR-TB cases on 2nd line regimen that are lost to follow-up.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>aRIhTkvSCDu</td>
      </tr>
      <tr>
        <td>TB_AGG - Previously treated (excluding relapses) pulmonary TB cases, bacteriologically confirmed</td>
        <td>TB - treated - pulmonary - bact</td>
        <td>TB_RET_NREL_LABCONF</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>aSliDbjlhox</td>
      </tr>
      <tr>
        <td>TB_AGG - Unknown treatment history patients tested for susceptibility to rifampicin</td>
        <td>Unknown hist tested for susc to rifampicin</td>
        <td>TB_RDST_UNK</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>azNkWe4xzP6</td>
      </tr>
      <tr>
        <td>TB_AGG - Unknown treatment history extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>TB unknown extrapulmonary</td>
        <td>TB_OTH_EP</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>B9OaviyjiPC</td>
      </tr>
      <tr>
        <td>2.09.07 - TB case - New and relapse TB cases - 15-19 years male</td>
        <td>New and relapse 15-19 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>BBMZo6tzlLw</td>
      </tr>
      <tr>
        <td>2.05(i) - TB case - Pulmonary TB cases, bacteriologically confirmed - New</td>
        <td>TB - new - pulmonary - bacteriological</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>bEelTQKUhQg</td>
      </tr>
      <tr>
        <td>2.43.03 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Treatment failed</td>
        <td>RR/MDR-TB - 2-line - Treatment failed</td>
        <td></td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen - Treatment failed</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>bLPtxJ52Xjw</td>
      </tr>
      <tr>
        <td>2.14 - TB Detection - Laboratory confirmed RR-TB or MDR-TB cases (excluding XDR cases)</td>
        <td>RR/MDR-TB cases - excl.XDR</td>
        <td></td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>bS1ZVLaujxF</td>
      </tr>
      <tr>
        <td>2.43.05 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Lost to follow-up</td>
        <td>RR/MDR-TB - 2-line - Lost to follow-up</td>
        <td></td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen - Lost to follow-up</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>bxca3bJItoQ</td>
      </tr>
      <tr>
        <td>TB_AGG - Unknown treatment history pulmonary TB cases, clinically diagnosed</td>
        <td>TB unknown pulmonary clinical</td>
        <td>TB_OTH_CLINDX</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>bxCmHHPPzDQ</td>
      </tr>
      <tr>
        <td>TB patients with no outcome record</td>
        <td>TB patients with no outcome record</td>
        <td></td>
        <td>TB patients with no outcome record</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>C77Z0rBR6tf</td>
      </tr>
      <tr>
        <td>2.40.04 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Died</td>
        <td>TB - new and relapse - HIV+ - Died</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>CchM3mn5FuB</td>
      </tr>
      <tr>
        <td>2.28.01(i) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - New</td>
        <td>TB - new - pulmonary - bacteriological - R tested</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>ckraG6QcAal</td>
      </tr>
      <tr>
        <td>2.43.06 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Not evaluated</td>
        <td>RR/MDR-TB - 2-line - Not evaluated</td>
        <td></td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen - Not evaluated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>clCbQFGkMYA</td>
      </tr>
      <tr>
        <td>2.39.03 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Treatment failed</td>
        <td>TB - Previously treated - Treatment failed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>cpDl0MWCsbB</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: not evaluated - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>Not eval RR/MDR HIV-positive cases on 2nd line</td>
        <td>TB_HIVMDR_NEVAL</td>
        <td>Confirmed RR/MDR-TB cases that are HIV positive, on second-line treatment regimen, excluding XDR cases, that are not evaluated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>cQKLW4zJWY7</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: not evaluated - previously treated (excluding relapse) cases</td>
        <td>Not evaluated previously treated, excl relapse</td>
        <td>TB_RET_NREL_NEVAL</td>
        <td>Previously treated (excluding relapse) TB cases except those moved to or started directly on second-line treatment that were not evaluated.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>cuS1pT1wWAn</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome - previously treated (excluding relapse) cases registered (cohort)</td>
        <td>Outcomes previously treated, excl relapse</td>
        <td>TB_RET_NREL_COH</td>
        <td>Previously treated (excluding relapse) TB cases registered except those moved to or started directly on second-line treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-10</td>
        <td>czdztQdLtvp</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 45-54 years female</td>
        <td>New & relapse 45-54 y female</td>
        <td>TB_NEWREL_4554F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>D3eZeSgzOhV</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 5-14 years male</td>
        <td>New & relapse 5-14 y male</td>
        <td>TB_NEWREL_514M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>D6fmWXsg4pM</td>
      </tr>
      <tr>
        <td>2.29.05(b) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - HIV negative</td>
        <td>TB - pulmonary - bact - R tested - R sus - HIV-</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>DLohQ8ka4tM</td>
      </tr>
      <tr>
        <td>2.44.04 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Died</td>
        <td>XDR-TB - 2-line - Died</td>
        <td></td>
        <td>Confirmed XDR-TB cases on second-line treatment regimen - Died</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>DVc4NJAGzGB</td>
      </tr>
      <tr>
        <td>2.29.01(a) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - HIV positive</td>
        <td>TB - pulmonary - bact - R tested - R res - HIV+</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Dy0ypgU2HJb</td>
      </tr>
      <tr>
        <td>2.09.13 - TB case - New and relapse TB cases - 35-44 years male</td>
        <td>New and relapse 35-44 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>E2fky3dIsN0</td>
      </tr>
      <tr>
        <td>2.31(ii) - TB test - Pulmonary RR/MDR TB cases, bacteriologically confirmed - resistant to any fluoroquinolone</td>
        <td>TB - pulmonary - bact - RR/MDR - FQ res</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>e9tXCLfhv63</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: not evaluated - TB/HIV new and relapse cases</td>
        <td>Not evaluated TB/HIV new and relapse</td>
        <td>TB_TBHIV_NEVAL</td>
        <td>All new and relapse TB/HIV cases registered except those moved to or started directly on second-line treatment that were not evaluated.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Eb9Gd37H6aO</td>
      </tr>
      <tr>
        <td>2.04 - TB case - Previously treated patients, excluding relapse cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed)</td>
        <td>TB - previously treated - excluding relapse</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>eeyV1nNafyJ</td>
      </tr>
      <tr>
        <td>2.15 - TB Detection - Laboratory confirmed MDR-TB cases (excluding XDR cases)</td>
        <td>MDR-TB cases - excl.XDR</td>
        <td></td>
        <td>Confirmed MDR-TB cases on second-line treatment regimen, excluding XDR cases.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>efyDakQPlNV</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment failed - clinically diagnosed new and relapse cases</td>
        <td>Treatment failed clindx new relapse</td>
        <td>TB_NEWREL_CLINDX_FAIL</td>
        <td>All clinically diagnosed new and relapse TB cases except those moved to or started directly on second-line treatment where treatment failed.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>eJbF4wquzx4</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: lost to follow-up - TB/HIV new and relapse cases</td>
        <td>Lost to f-up TB/HIV new and relapse</td>
        <td>TB_TBHIV_LOST</td>
        <td>All new and relapse TB/HIV cases registered except those moved to or started directly on second-line treatment that were lost to follow-up.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>eLkTBRFURvg</td>
      </tr>
      <tr>
        <td>2.02(i) - TB case - Pulmonary TB cases, clinically diagnosed - New, or previous treatment history unknown</td>
        <td>TB - new or unknown - pulmonary - clinical</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>EWUiMYjHPAq</td>
      </tr>
      <tr>
        <td>2.05(ii) - TB case - Pulmonary TB cases, bacteriologically confirmed - Previously treated (including relapses)</td>
        <td>TB - treated - pulmonary - bacteriological</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>ExcvvS28nkb</td>
      </tr>
      <tr>
        <td>2.28.04(ii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - RR - Previously treated (including relapses)</td>
        <td>TB - prev - pulmonary - bact - R tested - RR</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>FIWaUqszG5L</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment completed - TB/HIV new and relapse cases</td>
        <td>Treatment completed TB/HIV new and relapse</td>
        <td>TB_TBHIV_CMPLT</td>
        <td>All new and relapse TB/HIV cases registered except those moved to or started directly on second-line treatment that completed treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>FMqTHEACG9S</td>
      </tr>
      <tr>
        <td>Previously treated cases (all TB forms)</td>
        <td>TB - previously treated cases</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-13</td>
        <td>fv2mi0z837P</td>
      </tr>
      <tr>
        <td>TB smear positive cases confirmed by Xpert/Xpert Ultra</td>
        <td>Smear positive cases confirmed by Xpert/Ultra</td>
        <td></td>
        <td>TB cases that are smear positive and confirmed by positive Xpert/Xpert Ultra MTB result.</td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>fW00N22cQKu</td>
      </tr>
      <tr>
        <td>2.38.02 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>TB - new and relapse - Cured/Completed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Fwm1w3NeBCK</td>
      </tr>
      <tr>
        <td>TB_AGG - New patients tested for susceptibility to rifampicin</td>
        <td>New tested for susceptibility to rifampicin</td>
        <td>TB_RDST_NEW</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>FZwrly5hxUk</td>
      </tr>
      <tr>
        <td>2.09.19 - TB case - New and relapse TB cases - 65+ years male</td>
        <td>New and relapse 65+ y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>G28nlIwPd5U</td>
      </tr>
      <tr>
        <td>TB_AGG - New pulmonary TB cases, clinically diagnosed</td>
        <td>TB new pulmonary clinical</td>
        <td>TB_NEW_CLINDX</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>G3g4XfQKemC</td>
      </tr>
      <tr>
        <td>2.09.11 - TB case - New and relapse TB cases - 25-34 years male</td>
        <td>New and relapse 25-34 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>g9E46OVm80h</td>
      </tr>
      <tr>
        <td>2.29.03(a) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - HIV unknown</td>
        <td>TB - pulm - bact - R tested - R res - HIV unknown</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Ga3wBXN0Mtd</td>
      </tr>
      <tr>
        <td>2.28.02(i) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Previously treated (including relapses)</td>
        <td>TB - prev - pulmonary - bacteriological - R tested</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>gc1pSRqXnSY</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: not evaluated - bacteriologically confirmed new and relapse cases</td>
        <td>Not evaluated labconf new relapse</td>
        <td>TB_NEWREL_LABCONF_NEVAL</td>
        <td>Bacteriologically confirmed new and relapse TB cases except those moved to or started directly on second-line treatment that were not evaluated.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>GH7d54KUSXT</td>
      </tr>
      <tr>
        <td>TB - Cases that have not started on treatment</td>
        <td>Cases not on treatment</td>
        <td></td>
        <td>Enrolled cases that have not started on treatment</td>
        <td>EVENT</td>
        <td>2020-10-16</td>
        <td>GNgsosCnVv3</td>
      </tr>
      <tr>
        <td>2.29.02(a) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - HIV negative</td>
        <td>TB - pulmonary - bact - R tested - R res - HIV-</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>goRIAhBdWI8</td>
      </tr>
      <tr>
        <td>TB_AGG - Relapse pulmonary TB cases, clinically diagnosed</td>
        <td>TB relapse pulmonary clinical</td>
        <td>TB_RET_REL_CLINDX</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>gS5n5YA7pDZ</td>
      </tr>
      <tr>
        <td>2.01(ii) - TB case - Pulmonary TB cases, bacteriologically confirmed - Relapse</td>
        <td>TB - relapse - pulmonary - bacteriological</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>GuxCHZwaRwr</td>
      </tr>
      <tr>
        <td>2.28.07(iv) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - resistant to H - New</td>
        <td>TB - new - pulmonary - bact - R&H tested- H res</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>GvtxMLDy4r2</td>
      </tr>
      <tr>
        <td>New and relapse DS-TB cases registered in the previous year - Failed</td>
        <td>New and relapse DS-TB: Failed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>gXdZvVlriyU</td>
      </tr>
      <tr>
        <td>2.09.03 - TB case - New and relapse TB cases - 5-9 years male</td>
        <td>New and relapse 5-9 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>GY8498BoEGB</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome - clinically diagnosed new and relapse cases registered (cohort)</td>
        <td>Outcomes clindx new relapse cohort</td>
        <td>TB_NEWREL_CLINDX_COH</td>
        <td>All clinically diagnosed new and relapse TB cases registered except those moved to or started directly on second-line treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>GYEaZfyLm4T</td>
      </tr>
      <tr>
        <td>2.30.01(a) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - Age(0-14)</td>
        <td>TB - pulmonary - bact - R tested - R res - (0-14)</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>GZYHbHjsf12</td>
      </tr>
      <tr>
        <td>2.09.06 - TB case - New and relapse TB cases - 10-14 years female</td>
        <td>New and relapse 10-14 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>HcJ57ScuWYc</td>
      </tr>
      <tr>
        <td>Days from RIF resistance detected to start of second-line treatment</td>
        <td>Days from RIF res to 2nd line treatment start</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>HdGEwlnAt84</td>
      </tr>
      <tr>
        <td>2.09.15 - TB case - New and relapse TB cases - 45-54 years male</td>
        <td>New and relapse 45-54 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>HGmabhFtFVi</td>
      </tr>
      <tr>
        <td>New cases (all TB forms)</td>
        <td>TB - new case</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>HhHwJurxok6</td>
      </tr>
      <tr>
        <td>Tested for RR-TB</td>
        <td>Tested for susceptibility to rifampicin</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>HMxJoOFyaC6</td>
      </tr>
      <tr>
        <td>TB cases confirmed by Sputum Smear Microscopy</td>
        <td>TB cases confirmed by smear</td>
        <td></td>
        <td>TB cases that have been confirmed by positive smear result.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>IanRArM3Oyg</td>
      </tr>
      <tr>
        <td>2.28.03(ii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - RR - New</td>
        <td>TB - new - pulmonary - bact - R tested - RR</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>iePYwzgp7ol</td>
      </tr>
      <tr>
        <td>2.05(iii) - TB case - Pulmonary TB cases, bacteriologically confirmed - Previous treatment history unknown</td>
        <td>TB - unknown - pulmonary - bacteriological</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Iid3xCxad9o</td>
      </tr>
      <tr>
        <td>2.32(i) - TB test - Pulmonary MDR TB cases, bacteriologically confirmed with test results for any fluoroquinolone (FQ) and any second-line injectable agent (2LI)</td>
        <td>TB - pulmonary - bact - MDR - FQ&2LI tested</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>IjDJnGx9ltW</td>
      </tr>
      <tr>
        <td>2.40.02 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>TB - new and relapse - HIV+ - Cured/Completed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>ijSGiogUaCX</td>
      </tr>
      <tr>
        <td>2.34 - TB/HIV - New and relapse TB cases, tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis</td>
        <td>TB - new and relapse - HIV tested</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>IPULEreCaHJ</td>
      </tr>
      <tr>
        <td>2.35 - TB/HIV - New and relapse TB cases, HIV positive</td>
        <td>TB - new and relapse - HIV+</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>iPZPx2aOz2T</td>
      </tr>
      <tr>
        <td>TB_AGG - TB/HIV - HIV status positive</td>
        <td>TB/HIV positive</td>
        <td>TB_HIVTEST_POS</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>iQS9zGYpokL</td>
      </tr>
      <tr>
        <td>TB cases with valid test result for rifampicin</td>
        <td>TB cases with valid rifampicin test</td>
        <td></td>
        <td>TB lab confirmed cases that have a valid (resistant or sensitive) result for rifampicin resistance, (by Xpert, DST, Truenat or LPA)</td>
        <td>ENROLLMENT</td>
        <td>2020-08-13</td>
        <td>j40qQvDbCZU</td>
      </tr>
      <tr>
        <td>TB_AGG - Relapse pulmonary TB cases, bacteriologically confirmed</td>
        <td>TB - relapse - pulmonary - bact.</td>
        <td>TB_RET_REL_LABCONF</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>J5dqOCSj047</td>
      </tr>
      <tr>
        <td>2.01(i) - TB case - Pulmonary TB cases, bacteriologically confirmed - New, or previous treatment history unknown</td>
        <td>TB - new or unknown - pulmonary - bacteriological</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>j9ERFbo5Km8</td>
      </tr>
      <tr>
        <td>2.38.03 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Treatment failed</td>
        <td>TB - new and relapse - Treatment failed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>JlVDhjChVAx</td>
      </tr>
      <tr>
        <td>TB confirmed RR cases (excluding MDR and XDR)</td>
        <td>RR-TB cases (excl MDR/XDR)</td>
        <td></td>
        <td>TB cases resistant to at least rifampicin, but not isoniazid, i.e. excluding MDR and XDR cases</td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>jqPP4x1pJP0</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: death - bacteriologically confirmed new and relapse cases</td>
        <td>Death labconf new relapse</td>
        <td>TB_NEWREL_LABCONF_DIED</td>
        <td>Bacteriologically confirmed new and relapse TB cases except those moved to or started directly on second-line treatment that died.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>JrUWL08Ddnv</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: cured - bacteriologically confirmed new and relapse cases</td>
        <td>Cured labconf new relapse</td>
        <td>TB_NEWREL_LABCONF_CUR</td>
        <td>Bacteriologically confirmed new and relapse TB cases except those moved to or started directly on second-line treatment that were cured</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>jSEquR6y8Fx</td>
      </tr>
      <tr>
        <td>TB_AGG - Unknown treatment history pulmonary TB cases, bacteriologically confirmed</td>
        <td>TB - Prev status unknown - pulmonary - bact</td>
        <td>TB_OTH_LABCONF</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>jvbwDQuzrcA</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 15-24 years female</td>
        <td>New & relapse 15-24 y female</td>
        <td>TB_NEWREL_1524F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>jwKEkp66bbi</td>
      </tr>
      <tr>
        <td>2.09.04 - TB case - New and relapse TB cases - 5-9 years female</td>
        <td>New and relapse 5-9 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>JwXFsl4krgP</td>
      </tr>
      <tr>
        <td>2.43.01 - TB Detection - RR-TB/ MDR-TB cases on second-line TB treatment (2 years prior to reporting period) (cohort)</td>
        <td>RR/MDR - 2nd line</td>
        <td></td>
        <td>RR/MDR-TB cases started on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>K9xltx7wXIb</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: lost to follow-up - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>Lost to f-up RR/MDR HIV-positive cases on 2nd line</td>
        <td>TB_HIVMDR_LOST</td>
        <td>Confirmed RR/MDR-TB cases that are HIV positive, on second-line treatment regimen, excluding XDR cases, that are lost to follow-up</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>KgPvXVYytRH</td>
      </tr>
      <tr>
        <td>New and relapse DS-TB cases registered in the previous year - Cured</td>
        <td>New and relapse DS-TB: Cured</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>kI4SUMqwaSK</td>
      </tr>
      <tr>
        <td>2.09.12 - TB case - New and relapse TB cases - 25-34 years female</td>
        <td>New and relapse 25-34 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>KJoROII5Ynw</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 55-64 years male</td>
        <td>New & relapse 55-64 y male</td>
        <td>TB_NEWREL_5564M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>kmDgwo2xyPG</td>
      </tr>
      <tr>
        <td>2.38.01 - TB Case - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>TB - new and relapse</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>koVBk2KCseJ</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment completed - clinically diagnosed new and relapse cases</td>
        <td>Treatment completed clindx new relapse</td>
        <td>TB_NEWREL_CLINDX_CMPLT</td>
        <td>All clinically diagnosed new and relapse TB cases except those moved to or started directly on second-line treatment that completed treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>kQp74SERV3T</td>
      </tr>
      <tr>
        <td>2.39.05 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Lost to follow up</td>
        <td>TB - Previously treated - Lost to follow up</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>kVHCjqlEC61</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 65+ years female</td>
        <td>New & relapse 65+ y female</td>
        <td>TB_NEWREL_65F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>kvIrnIoJAYR</td>
      </tr>
      <tr>
        <td>2.09.10 - TB case - New and relapse TB cases - 20-24 years female</td>
        <td>New and relapse 20-24 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>L34ycD00LSG</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: death - TB/HIV new and relapse cases</td>
        <td>Deaths TB/HIV new and relapse</td>
        <td>TB_TBHIV_DIED</td>
        <td>All new and relapse TB/HIV cases registered except those moved to or started directly on second-line treatment that died.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>LichImvUvB6</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 25-34 years female</td>
        <td>New & relapse 25-34 y female</td>
        <td>TB_NEWREL_2534F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>lmlfITJdHAw</td>
      </tr>
      <tr>
        <td>2.03(ii) - TB case - Extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed - Relapse</td>
        <td>TB - relapse - extrapulmonary</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>LmLuG771h1g</td>
      </tr>
      <tr>
        <td>2.43.02 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Cured or treatment completed</td>
        <td>RR/MDR-TB - 2-line - Cured/completed</td>
        <td></td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>loeESUTz5DN</td>
      </tr>
      <tr>
        <td>TB_AGG - Patients with presumptive TB with positive bacteriological examination results</td>
        <td>Lab - bacteriologically confirmed</td>
        <td>TB_PRESUMPTIVE_TESTPOS</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>lv098ob7lcD</td>
      </tr>
      <tr>
        <td>2.16 - TB Detection - Laboratory confirmed XDR-TB cases (including MDR-TB cases from previous years)</td>
        <td>XDR-TB cases</td>
        <td></td>
        <td>Confirmed XDR-TB cases on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>lva8WWCgm6I</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: death - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>Died RR/MDR HIV-positive cases on 2nd line</td>
        <td>TB_HIVMDR_DIED</td>
        <td>Confirmed RR/MDR-TB cases that are HIV positive, on second-line treatment regimen, excluding XDR cases, that died</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>lXNyCenjXnr</td>
      </tr>
      <tr>
        <td>TB rifampicin resistance detected by Xpert/Xpert Ultra</td>
        <td>TB RIF resistance by Xpert/Ultra</td>
        <td></td>
        <td>TB cases where rifampicin resistance is detected by Xpert/Xpert Ultra.</td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>m6o3AGQzaOZ</td>
      </tr>
      <tr>
        <td>TB previously treated cases confirmed by Xpert/Xpert Ultra</td>
        <td>TB cases confirmed by Xpert/Ultra - prev treated</td>
        <td></td>
        <td>Previously treated TB cases that have been confirmed by positive Xpert/Xpert Ultra MTB result.</td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>m7hXZQve8sf</td>
      </tr>
      <tr>
        <td>2.29.04(b) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - HIV positive</td>
        <td>TB - pulmonary - bact - R tested - R sus - HIV+</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>M832SsV7XlM</td>
      </tr>
      <tr>
        <td>New and relapse DS-TB cases registered in the previous year - Completed</td>
        <td>New and relapse DS-TB: Completed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>MarJBwWbuX8</td>
      </tr>
      <tr>
        <td>2.09.20 - TB case - New and relapse TB cases - 65+ years female</td>
        <td>New and relapse 65+ y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>MeRodi5qCj1</td>
      </tr>
      <tr>
        <td>TB/HIV - positive</td>
        <td>TB/HIV - positive</td>
        <td>TB_HIV_POS</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>MjW9Kd1tdR6</td>
      </tr>
      <tr>
        <td>2.39.01 - TB Case - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>TB - previously treated</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>mRKV7yWZoQy</td>
      </tr>
      <tr>
        <td>2.30.04(b) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - Age (15+)</td>
        <td>TB - pulmonary - bact - R tested - R sus - (15+)</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>MtVmvly5X0J</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: lost to follow-up - clinically diagnosed new and relapse cases</td>
        <td>Lost to f-up clindx new relapse</td>
        <td>TB_NEWREL_CLINDX_LOST</td>
        <td>All clinically diagnosed new and relapse TB cases except those moved to or started directly on second-line treatment that were lost to follow-up.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>mvlf2nQYvV9</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 35-44 years male</td>
        <td>New & relapse 35-44 y male</td>
        <td>TB_NEWREL_3544M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>mweuNzij888</td>
      </tr>
      <tr>
        <td>2.17 - TB Treatment - Not laboratory-confirmed RR and MDR cases who started treatment for MDR-TB</td>
        <td>RR/MDR cases - 2nd line</td>
        <td></td>
        <td>Not laboratory-confirmed RR/MDR-TB cases on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>MwZSCg7C9DU</td>
      </tr>
      <tr>
        <td>2.09.09 - TB case - New and relapse TB cases - 20-24 years male</td>
        <td>New and relapse 20-24 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>mYnHzn6wWdh</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: cured - previously treated (excluding relapse) cases</td>
        <td>Cured previously treated, excl relapse</td>
        <td>TB_RET_NREL_CUR</td>
        <td>Previously treated (excluding relapse) TB cases except those moved to or started directly on second-line treatment that were cured.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>MyOZiGalvsI</td>
      </tr>
      <tr>
        <td>2.28.10(v) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - Resistant to R - Previously treated (including relapses)</td>
        <td>TB - prev - pulmonary - bact - R&H tested - R res</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>n0fN5DOHRsj</td>
      </tr>
      <tr>
        <td>2.09.08 - TB case - New and relapse TB cases - 15-19 years female</td>
        <td>New and relapse 15-19 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>n5E1PHDcShv</td>
      </tr>
      <tr>
        <td>2.40.01 - TB Case - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>TB - new&relapse - HIV+</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>n5xUcQS5Lim</td>
      </tr>
      <tr>
        <td>2.40.05 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Lost to followup</td>
        <td>TB - new and relapse - HIV+ - Lost to followup</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>n6V3gvdRppU</td>
      </tr>
      <tr>
        <td>2.39.06 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Not evaluated</td>
        <td>TB - Previously treated - Not evaluated</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>nA35a1OteGT</td>
      </tr>
      <tr>
        <td>2.44.05 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Lost to follow-up</td>
        <td>XDR-TB - 2-line - Lost to follow-up</td>
        <td></td>
        <td>Confirmed XDR-TB cases on second-line treatment regimen - Lost to follow-up</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>nAos1lanETk</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment failed - previously treated (excluding relapse) cases</td>
        <td>Treat fail previously treated, excl relapse</td>
        <td>TB_RET_NREL_FAIL</td>
        <td>Previously treated (excluding relapse) TB cases except those moved to or started directly on second-line treatment where treatment failed.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Ndssi9W1fix</td>
      </tr>
      <tr>
        <td>TB_AGG - Relapse extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>TB - relapse - extrapulmonary</td>
        <td>TB_RET_REL_EP</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>NfgFScH9jCr</td>
      </tr>
      <tr>
        <td>Lab-confirmed RR/MDR-TB started MDR treatment</td>
        <td>RR/MDR-TB cases - MDR treatment</td>
        <td>TB_LAB_CONF_RRMDR_TX</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases.</td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>NhdSPPqMQ6G</td>
      </tr>
      <tr>
        <td>2.28.08(iv) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - Resistant to H - Previously treated (including relapses)</td>
        <td>TB - prev - pulmonary - bact - R&H tested - H res</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>nOoCupuvVyG</td>
      </tr>
      <tr>
        <td>2.30.02(a) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - Age(15+)</td>
        <td>TB - pulmonary - bact - R tested - R res - (15+)</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>nRbutMsw93F</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: death - confirmed XDR cases on second line regimen</td>
        <td>Died XDR-TB cases on 2nd line</td>
        <td>TB_XDR_DIED</td>
        <td>XDR-TB cases on 2nd line regimen that tied.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>NRdnhrWhU5x</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: not evaluated - clinically diagnosed new and relapse cases</td>
        <td>Not evaluated clindx new relapse</td>
        <td>TB_NEWREL_CLINDX_NEVAL</td>
        <td>All clinically diagnosed new and relapse TB cases except those moved to or started directly on second-line treatment that were not evaluated.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>NRHSfORo0MH</td>
      </tr>
      <tr>
        <td>TB_AGG - Previously treated extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>TB prev treated - extrapulmonary</td>
        <td>TB_RET_NREL_EP</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Nrit96cdaRl</td>
      </tr>
      <tr>
        <td>TB rifampicin resistance detected by Xpert/Xpert Ultra in previously treated cases (excluding relapse)</td>
        <td>TB RIF resistance by Xpert/Ultra - prev treated</td>
        <td></td>
        <td>Previously treated TB cases that where rifampicin resistance is detected by Xpert/Xpert Ultra</td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>o3V2cL9Sclf</td>
      </tr>
      <tr>
        <td>2.18 - TB Treatment - laboratory-confirmed RR-TB or MDR-TB patients who started treatment for MDR-TB</td>
        <td>Lab confirmed RR/MDR TB cases - 2nd line</td>
        <td></td>
        <td>Laboratory-confirmed RR-TB or MDR-TB patients who started treatment for MDR-TB (Second-line treatment)</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>o8aunPo6Lek</td>
      </tr>
      <tr>
        <td>2.28.09(v) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - resistant to R - New</td>
        <td>TB - new - pulmonary - bact - R&H tested- R res</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>obUamd4MrWm</td>
      </tr>
      <tr>
        <td>2.06 - TB case - Total number of TB cases reported among foreign-born individuals</td>
        <td>TB - total - foreign-born</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>OkpGxKo3KV0</td>
      </tr>
      <tr>
        <td>2.19 - TB Treatment - RR and MDR cases (Age <15) who started treatment for MDR-TB</td>
        <td>RR/MDR cases - 2nd line - Age <15< /td>
        <td></td>
        <td>RR/MDR-TB cases (Age <15) started on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>oNynyr6rNtl</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: cured - confirmed XDR cases on second line regimen</td>
        <td>Cured XDR-TB cases on 2nd line</td>
        <td>TB_XDR_CUR</td>
        <td>XDR-TB cases on 2nd line regimen that are cured.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>oPnDPdsC9Ic</td>
      </tr>
      <tr>
        <td>TB patients that have not started treatment</td>
        <td>TB patients not on treatment</td>
        <td></td>
        <td>TB patients that have not started treatment</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>OrvVU0I9wTT</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 45-54 years male</td>
        <td>New & relapse 45-54 y male</td>
        <td>TB_NEWREL_4554M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>oSaoqqQ2MSt</td>
      </tr>
      <tr>
        <td>TB_AGG - New extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>TB - new - extrapulmonary</td>
        <td>TB_NEW_EP</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>oVD0Omx832C</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 35-44 years female</td>
        <td>New & relapse 35-44 y female</td>
        <td>TB_NEWREL_3544F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>OwzSNSMtcgA</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment completed - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>Treatment completed RR and MDR cases on 2nd line</td>
        <td>TB_MDR_CMPLT</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases, that completed treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>oYKZO6PawO4</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 0-4 years male</td>
        <td>New & relapse - 0-4 y male</td>
        <td>TB_NEWREL_04M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>p37LM8QH1y5</td>
      </tr>
      <tr>
        <td>2.44.06 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Not evaluated</td>
        <td>XDR-TB - 2-line - Not evaluated</td>
        <td></td>
        <td>Confirmed XDR-TB cases on second-line treatment regimen - Not evaluated</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>p3VRjjM3ZM7</td>
      </tr>
      <tr>
        <td>2.42.02 - TB Outcome - New and relapse TB cases registered in the previous year, 0-14 years, (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>TB - new and relapse - 0-14 yo - Cured/Completed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>pFhfF6xssTm</td>
      </tr>
      <tr>
        <td>2.42.01 - TB Case - New and relapse TB cases registered in the previous year , 0-14 years, (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>TB - new and relapse - 0-14 yo</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>PhMxH0ohHIe</td>
      </tr>
      <tr>
        <td>TB_AGG - Laboratory-confirmed RR-TB or MDR-TB cases</td>
        <td>RR/MDR-TB confirmed cases</td>
        <td>TB_CONF_RRMDR</td>
        <td>Confirmed RR/MDR-TB cases excluding XDR cases</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>pkN8Etipkfm</td>
      </tr>
      <tr>
        <td>TB case - previously treated - pulmonary, bacteriologically confirmed</td>
        <td>TB previously treated pulmonary bacteriological</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>pL6Kh1R46EQ</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 5-14 years female</td>
        <td>New & relapse 5-14 y female</td>
        <td>TB_NEWREL_514F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>PQhiQM94UYf</td>
      </tr>
      <tr>
        <td>2.38.06 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Not evaluated</td>
        <td>TB - new and relapse - Not evaluated</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>q1AOyVwCjMh</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 25-34 years male</td>
        <td>New & relapse 25-34 y male</td>
        <td>TB_NEWREL_2534M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>QbplzyMJIHI</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment failed - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>Failed RR/MDR HIV-positive cases on 2nd line</td>
        <td>TB_HIVMDR_FAIL</td>
        <td>Confirmed RR/MDR-TB cases that are HIV positive, on second-line treatment regimen, excluding XDR cases, where treatment failed.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>QC5QxnAGu9D</td>
      </tr>
      <tr>
        <td>2.19b - TB Treatment - RR and MDR cases (Age <15) who started treatment for MDR-TB - (Offset 1 year)</td>
        <td>RR/MDR cases - 2nd line - Age <15 - offset</td>
        <td></td>
        <td>RR/MDR-TB cases (Age <15) started on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>QeY8kipz7E2</td>
      </tr>
      <tr>
        <td>2.02(ii) - TB case - Pulmonary TB cases, clinically diagnosed - Relapse</td>
        <td>TB - relapse - pulmonary - clinical</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>QXMznIjvAOV</td>
      </tr>
      <tr>
        <td>2.03(i) - TB case - Extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed - New, or previous treatment history unknown</td>
        <td>TB - new or unknown - extrapulmonary</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>QXUPxRVUrRS</td>
      </tr>
      <tr>
        <td>TB_AGG - Previously treated pulmonary TB cases, clinically diagnosed</td>
        <td>TB previously treated pulmonary clinical</td>
        <td>TB_RET_NREL_CLINDX</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>rCh3rLTcUpi</td>
      </tr>
      <tr>
        <td>2.44.01 - TB Detection - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period (cohort)</td>
        <td>XDR-TB cases - 2nd-line treatment</td>
        <td></td>
        <td>Confirmed XDR-TB cases on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>rEH6P6rDI70</td>
      </tr>
      <tr>
        <td>TB lab confirmed cases</td>
        <td>TB lab confirmed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>RIuJAIU6Ke9</td>
      </tr>
      <tr>
        <td>TB rifampicin resistance detected by Xpert/Xpert Ultra in new cases</td>
        <td>TB RIF resistance by Xpert/Ultra in new cases</td>
        <td></td>
        <td>New TB cases that where rifampicin resistance is detected by Xpert/Xpert Ultra.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>RjZ6QHK4SdB</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment completed - bacteriologically confirmed new and relapse cases</td>
        <td>Completed labconf new relapse</td>
        <td>TB_NEWREL_LABCONF_CMPLT</td>
        <td>Bacteriologically confirmed new and relapse TB cases except those moved to or started directly on second-line treatment that completed treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>rMDJ40j7Gdz</td>
      </tr>
      <tr>
        <td>2.36 - TB/HIV - New and relapse TB cases - HIV positive - started or continued on antiretroviral therapy (ART)</td>
        <td>TB - new and relapse - HIV+ - ART</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>rmjYUeBHgxR</td>
      </tr>
      <tr>
        <td>2.09.01 - TB case - New and relapse TB cases - 0-4 years male</td>
        <td>New and relapse 0-4 y male</td>
        <td>newrel</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>ROZvV7ifMzP</td>
      </tr>
      <tr>
        <td>TB_AGG - Laboratory confirmed MDR-TB cases (excluding XDR)</td>
        <td>MDR-TB cases (excl XDR)</td>
        <td>TB_CONF_MDR</td>
        <td>MDR-TB cases. Cases resistant to at least rifampicin and isoniazid, but not both fluroquinolones and second-line injectables (excluding streptomycin) i.e. excluding XDR cases.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>rp8sBCRlPXK</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment failed - bacteriologically confirmed new and relapse cases</td>
        <td>Failed labconf new relapse</td>
        <td>TB_NEWREL_LABCONF_FAIL</td>
        <td>Bacteriologically confirmed new and relapse TB cases except those moved to or started directly on second-line treatment where treatment failed.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>RQ3sKIsE5TJ</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: cured - TB/HIV new and relapse cases</td>
        <td>Cured TB/HIV new and relapse</td>
        <td>TB_TBHIV_CUR</td>
        <td>All new and relapse TB/HIV cases registered except those moved to or started directly on second-line treatment that were cured.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>rrtwzWk80lS</td>
      </tr>
      <tr>
        <td>New and relapse cases registered in the previous year</td>
        <td>New and relapse TB</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>RTVZ6viHiST</td>
      </tr>
      <tr>
        <td>TB new cases confirmed by Xpert/Xpert Ultra</td>
        <td>TB new cases confirmed by Xpert/Xpert Ultra</td>
        <td></td>
        <td>New TB cases that have been confirmed by positive Xpert/Xpert Ultra MTB result.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Ry81r5wNOhd</td>
      </tr>
      <tr>
        <td>TB_AGG - TB/HIV - HIV positive on ART</td>
        <td>TB/HIV on ART</td>
        <td>TB_HIV_ART</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Rz1R6RuKUwJ</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment failed - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>Treatment failed RR and MDR cases on 2nd line</td>
        <td>TB_MDR_FAIL</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases, where treatment failed.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>S1QUkIjBtRh</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment failed - TB/HIV new and relapse cases</td>
        <td>Treatment failed TB/HIV new and relapse</td>
        <td>TB_TBHIV_FAIL</td>
        <td>All new and relapse TB/HIV cases registered except those moved to or started directly on second-line treatment that failed treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>SaXYEOgPoae</td>
      </tr>
      <tr>
        <td>2.09.02 - TB case - New and relapse TB cases - 0-4 years female</td>
        <td>New and relapse 0-4 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>sFqDZGHXcO1</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 65+ years male</td>
        <td>New & relapse 65+ y male</td>
        <td>TB_NEWREL_65M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>SgOZ40SAyBF</td>
      </tr>
      <tr>
        <td>2.32(ii) - TB test - Pulmonary XDR TB cases, bacteriologically confirmed</td>
        <td>TB - pulmonary - bact - XDR</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>sRMkfFBN5C9</td>
      </tr>
      <tr>
        <td>New and relapse DS-TB cases registered in the previous year - Died</td>
        <td>New and relapse DS-TB: Died</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>St3jDtJRslC</td>
      </tr>
      <tr>
        <td>2.09.17 - TB case - New and relapse TB cases - 55-64 years male</td>
        <td>New and relapse 55-64 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>suOzy2QXSMK</td>
      </tr>
      <tr>
        <td>TB cases notified (total)</td>
        <td>TB cases</td>
        <td></td>
        <td>All TB cases, i.e. all cases enrolled in the TB program except those that were denotified (i.e. "Not TB" indicated).</td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>svi5rSf4zNR</td>
      </tr>
      <tr>
        <td>TB/HIV - tested</td>
        <td>HIV positive/negative recorded</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>SzBkyKHWux0</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: death - clinically diagnosed new and relapse cases</td>
        <td>Deaths clindx new relapse</td>
        <td>TB_NEWREL_CLINDX_DIED</td>
        <td>All clinically diagnosed new and relapse TB cases except those moved to or started directly on second-line treatment who died.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>szVjaIR5Y0w</td>
      </tr>
      <tr>
        <td>2.39.02 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>TB - Previously treated - Cured/Completed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>TFsioIbdHo6</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: lost to follow-up - previously treated (excluding relapse) cases</td>
        <td>Lost to f-up previously treated, excl relapse</td>
        <td>TB_RET_NREL_LOST</td>
        <td>Previously treated (excluding relapse) TB cases except those moved to or started directly on second-line treatment that were lost to follow-up.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>TKh36q9byZ2</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment failed - confirmed XDR cases on second line regimen</td>
        <td>Treatment failed XDR-TB cases on 2nd line</td>
        <td>TB_XDR_FAIL</td>
        <td>XDR-TB cases on 2nd line regimen where treatment failed.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>tKlafE4iYmF</td>
      </tr>
      <tr>
        <td>Previously treated (including relapse) TB patients diagnosed without using a WHO recommended rapid diagnostic test</td>
        <td>Tested w/o rapid diagnostic test</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>TnSBORHgIL2</td>
      </tr>
      <tr>
        <td>TB_AGG - Previously treated patients tested for susceptibility to rifampicin</td>
        <td>Prev treated tested for susc to rifampicin</td>
        <td>TB_RDST_RET</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>TO5t4GynFmy</td>
      </tr>
      <tr>
        <td>2.31(i) - TB test - Pulmonary RR/MDR TB cases, bacteriologically confirmed with test results for any fluoroquinolone</td>
        <td>TB - pulmonary - bact - RR/MDR - FQ tested</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>TrGi5iJmFFm</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: death - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>Died RR and MDR cases on 2nd line</td>
        <td>TB_MDR_DIED</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases, that died.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>tRlRFI5clem</td>
      </tr>
      <tr>
        <td>2.20 - TB Treatment - laboratory-confirmed XDR-TB patients who started treatment for XDR-TB</td>
        <td>Confirmed XDR-TB - second-line</td>
        <td></td>
        <td>Laboratory-confirmed XDR-TB patients who started treatment for XDR-TB (Second-line treatment)</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>tsCchEKn7Br</td>
      </tr>
      <tr>
        <td>Lab-confirmed RR/MDR-TB</td>
        <td>RR/MDR-TB lab-confirmed cases</td>
        <td>TB_LAB_CONF_RRMDR</td>
        <td>Confirmed RR/MDR-TB cases excluding XDR cases</td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>TsGkTLQxLYN</td>
      </tr>
      <tr>
        <td>2.43.04 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Died</td>
        <td>RR/MDR-TB - 2-line - Died</td>
        <td></td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen - Died</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>TylI5dxJdUl</td>
      </tr>
      <tr>
        <td>TB_AGG - Not laboratory-confirmed RR and MDR cases who started treatment for MDR-TB</td>
        <td>RR/MDR cases - not confirmed - 2nd line</td>
        <td>TB_UNCONF_RRMDR_TX</td>
        <td>Not laboratory-confirmed RR/MDR-TB cases on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>ubKa6QPpGPU</td>
      </tr>
      <tr>
        <td>GTB - TB Treatment - Patients who started treatment for MDR-TB</td>
        <td>TB cases - 2nd line</td>
        <td></td>
        <td>Patients started treatment for MDR-TB (Second-line treatment)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>UC5A1tourVG</td>
      </tr>
      <tr>
        <td>New and relapse cases (all TB forms)</td>
        <td>TB - new and relapse case</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>UG8KMWTNHTA</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome - TB/HIV new and relapse cases registered (cohort)</td>
        <td>Outcomes TB/HIV new and relapse cohort</td>
        <td>TB_TBHIV_COH</td>
        <td>All new and relapse TB/HIV cases registered except those moved to or started directly on second-line treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-10</td>
        <td>usOS0aEFimg</td>
      </tr>
      <tr>
        <td>2.09.16 - TB case - New and relapse TB cases - 45-54 years female</td>
        <td>New and relapse 45-54 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>UVyRsJoYkoL</td>
      </tr>
      <tr>
        <td>TESTTESTTEST</td>
        <td>TESTTESTTEST</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-01</td>
        <td>uxcX8MsiNoG</td>
      </tr>
      <tr>
        <td>TB_AGG - Patients with presumptive TB undergoing bacteriological examination</td>
        <td>Lab - cases being tested</td>
        <td>TB_PRESUMPTIVE_TEST</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>uxRQkvPX3O0</td>
      </tr>
      <tr>
        <td>TB_AGG - TB/HIV - New and relapse TB cases, tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis</td>
        <td>TB - new and relapse - HIV test</td>
        <td>TB_HIVTEST</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>uyJRjx7Kg62</td>
      </tr>
      <tr>
        <td>2.44.03 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Treatment failed</td>
        <td>XDR-TB - 2-line - Treatment failed</td>
        <td></td>
        <td>Confirmed XDR-TB cases on second-line treatment regimen - Treatment failed</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>uyVkItSis8Z</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 15-24 years male</td>
        <td>New & relapse 15-24 y male</td>
        <td>TB_NEWREL_1524M</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>V14skZKSqwe</td>
      </tr>
      <tr>
        <td>2.38.05 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Lost to followup</td>
        <td>TB - new and relapse - Lost to followup</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>VdTczAataUy</td>
      </tr>
      <tr>
        <td>2.30.03(b) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - Age (0-14)</td>
        <td>TB - pulmonary - bact - R tested - R sus - (0-14)</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Vg8Pecklo8m</td>
      </tr>
      <tr>
        <td>2.09.18 - TB case - New and relapse TB cases - 55-64 years female</td>
        <td>New and relapse 55-64 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>vjbnO9EU7e5</td>
      </tr>
      <tr>
        <td>TB_AGG - Patients (laboratory-confirmed RR-TB or MDR-TB) who started treatment for MDR-TB</td>
        <td>RR/MDR-TB cases - 2-line treatment</td>
        <td>TB_CONF_RRMDR_TX</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>vlzsn2ahiPt</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome - bacteriologically confirmed new and relapse cases registered (cohort)</td>
        <td>Outcomes labconf new relapse cohort</td>
        <td>TB_NEWREL_LABCONF_COH</td>
        <td>All bacteriologically confirmed new and relapse TB cases registered except those moved to or started directly on second-line treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Vq2QZrz5t7e</td>
      </tr>
      <tr>
        <td>2.11 - TB Test - New and relapse cases tested using a WHO-recommended rapid diagnostic</td>
        <td>New and relapse - WHO rapid diagnostic</td>
        <td></td>
        <td>Number of new and relapse cases tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) as the initial diagnostic test (regardless of test result). Pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant.</td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>vU3ODjQ6JzS</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment completed - confirmed XDR cases on second line regimen</td>
        <td>Treatment completed XDR-TB cases on 2nd line</td>
        <td>TB_XDR_CMPLT</td>
        <td>XDR-TB cases on 2nd line regimen that complete treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>vuG9jUefhvX</td>
      </tr>
      <tr>
        <td>2.28.12(vi) - TB test - Pulmonary TB cases, bacteriologically confirmed - MDR - Previously treated (including relapses)</td>
        <td>TB - prev - pulmonary - bact - R&H tested - MDR</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>WcF7wOPcINj</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 55-64 years female</td>
        <td>New & relapse 55-64 y female</td>
        <td>TB_NEWREL_5564F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>wGetVr8DIzX</td>
      </tr>
      <tr>
        <td>TB_AGG - New and relapse TB cases - 0-4 years female</td>
        <td>New & relapse 0-4 y female</td>
        <td>TB_NEWREL_04F</td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>wHpLgrq0RhX</td>
      </tr>
      <tr>
        <td>TB cases confirmed by Xpert/Xpert Ultra</td>
        <td>TB cases confirmed by Xpert/Ultra</td>
        <td></td>
        <td>TB cases that have been confirmed by positive Xpert/Xpert Ultra MTB result.</td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>wIWezCzFIWx</td>
      </tr>
      <tr>
        <td>TB - Patient's age</td>
        <td>TB - Patient's age</td>
        <td></td>
        <td>Age of the patient</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>WlgSirxU9bG</td>
      </tr>
      <tr>
        <td>New and relapse DS-TB cases registered in the previous year - Cured or treatment completed</td>
        <td>New/ relapse DS-TB: Cured/Completed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>wQWTOm3n7RC</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: lost to follow-up - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>Lost to f/u RR and MDR cases on 2nd line</td>
        <td>TB_MDR_LOST</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases, that are lost to follow-up.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>WR5MkUOzYQx</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR) (cohort)</td>
        <td>RR/MDR HIV-positive cases on 2nd line</td>
        <td>TB_HIVMDR_COH</td>
        <td>Confirmed RR/MDR-TB cases that are HIV positive, on second-line treatment regimen, excluding XDR cases.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>WXGJbirp6DL</td>
      </tr>
      <tr>
        <td>2.09.05 - TB case - New and relapse TB cases - 10-14 years male</td>
        <td>New and relapse 10-14 y male</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>wyrybOcxzcd</td>
      </tr>
      <tr>
        <td>2.39.04 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Died</td>
        <td>TB - Previously treated - Died</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>xClehUT1Wz1</td>
      </tr>
      <tr>
        <td>2.40.03 - TB Outcome - Previously treated HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Treatment failed</td>
        <td>TB - Previously treated - TB+ - Treatment failed</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>xDCf04DhseZ</td>
      </tr>
      <tr>
        <td>2.09.14 - TB case - New and relapse TB cases - 35-44 years female</td>
        <td>New and relapse 35-44 y female</td>
        <td></td>
        <td>New and relapse TB cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed, drug-susceptible or drug-resistant)</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>XE5DnJncyFA</td>
      </tr>
      <tr>
        <td>2.38.04 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Died</td>
        <td>TB - new and relapse - Died</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>XH7TFzwdcNo</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment completed - previously treated (excluding relapse) cases</td>
        <td>Treat completed previously treated, excl relapse</td>
        <td>TB_RET_NREL_CMPLT</td>
        <td>Previously treated (excluding relapse) TB cases except those moved to or started directly on second-line treatment that completed treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>XvDSvGx9euM</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: death - previously treated (excluding relapse) cases</td>
        <td>Deaths previously treated, excl relapse</td>
        <td>TB_RET_NREL_DIED</td>
        <td>Previously treated (excluding relapse) TB cases except those moved to or started directly on second-line treatment that died.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Y4IC1OjAdf3</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: lost to follow-up - bacteriologically confirmed new and relapse cases</td>
        <td>Lost to f-up labconf new relapse</td>
        <td>TB_NEWREL_LABCONF_LOST</td>
        <td>Bacteriologically confirmed new and relapse TB cases except those moved to or started directly on second-line treatment that are lost to follow-up.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Y8wvwRgGcUS</td>
      </tr>
      <tr>
        <td>New and relapse DS-TB cases registered in the previous year - Lost to follow-up</td>
        <td>New and relapse DS-TB: Lost to follow-up</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>yGFpCtuXgQj</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: not evaluated - confirmed XDR cases on second line regimen</td>
        <td>Not evaluated XDR-TB cases on 2nd line</td>
        <td>TB_XDR_NEVAL</td>
        <td>XDR-TB cases on 2nd line regimen that are not evaluated.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>YsxMI4Dv7s7</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR) (cohort)</td>
        <td>RR and MDR cases on 2nd line</td>
        <td>TB_MDR_COH</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>yVo8pfW8opl</td>
      </tr>
      <tr>
        <td>2.28.06(iii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - Previously treated (including relapses)</td>
        <td>TB - prev - pulmonary - bact - R&H tested</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>YzSvXLoUYoy</td>
      </tr>
      <tr>
        <td>New and relapse DS-TB cases registered in the previous year - Not evaluated</td>
        <td>New and relapse DS-TB: Not evaluated</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>z1J7ACEYJgy</td>
      </tr>
      <tr>
        <td> TB/HIV on ART</td>
        <td>TB/HIV - ART</td>
        <td>TB_HIV_POS_ART</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-12-09</td>
        <td>z6ynKOp9PMS</td>
      </tr>
      <tr>
        <td>2.40.06 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Not evaluated</td>
        <td>TB - new and relapse - HIV+ - Not evaluated</td>
        <td></td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>z7eXLnunj8d</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: cured - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>Cured RR and MDR cases on 2nd line</td>
        <td>TB_MDR_CUR</td>
        <td>Confirmed RR/MDR-TB cases on second-line treatment regimen, excluding XDR cases, that are cured.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>Z7r9H312QOu</td>
      </tr>
      <tr>
        <td>2.44.02 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Cured or treatment completed</td>
        <td>XDR-TB - 2-line - Cured/completed</td>
        <td></td>
        <td>Confirmed XDR-TB cases on second-line treatment regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>z8pnOFkWAYl</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: cured - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>Cured RR/MDR HIV-positive cases on 2nd line</td>
        <td>TB_HIVMDR_CUR</td>
        <td>Confirmed RR/MDR-TB cases that are HIV positive, on second-line treatment regimen, excluding XDR cases, that are cured.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>ZeSCOQzujFZ</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome - confirmed XDR cases on second line regimen (cohort)</td>
        <td>XDR-TB cases on 2nd line</td>
        <td>TB_XDR_COH</td>
        <td>TB cases resistant to at least rifampicin, isoniazid, fluoroquinolones and second-line injectables (excluding Streptomycin), that are on 2nd line regimen</td>
        <td>ENROLLMENT</td>
        <td>2020-09-24</td>
        <td>zgjfcJiBlED</td>
      </tr>
      <tr>
        <td>TB_AGG - Outcome: treatment completed - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>Completed RR/MDR HIV-positive cases on 2nd line</td>
        <td>TB_HIVMDR_CMPLT</td>
        <td>Confirmed RR/MDR-TB cases that are HIV positive, on second-line treatment regimen, excluding XDR cases, that complete treatment.</td>
        <td>ENROLLMENT</td>
        <td>2020-10-16</td>
        <td>ZkenguAQ0U6</td>
      </tr>
      <tr>
        <td>TB_AGG - New pulmonary TB cases, bacteriologically confirmed</td>
        <td>TB - Prev status new - pulmonary - bacteriological</td>
        <td>TB_NEW_LABCONF</td>
        <td> </td>
        <td>ENROLLMENT</td>
        <td>2020-08-04</td>
        <td>zUjUpQKcgc9</td>
      </tr>
    </table>
    <h4 id="programRules">Program Rules</h4>
    <table>
      <tr>
        <th>Program rule</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Treatment: Hide second line regimen option if second line regimen in previous event</td>
        <td></td>
        <td>2020-09-24</td>
        <td>A2fuDAKgZJi</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Amk not resistant</td>
        <td>Set the status of resistance to Amk based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>AaLJV5xaNDS</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>acrhAI8WsOu</td>
      </tr>
      <tr>
        <td>Display number of months since diagnosis</td>
        <td>Display number of months since Diagnosis in the Top Bar</td>
        <td>2020-11-05</td>
        <td>aIbtD3KEYiR</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>aKPzWftcfNb</td>
      </tr>
      <tr>
        <td>Hide second-line drugs</td>
        <td>Hide Second-line Drugs unless on Second-line Treatment</td>
        <td>2020-11-05</td>
        <td>alAoqqSMlSC</td>
      </tr>
      <tr>
        <td>Date validation: Date for solid culture lab results must be on or after date of sample collection</td>
        <td>The date for solid culture lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>b0pv7Mco16K</td>
      </tr>
      <tr>
        <td>Display outcome definition "Lost to follow-up" if case is not on treatment</td>
        <td>Display utcome definition "Lost to follow-up" if case is not on treatment</td>
        <td>2020-11-05</td>
        <td>b5h61KtaHyj</td>
      </tr>
      <tr>
        <td>Treatment: drug resistance detected, but case is registered on first-line</td>
        <td>Drug resistance is detected, but case is registered on first-line</td>
        <td>2020-09-24</td>
        <td>Biaw9nKhMQr</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-08-13</td>
        <td>BiXBdOLEKZj</td>
      </tr>
      <tr>
        <td>Lab: resistance to any drug</td>
        <td>Resistance to any drug</td>
        <td>2020-08-04</td>
        <td>BpxoEe6qf3f</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (Xpert)</td>
        <td>Lab: Assign date Rif resistance detected (Xpert) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>bQPAYhM5RuE</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-08-13</td>
        <td>BrNos448Ukk</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (DST SUB SM)</td>
        <td>Lab: Assign date Rif resistance detected (DST SUB SM) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>BV7c6e1GCHC</td>
      </tr>
      <tr>
        <td>CONSTANT - Treatment: Hide First-Line and second-line drugs</td>
        <td>Treatment Stage: Hide First-Line and second-line drugs</td>
        <td>2020-11-05</td>
        <td>bvKU4RArJjo</td>
      </tr>
      <tr>
        <td>Display 1-line Treatment Outcome definition "Died"</td>
        <td>Display 1-line Treatment Outcome definition "Died"</td>
        <td>2020-08-04</td>
        <td>CdCnbgBTDTB</td>
      </tr>
      <tr>
        <td>Baseline: Site of disease from smear result pulmonary</td>
        <td>Check if site of disease is valid if smear result is positive</td>
        <td>2020-11-05</td>
        <td>chpN8GEd7kj</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>cJVuXdpXhxf</td>
      </tr>
      <tr>
        <td>Date validation: Date for Subsequent DST LM lab results must be on or after date of sample collection</td>
        <td>The date for Subsequent DST LM lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>cmEUKlrQrxr</td>
      </tr>
      <tr>
        <td>Treatment: assign second line treatment start date when selecting second line treatment</td>
        <td></td>
        <td>2020-09-24</td>
        <td>CoT3CKSvJba</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Culture in Solid Media (e.g. LJ) Test</td>
        <td>Hide Culture in Solid Media (e.g. LJ) Test</td>
        <td>2020-08-04</td>
        <td>CsK7wMEAHXb</td>
      </tr>
      <tr>
        <td>Assign Positive HIV status</td>
        <td></td>
        <td>2020-11-05</td>
        <td>ct8Dtosl7RP</td>
      </tr>
      <tr>
        <td>Display - HIV Status</td>
        <td></td>
        <td>2020-08-04</td>
        <td>CWbxPdO9jF0</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Emb resistant</td>
        <td>Set the status of resistance to Emb based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>D27vvHHOipm</td>
      </tr>
      <tr>
        <td>Lab: Xpert result - hide specimen and date unless Xpert data has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>ddOHHTjNI7R</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>dgXKJserGKv</td>
      </tr>
      <tr>
        <td>LAB: Hide "Truenat RIF" field</td>
        <td>Hide "Truenat RIF" field unless MTB is detected</td>
        <td>2020-08-04</td>
        <td>DNcF6aRO2aw</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-08-13</td>
        <td>DOnWKphNpis</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Kan not resistant</td>
        <td>Set the status of resistance to Kan based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>DRUyd728B6E</td>
      </tr>
      <tr>
        <td>Outcome - Hide Outcome Dropdown Option Failed - first-line treatment</td>
        <td>Hide Outcome dropdown option Failed - if Outcome is recorded within first 5 months of first-line treatment</td>
        <td>2020-11-05</td>
        <td>dTRcKyoJr6q</td>
      </tr>
      <tr>
        <td>Date validation: Event date (all stages except lab results) should be greater or equal to enrollment date</td>
        <td>The event date for any stage except lab results should be greater than or equal to the enrollment date</td>
        <td>2020-11-05</td>
        <td>duaOyYbv5r2</td>
      </tr>
      <tr>
        <td>Treatment: assign first line treatment start date from previous event</td>
        <td></td>
        <td>2020-11-05</td>
        <td>dx7BkeMco7Z</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Inh CC not resistant</td>
        <td>Set the status of resistance to Inh CC based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>e3ExlVkeev0</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Emb not resistant</td>
        <td>Set the status of resistance to Emb based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>EKPNg18cJaI</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Mfx CB resistant</td>
        <td>Set the status of resistance to Mfx CB based on current event and previous status</td>
        <td>2020-08-04</td>
        <td>EkvvAbduUye</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Xpert MTB/RIF Test</td>
        <td>Hide Xpert MTB/RIF Test</td>
        <td>2020-08-04</td>
        <td>ElCDntKk8Y7</td>
      </tr>
      <tr>
        <td>Assign "Date RIF Resistance First Detected" if not previously detected</td>
        <td></td>
        <td>2020-11-05</td>
        <td>eLFnfA7RoTh</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-08-13</td>
        <td>EnciaiePELz</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Mfx CB not resistant</td>
        <td>Set the status of resistance to Mfx CB based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>eRphfdUn5yY</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>eVBEJs1jrdy</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-08-13</td>
        <td>ExDbDG74KW3</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Inh CB resistant</td>
        <td>Set the status of resistance to Inh CB based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>eyCrtJciRE2</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert MTB/RIF" fields</td>
        <td>Hide "Xpert MTB/RIF" fields unless "Xpert MTB/RIF" is selected</td>
        <td>2020-08-04</td>
        <td>EyHr97oy0l8</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>ez77J4dVwsE</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-08-13</td>
        <td>F42Z7MkBkLO</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide LPA (Fq/2LI) Test</td>
        <td>Hide LPA (Fq/2LI) Test</td>
        <td>2020-12-09</td>
        <td>f504Q5tVSjp</td>
      </tr>
      <tr>
        <td>Date validation: Date for Subsequent DST SM lab results must be on or after date of sample collection</td>
        <td>The date for Subsequent DST SM lab results must be on or after date of sample collection</td>
        <td>2020-08-13</td>
        <td>F6rsp5bxUoA</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>f8JjbVC90G0</td>
      </tr>
      <tr>
        <td>Outcome: hide options "Cured", "Completed" or "Failed" if not on treatment</td>
        <td>Prevent selection of "Cured", "Completed" or "Failed" as treatment outcome if the patient has not started treatment</td>
        <td>2020-11-05</td>
        <td>fCMEJvGpJCK</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-08-13</td>
        <td>Fhu2acBXHxN</td>
      </tr>
      <tr>
        <td>Date validation: Date for LPA (Fq/2LI) lab results must be on or after date of sample collection</td>
        <td>The date for Subsequent LPA FQ/2LI lab results must be on or after date of sample collection</td>
        <td>2020-12-09</td>
        <td>fhyG2cHwQWE</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (DST INIT LM)</td>
        <td>Lab: Assign date Rif resistance detected (DST INIT LM) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>FmCA1YEAgZp</td>
      </tr>
      <tr>
        <td>Lab: LPA (Rif/Inh) result - hide specimen and date unless LPA data has been entered</td>
        <td></td>
        <td>2020-12-09</td>
        <td>FpKYk3c96wB</td>
      </tr>
      <tr>
        <td>Clear "Date RIF Resistance First Detected"</td>
        <td></td>
        <td>2020-11-05</td>
        <td>fTGQSqswlQz</td>
      </tr>
      <tr>
        <td>Lab: Warning about de-notification if MTB is not detected</td>
        <td>If MTB "not detected" result is recorded, show a message that this might not be a TB case.</td>
        <td>2020-11-05</td>
        <td>fweDnS312ta</td>
      </tr>
      <tr>
        <td>LAB: Hide "LPA (Fq/2LI)" fields</td>
        <td>Hide "LPA (Fq/2LI)" unless "LPA (Fq/2LI)" is selected</td>
        <td>2020-12-09</td>
        <td>FYm979gH3IG</td>
      </tr>
      <tr>
        <td>Date validation: Date for TB-LAMP lab results must be on or after date of sample collection</td>
        <td>The date for TB-LAMP lab results must be on or after date of sample collection</td>
        <td>2020-08-04</td>
        <td>G3EbLZXRNJz</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Cfz resistant</td>
        <td>Set the status of resistance to Cfz based on current event and previous status</td>
        <td>2020-08-04</td>
        <td>GhQHc7kJzxk</td>
      </tr>
      <tr>
        <td>Manually Assign Resistance Classification XDR</td>
        <td>Manually Assign Resistance Classification XDR</td>
        <td>2020-11-05</td>
        <td>go3c9jVMu5U</td>
      </tr>
      <tr>
        <td>Display 1-line Treatment Outcome definition "Completed" </td>
        <td>Display 1-line Treatment Outcome definition "Completed"</td>
        <td>2020-08-04</td>
        <td>Gp2ulJYAL2w</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide TB-LAMP Test</td>
        <td>Hide TB-LAMP Test</td>
        <td>2020-08-04</td>
        <td>Gpd1HI9ixwY</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>gqwpMHUt3NJ</td>
      </tr>
      <tr>
        <td>Classification: XDR</td>
        <td>Classify as XDR case</td>
        <td>2020-08-04</td>
        <td>GUPevrPYqdl</td>
      </tr>
      <tr>
        <td>Date validation: Date for LPA (Rif/Inh) lab results must be on or after date of sample collection</td>
        <td>The date for Subsequent LPA RIF/INH lab results must be on or after date of sample collection</td>
        <td>2020-12-09</td>
        <td>GWZsesG0sgI</td>
      </tr>
      <tr>
        <td>Assign "Date RIF Resistance First Detected" based on previous event</td>
        <td></td>
        <td>2020-08-04</td>
        <td>GY9juHFF6Es</td>
      </tr>
      <tr>
        <td>Lab: Smear result - hide specimen and date unless smear result has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>gyY1pifkcL3</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Inh not resistant</td>
        <td>Set the status of resistance to Inh based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>GYZoSZgnoaV</td>
      </tr>
      <tr>
        <td>Classification: Poly Res</td>
        <td>Classify as Poly Res</td>
        <td>2020-08-04</td>
        <td>GZfLc6dCmXO</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>h1aN1zseCvm</td>
      </tr>
      <tr>
        <td>LAB: Hide "Sputum Smear Microscopy" fields</td>
        <td>Hide "Sputum Smear Microscopy Fields" unless "Sputum Smear Microscopy" is selected</td>
        <td>2020-08-04</td>
        <td>H7tPdPg91Cv</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Cfz not resistant</td>
        <td>Set the status of resistance to Cfz based on current event and previous status</td>
        <td>2020-08-04</td>
        <td>H9zBMMWLPEx</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Bdq not resistant</td>
        <td>Set the status of resistance to Bdq based on current event and previous status</td>
        <td>2020-08-04</td>
        <td>HDA0bMiGZeZ</td>
      </tr>
      <tr>
        <td>Hide first-line drugs</td>
        <td>Hide First-line Drugs unless on First-line Treatment</td>
        <td>2020-11-05</td>
        <td>hL4riNAvXLq</td>
      </tr>
      <tr>
        <td>Outcome: outcome due date - first-line treatment</td>
        <td>Calculate an outcome due date for first-line treatment from date of diagnosis (9 months)</td>
        <td>2020-09-24</td>
        <td>HMu1xZ8dxem</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>hPm41O0flZH</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>hSifLCqKFwY</td>
      </tr>
      <tr>
        <td>Assign number of months since diagnosis</td>
        <td>Assign number of months since diagnosis in the Top Bar</td>
        <td>2020-11-05</td>
        <td>hSYBGQOsVYw</td>
      </tr>
      <tr>
        <td>Classification: MDR</td>
        <td>Classify as MDR case</td>
        <td>2020-11-05</td>
        <td>huUNJJH942b</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Culture in Liquid Media (e.g. MGIT) Test</td>
        <td>Hide Culture in Liquid Media (e.g. MGIT) Test</td>
        <td>2020-11-05</td>
        <td>hWoGfJo0tXc</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>hXPv3dXuWHk</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>hYBirds39sk</td>
      </tr>
      <tr>
        <td>Display diagnosis date in widget</td>
        <td></td>
        <td>2020-11-05</td>
        <td>i4Syz9yBhJP</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Dlm not resistant</td>
        <td>Set the status of resistance to Dlm based on current event and previous status</td>
        <td>2020-08-04</td>
        <td>I8l2TMZ7XIY</td>
      </tr>
      <tr>
        <td>HIV: Hide ART start date unless ART is started</td>
        <td>Hide ART start date unless ART is started</td>
        <td>2020-11-05</td>
        <td>iaew36EWn8e</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>iLRrfeyOtt9</td>
      </tr>
      <tr>
        <td>Display 2-line Treatment Outcome definition "Lost to follow-up"</td>
        <td>Display 2-line Treatment Outcome definition "Lost to follow-up"</td>
        <td>2020-11-05</td>
        <td>isqj9hdWhJU</td>
      </tr>
      <tr>
        <td>LAB: Hide " Culture in Liquid Media (e.g. MGIT)" fields</td>
        <td>Hide "Culture in Liquid Media (e.g. MGIT)" fields unless "Liquid (e.g. MGIT)" is selected</td>
        <td>2020-11-05</td>
        <td>IZOzyjcv8sP</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Inh resistant</td>
        <td>Set the status of resistance to Inh based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>jAjf0yUpaW3</td>
      </tr>
      <tr>
        <td>Outcome - Hide Field "Provide duplicate's record number</td>
        <td></td>
        <td>2020-11-05</td>
        <td>JbtamS7I0zI</td>
      </tr>
      <tr>
        <td>Date validation: Date for smear lab results must be on or after date of sample collection</td>
        <td>The date for smear lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>jdzLwzkqGvB</td>
      </tr>
      <tr>
        <td>Treatment: Calculate Treatment Initiation delay in days (second treatment event)</td>
        <td>Assign delay in days between Treatment Initiation date of diagnosis</td>
        <td>2020-11-05</td>
        <td>jEKqEElMOqZ</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>jEmMKW3smcf</td>
      </tr>
      <tr>
        <td>Manually Assign Resistance Classification DS</td>
        <td>Manually Assign Resistance Classification DS</td>
        <td>2020-11-05</td>
        <td>jGqPLbMU4QS</td>
      </tr>
      <tr>
        <td>Treatment: on first line initial treatment</td>
        <td></td>
        <td>2020-11-05</td>
        <td>JiTEKv3E5EK</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Lfx resistant</td>
        <td>Set the status of resistance to Lfx based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>JvmLHi9Rgkc</td>
      </tr>
      <tr>
        <td>Display 2-line Treatment Outcome definition "Cured"</td>
        <td>Display 2-line Treatment Outcome definition "Cured"</td>
        <td>2020-11-05</td>
        <td>jxCYbXfBqSM</td>
      </tr>
      <tr>
        <td>Hide manually assigned resistance classification field</td>
        <td>Hide "Manually Assigned Resistance Classification" field</td>
        <td>2020-11-05</td>
        <td>K5lwAgtIp4F</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>KcUXXjSSU29</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>kD6155Giuom</td>
      </tr>
      <tr>
        <td>Display Definition "Relapse patient" in Treatment History</td>
        <td>Display Definition "Relapse patient" in Treatment History</td>
        <td>2020-11-05</td>
        <td>KEiFzV085Oc</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Mfx CC resistant</td>
        <td>Set the status of resistance to Mfx based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>kFuaFqhALj0</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Amk resistant</td>
        <td>Set the status of resistance to Amk based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>kmmAOhgvgYq</td>
      </tr>
      <tr>
        <td>Treatment: Calculate Treatment Initiation delay in days (first treatment event)</td>
        <td>Assign delay in days between Treatment Initiation date of diagnosis</td>
        <td>2020-11-05</td>
        <td>KN1yc4MV3P9</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>kQ6NL7kN4YQ</td>
      </tr>
      <tr>
        <td>Lab: resistance to fluoroquinolones</td>
        <td>Resistance to fluoroquinolones</td>
        <td>2020-11-05</td>
        <td>kSqupNOYxvZ</td>
      </tr>
      <tr>
        <td>Lab: LF-LAM result - hide specimen and date unless LF-LAM has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>Ktg3XAkB9w9</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>kUADOirWNMC</td>
      </tr>
      <tr>
        <td>LAB: Hide "TB Truenat" fields</td>
        <td>Hide "TB Truenat" fields unless "TB Truenat" is selected</td>
        <td>2020-11-05</td>
        <td>KVmfXduoTN2</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Lfx not resistant</td>
        <td>Set the status of resistance to Lfx based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>kwbbicEX3UG</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Fq resistant</td>
        <td>Set the status of resistance to Fq based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>kWlgjIvpSfh</td>
      </tr>
      <tr>
        <td>LAB: Hide "TB LF-LAM" fields</td>
        <td>Hide "TB LF-LAM" fields unless "TB LF-LAM" is selected</td>
        <td>2020-11-05</td>
        <td>KWrKRZMqeRq</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>KYR8EALo128</td>
      </tr>
      <tr>
        <td>Display Definition "New patient" in Treatment History</td>
        <td>Display Definition "New patient" in Treatment History</td>
        <td>2020-11-05</td>
        <td>l0ZzFu99UqQ</td>
      </tr>
      <tr>
        <td>Lab: Solid culture result - hide specimen and date unless culture has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>LCQA5yCMOAh</td>
      </tr>
      <tr>
        <td>Display Definition "Treatment after failure patient" in Treatment History</td>
        <td>Display Definition "Treatment after failure patient" in Treatment History</td>
        <td>2020-11-05</td>
        <td>leTOUOr2HJ5</td>
      </tr>
      <tr>
        <td>Lab: summarise resistance</td>
        <td>Summarise resistant drugs into one data element</td>
        <td>2020-11-05</td>
        <td>lJwQjWza125</td>
      </tr>
      <tr>
        <td>Display Definition "Treatment after lost to follow-up patient" in Treatment History</td>
        <td>Display Definition "Treatment after lost to follow-up patient" in Treatment History</td>
        <td>2020-11-05</td>
        <td>Losodtyr21x</td>
      </tr>
      <tr>
        <td>Treatment: hide second-line options unless category is second-line</td>
        <td>Hide details on second-line treatment unless treatment category is set to second-line</td>
        <td>2020-11-05</td>
        <td>LpKWv4PVI8U</td>
      </tr>
      <tr>
        <td>LAB: Hide Final LPA (Rif/Inh) Results for Rif and Inh fields</td>
        <td>Hide final LPA (Rif/Inh) results for Rif and Inh fields unless MTBc is detected</td>
        <td>2020-12-09</td>
        <td>LVPvzo6Baw0</td>
      </tr>
      <tr>
        <td>Display reminder to provide laboratory results</td>
        <td>Display reminder to provide Laboratory Results</td>
        <td>2020-11-05</td>
        <td>LzOoWYkCz68</td>
      </tr>
      <tr>
        <td>LAB: Hide "LPA (Rif/Inh)" Fields</td>
        <td>Hide "LPA (Rif/Inh)" unless "LPA (Rif/Inh)" is selected</td>
        <td>2020-12-09</td>
        <td>m5IVZxJY8Kw</td>
      </tr>
      <tr>
        <td>Treatment: assign first line treatment start date when starting first line treatment</td>
        <td></td>
        <td>2020-11-05</td>
        <td>M6kzYHBLjRX</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>mbx4iBjIzLC</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>mcMdzWxEgZu</td>
      </tr>
      <tr>
        <td>HIV: hide HIV Number and ART unless positive</td>
        <td>Hide the fields related to HIV number and ART unless the person is HIV positive</td>
        <td>2020-11-05</td>
        <td>Meja9tgN8Fj</td>
      </tr>
      <tr>
        <td>Classification: RR</td>
        <td>Classify as RR case</td>
        <td>2020-11-05</td>
        <td>MGCfC4z3XJz</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>mI1xXuZxAhw</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Rifampicin</td>
        <td>Hide Rifampicin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>mjfuvMPH1Zq</td>
      </tr>
      <tr>
        <td>Lab: resistance to Amk, Kan or Cap</td>
        <td>Resistance to Amk, Kan or Cap</td>
        <td>2020-12-09</td>
        <td>mlXLED2c73C</td>
      </tr>
      <tr>
        <td>Outcome - Hide Outcome Dropdown Options Cured, Completed, Not evaluated - first-line treatment</td>
        <td>Hide Outcome dropdown options Cured, Completed, Not evaluated - if Outcome is recorded within first 6 months of first-line treatment</td>
        <td>2020-11-05</td>
        <td>MR8SdkcKX1g</td>
      </tr>
      <tr>
        <td>Hide "Error" and "No result" options for LPA</td>
        <td></td>
        <td>2020-11-16</td>
        <td>mU6cEKOVhr5</td>
      </tr>
      <tr>
        <td>Display 1-line Treatment Outcome definition "Not evaluated"</td>
        <td>Display 1-line Treatment Outcome definition "Not evaluated"</td>
        <td>2020-11-05</td>
        <td>MupySNS4dOi</td>
      </tr>
      <tr>
        <td>Date validation: Date for TB-LF-LAM lab results must be on or after date of sample collection</td>
        <td>The date for TB-LF-LAM lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>MWNxZGFHUy8</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert MTB/RIF Ultra" fields</td>
        <td>Hide "Xpert MTB/RIF Ultra" fields unless "Xpert MTB/RIF Ultra" is selected</td>
        <td>2020-11-05</td>
        <td>MZMmcvf5KlH</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Pyrazinamide</td>
        <td>Hide Pyrazinamide from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>n38RuJpU2VD</td>
      </tr>
      <tr>
        <td>Date validation: Date for Initial DST SM lab results must be on or after date of sample collection</td>
        <td>The date for Initial DST SM lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>n5Z7gqKZsnS</td>
      </tr>
      <tr>
        <td>Display 2-line Treatment Outcome definition "Died"</td>
        <td>Display 2-line Treatment Outcome definition "Died"</td>
        <td>2020-11-05</td>
        <td>n6ib7MHIwns</td>
      </tr>
      <tr>
        <td>Manually Assign Resistance Classification RR</td>
        <td>Manually Assign Resistance Classification RR</td>
        <td>2020-11-05</td>
        <td>na4ODahOe0V</td>
      </tr>
      <tr>
        <td>Outcome: Error and message - denotification or outcome is required</td>
        <td></td>
        <td>2020-11-05</td>
        <td>nasXvaEoFP8</td>
      </tr>
      <tr>
        <td>Treatment: No regimen selected</td>
        <td></td>
        <td>2020-11-05</td>
        <td>nbdzNqWpe3b</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Amikacin</td>
        <td>Hide Amikacin from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>ne2WPumDOmO</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in Liquid Media (e.g. MGIT) Test</td>
        <td>Hide Initial DST in Liquid Media (e.g. MGIT) Test</td>
        <td>2020-11-05</td>
        <td>NpEcuQKcPlS</td>
      </tr>
      <tr>
        <td>LAB: Hide "Initial DST in Solid Media (LJ)" fields</td>
        <td>Hide "Initial DST in Solid Media (LJ)" fields unless "Initial DST in Solid Media (LJ)" is selected</td>
        <td>2020-11-05</td>
        <td>Nq7kUHt8mrO</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Pza not resistant</td>
        <td>Set the status of resistance to Pza based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>NvcnFkQpwN6</td>
      </tr>
      <tr>
        <td>Lab: resistance to pyrazinamide</td>
        <td>Resistance to pyrazinamide</td>
        <td>2020-11-05</td>
        <td>nwyLDTjPSsc</td>
      </tr>
      <tr>
        <td>Treatment: Display Treatment Initiation delay in days</td>
        <td>Display delay in days between Treatment Initiation date of diagnosis</td>
        <td>2020-11-05</td>
        <td>NXT3pzrG6qe</td>
      </tr>
      <tr>
        <td>Lab: resistance to isoniazid</td>
        <td>Resistance to isoniazid</td>
        <td>2020-11-05</td>
        <td>o7AKNV1ASFi</td>
      </tr>
      <tr>
        <td>Classification: Mono Res</td>
        <td>Classify as Mono Res</td>
        <td>2020-11-05</td>
        <td>o8yRlwChfwf</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Clofazimine</td>
        <td>Hide Clofazimine from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>OGUFaC3CIyw</td>
      </tr>
      <tr>
        <td>Lab: Assign date RIF resistance detected if RIF resistance is detected</td>
        <td></td>
        <td>2020-11-05</td>
        <td>oims46EAbOI</td>
      </tr>
      <tr>
        <td>Lab: set classification to clinically diagnosed if no positive lab results is available</td>
        <td>Set the confirmation method to clinically diagnosed if no positive lab result have been recorded</td>
        <td>2020-11-05</td>
        <td>oKMlhuYgWDd</td>
      </tr>
      <tr>
        <td>Display 1-line Treatment Outcome definition "Lost to follow-up"</td>
        <td>Display 1-line Treatment Outcome definition "Lost to follow-up"</td>
        <td>2020-11-05</td>
        <td>oL6pDjGuo16</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>ON359prH6rh</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>OnMFNYbYv4t</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>oTvTwVawAcA</td>
      </tr>
      <tr>
        <td>Treatment: Prevent completing third event - maximum two (one change of regimen) allowed</td>
        <td></td>
        <td>2020-11-05</td>
        <td>ov1MiHaD9Xe</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>oZoixpklCZn</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (Truenat)</td>
        <td>Lab: Assign date Rif resistance detected (Truenat) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>p20SMCO0ekJ</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Lzd not resistant</td>
        <td>Set the status of resistance to Lzd based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>p2NmaymVsXF</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Inh CC resistant</td>
        <td>Set the status of resistance to Inh CC based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>p5etdw51BLo</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (DST INIT SM)</td>
        <td>Lab: Assign date Rif resistance detected (DST INIT SM) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>PA0rr6ZqlPg</td>
      </tr>
      <tr>
        <td>Treatment: deassign first line treatment start date</td>
        <td></td>
        <td>2020-11-05</td>
        <td>PByrDZo3Yqx</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Bedaquiline</td>
        <td>Hide Bedaquiline from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>pEQFQIl47oo</td>
      </tr>
      <tr>
        <td>Enrollment: display notification if date of birth is estimated</td>
        <td>Prompt the user to set date of birth to January 1 if date of birth is estimated</td>
        <td>2020-11-05</td>
        <td>phtSTAYPHDi</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (Xpert Ultra)</td>
        <td>Lab: Assign date Rif resistance detected (Xpert Ultra) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>pm9wXsa7cRe</td>
      </tr>
      <tr>
        <td>Make mandatory: "RIF result" field for Xpert Ultra</td>
        <td>
          Make "RIF result" field mandatory if MTB is detected</td>
        <td>2020-11-05</td>
        <td>PUjO79I3xLm</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>PxN2xn7ncEI</td>
      </tr>
      <tr>
        <td>HIV: Display message if HIV Status is Unknown</td>
        <td>Display message if HIV Status is Unknown</td>
        <td>2020-11-05</td>
        <td>q2pZ5zANR1o</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide LPA (Rif/Inh) Test</td>
        <td>Hide LPA (Rif/Inh) Test</td>
        <td>2020-12-09</td>
        <td>Q7iWy2cdZdA</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Rif resistant</td>
        <td>Set the status of resistance to Rif based on current event and previous status for DST, as well as Xpert RIF</td>
        <td>2020-12-09</td>
        <td>qa1IedlrDK9</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Fq not resistant</td>
        <td>Set the status of resistance to Fq based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>qcxV27RqtLF</td>
      </tr>
      <tr>
        <td>Lab: LAMP result - hide specimen and date unless LAMP has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>QD9LlkEDDsW</td>
      </tr>
      <tr>
        <td>Lab: LPA (Fq/2LI) result - hide specimen and date unless LPA data has been entered</td>
        <td></td>
        <td>2020-12-09</td>
        <td>qIJATnCd0Hw</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Levofloxacin</td>
        <td>Hide Levofloxacin from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>qk8wvulE6j2</td>
      </tr>
      <tr>
        <td>Clear Date RIF Resistance Detected</td>
        <td>Clear Date RIF Resistance Detected if Resistance was not detected</td>
        <td>2020-11-05</td>
        <td>QkcAEuYsBiH</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (LPA Rif/Inh)</td>
        <td>Lab: Assign date Rif resistance detected (LPA Rif/Inh) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>qmjrsE6QWaD</td>
      </tr>
      <tr>
        <td>Assign Negative HIV Status</td>
        <td></td>
        <td>2020-11-05</td>
        <td>qPaCFbCpctf</td>
      </tr>
      <tr>
        <td>Outcome: Hide delay in weeks if not overdue</td>
        <td>Hide delay in weeks</td>
        <td>2020-11-05</td>
        <td>Qt1dpUflhQu</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Moxifloxacin CB</td>
        <td>Hide Moxifloxacin CB from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>QYeLd33QkrI</td>
      </tr>
      <tr>
        <td>Display Definition "Other previously treated patient" in Treatment History</td>
        <td>Display Definition "Other previously treated patient" in Treatment History</td>
        <td>2020-11-05</td>
        <td>r84ehL23Zns</td>
      </tr>
      <tr>
        <td>Date validation: Date for liquid culture lab results must be on or after date of sample collection</td>
        <td>The date for liquid culture lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>rcBmE3uTdD8</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Kan resistant</td>
        <td>Set the status of resistance to Kan based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>rdmT7qPhyDl</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>rex0ByoDhn7</td>
      </tr>
      <tr>
        <td>Date validation: Date of birth must be before enrolment date</td>
        <td>Date of birth should be before enrolment date</td>
        <td>2020-11-05</td>
        <td>RF68nMu9hNM</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in SM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Subsequent DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>RKD1J7MIQlp</td>
      </tr>
      <tr>
        <td>Classification: show case classification</td>
        <td></td>
        <td>2020-11-05</td>
        <td>rkLdbnSecmD</td>
      </tr>
      <tr>
        <td>Treatment: Hide outcome due until regimen selected</td>
        <td>Hide the outcome due date until a treatment regimen has been selected</td>
        <td>2020-11-05</td>
        <td>rm48HLxFiBi</td>
      </tr>
      <tr>
        <td>Display current age ( >= 2) in the top bar</td>
        <td>Display Age ( >= 2) in the top bar</td>
        <td>2020-11-05</td>
        <td>rOG0oCUnsRh</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Lzd resistant</td>
        <td>Set the status of resistance to Lzd based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>S1iRKyMyNDd</td>
      </tr>
      <tr>
        <td>Outcome - Hide Outcome Dropdown Options Cured, Completed, Not evaluated - second-line treatment</td>
        <td>Hide Outcome dropdown options Cured, Completed, Not evaluated - if Outcome is recorded within first 6 months of second-line treatment</td>
        <td>2020-11-05</td>
        <td>s82pEdT3gAb</td>
      </tr>
      <tr>
        <td>Date validation: Date for GeneXpert Ultra lab results must be on or after date of sample collection</td>
        <td>The date for GeneXpert Ultra lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>S8gDa0OjQIq</td>
      </tr>
      <tr>
        <td>Treatment: Error and message - Treatment Regimen is required</td>
        <td></td>
        <td>2020-11-05</td>
        <td>SBLJgpP1ru8</td>
      </tr>
      <tr>
        <td>Lab: Xpert Ultra result - hide specimen and date unless Xpert Ultra data has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>seviThsTn2u</td>
      </tr>
      <tr>
        <td>Display 2-line Treatment Outcome definition "Failed"</td>
        <td>Display 2-line Treatment Outcome definition "Failed"</td>
        <td>2020-11-05</td>
        <td>sIKc4ZDYHht</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Linezolid</td>
        <td>Hide Linezolid from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>sIKQDhcYyLk</td>
      </tr>
      <tr>
        <td>Lab: resistance to ethambutol</td>
        <td>Resistance to ethambutol</td>
        <td>2020-11-05</td>
        <td>SLj9qkFTOgt</td>
      </tr>
      <tr>
        <td>Classification: DS</td>
        <td>Classify as regular/drug susceptible case</td>
        <td>2020-11-05</td>
        <td>smjssvFZRgK</td>
      </tr>
      <tr>
        <td>Make mandatory: "RIF result" field for Truenat</td>
        <td>
          Make "RIF result" field mandatory if MTB is detected</td>
        <td>2020-11-05</td>
        <td>SoxfAmo0n4K</td>
      </tr>
      <tr>
        <td>Outcome: Assign delay in weeks for overdue outcome</td>
        <td>Assign and display delay in weeks between due and factual dates of treatment outcome</td>
        <td>2020-11-05</td>
        <td>Squ4WU7LwDm</td>
      </tr>
      <tr>
        <td>Date validation: Age cannot be greater than 120 years</td>
        <td>Age cannot be greater than 120 years</td>
        <td>2020-11-05</td>
        <td>SSpRt9vj5a0</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert Ultra RIF" field</td>
        <td>Hide "Xpert Ultra RIF" field unless MTB is detected</td>
        <td>2020-11-05</td>
        <td>sSUAxE44Epf</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>SXA5pIZdfX7</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Isoniazid CC</td>
        <td>Hide Isoniazid CC from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>sYTzxcezzqo</td>
      </tr>
      <tr>
        <td>Outcome: warning if estimated outcome is overdue</td>
        <td>Show a message if passed the outcome due date (based on date of diagnosis) and no outcome is recorded</td>
        <td>2020-11-05</td>
        <td>t1hjlCWKM0J</td>
      </tr>
      <tr>
        <td>Date validation: date ART started must be on or after HIV status date</td>
        <td>The date of starting ART must be on or after HIV status date</td>
        <td>2020-11-05</td>
        <td>T5s2O2fnrIw</td>
      </tr>
      <tr>
        <td>Treatment: on second line treatment</td>
        <td>Show message that person is on second line treatment regimen</td>
        <td>2020-11-05</td>
        <td>tAw3a78NibH</td>
      </tr>
      <tr>
        <td>Display 1-line Treatment Outcome definition "Failed"</td>
        <td>Display 1-line Treatment Outcome definition "Failed"</td>
        <td>2020-11-05</td>
        <td>tB3Ogr5KdEH</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in Solid Media (e.g. LJ) Test</td>
        <td>Hide Initial DST in Solid Media (e.g. LJ) Test</td>
        <td>2020-11-05</td>
        <td>TcyLkaCsMUH</td>
      </tr>
      <tr>
        <td>Display 2-line Treatment Outcome definition "Completed" </td>
        <td>Display 2-line Treatment Outcome definition "Completed"</td>
        <td>2020-11-05</td>
        <td>Til33tI7uEp</td>
      </tr>
      <tr>
        <td>Outcome - Hide Field "Provide evidence for denotification"</td>
        <td></td>
        <td>2020-11-05</td>
        <td>tIRrYTHgOLr</td>
      </tr>
      <tr>
        <td>Treatment: assign second line treatment start date from previous event</td>
        <td></td>
        <td>2020-11-05</td>
        <td>tnXwGDObIfL</td>
      </tr>
      <tr>
        <td>Assign number of months (0) since diagnosis</td>
        <td>Assign number of months (0) since diagnosis in the top bar</td>
        <td>2020-11-05</td>
        <td>tQ1qlBym4JZ</td>
      </tr>
      <tr>
        <td>Date validation: date ART started must be on or after DoB</td>
        <td>The date of starting ART must be on or after the date of birth</td>
        <td>2020-11-05</td>
        <td>UD5VjrlmdR2</td>
      </tr>
      <tr>
        <td>Date validation: Date of birth can not be in the future</td>
        <td>Date of birth should be before the current date</td>
        <td>2020-11-05</td>
        <td>UfQ378gSBCa</td>
      </tr>
      <tr>
        <td>LAB: Hide "Subsequent DST in Solid Media (LJ)" fields</td>
        <td>Hide "Subsequent DST in Solid Media (LJ)" fields unless "Subsequent DST in Solid Media (LJ)" is selected</td>
        <td>2020-11-05</td>
        <td>UgRq1QNPADR</td>
      </tr>
      <tr>
        <td>Display outcome definition "Died" if case not on treatment</td>
        <td>Display outcome definition "Died" if case not on treatment</td>
        <td>2020-11-05</td>
        <td>uhGVwiRYlHq</td>
      </tr>
      <tr>
        <td>Lab: resistance to rifampicin</td>
        <td>Resistance to rifampicin</td>
        <td>2020-11-05</td>
        <td>uJnxydzZ4s2</td>
      </tr>
      <tr>
        <td>Outcome: prevent selection of "cured" if clinically diagnosed</td>
        <td>Prevent selection of "cured" as treatment outcome if the patient is clinically diagnosed</td>
        <td>2020-11-05</td>
        <td>UOJC4yC2aoj</td>
      </tr>
      <tr>
        <td>LAB: Hide "Culture in Solid Media (e.g. LJ)" fields</td>
        <td>Hide "Culture in Solid Media (e.g. LJ)" fields unless "Culture in Solid Media (e.g. LJ)" is selected</td>
        <td>2020-11-05</td>
        <td>uoX3PoKdgcD</td>
      </tr>
      <tr>
        <td>Treatment: deassign second line treatment start date</td>
        <td></td>
        <td>2020-11-05</td>
        <td>uv5FPnv7BLa</td>
      </tr>
      <tr>
        <td>Outcome: hide outcome if denotification selected</td>
        <td>If the case is marked as "denotified", hide the "Outcome" field</td>
        <td>2020-11-05</td>
        <td>uVvznXzOCa5</td>
      </tr>
      <tr>
        <td>Outcome: Assign "No value" to delay in weeks</td>
        <td>Assign no value to delay in weeks</td>
        <td>2020-11-05</td>
        <td>UY8MT0U1yoK</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Bdq resistant</td>
        <td>Set the status of resistance to Bdq based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>uyBB2KcpxLw</td>
      </tr>
      <tr>
        <td>Display 2-line Treatment Outcome definition "Not evaluated"</td>
        <td>Display 2-line Treatment Outcome definition "Not evaluated"</td>
        <td>2020-11-05</td>
        <td>V4XWGAeZs61</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Moxifloxacin CC</td>
        <td>Hide Moxifloxacin CC from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>v5nV6pnsC6d</td>
      </tr>
      <tr>
        <td>LAB: Hide "Initial DST in Liquid Media (Mgit)" fields</td>
        <td>Hide "Initial DST in Liquid Media (Mgit)" fields unless "Initial DST in Liquid Media (Mgit)" is selected</td>
        <td>2020-11-05</td>
        <td>VFjTb394lD2</td>
      </tr>
      <tr>
        <td>Assign HIV status "Unknown"</td>
        <td></td>
        <td>2020-11-05</td>
        <td>vkfvIY4KBLu</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Amk/Cap resistant</td>
        <td>Set the status of resistance to Amk/Cap based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>vkkL2FL0Tm8</td>
      </tr>
      <tr>
        <td>LAB: Hide Final LPA (Fq/2LI) Results for FQ, 2LI and Emb fields</td>
        <td>Hide final LPA (Fq/2LI) results for FQ, 2LI and Emb fields unless MTBc is detected</td>
        <td>2020-12-09</td>
        <td>VLNPVPyvGSK</td>
      </tr>
      <tr>
        <td>Date validation: date of HIV status must be on or after DoB</td>
        <td>The date of HIV status must be on or after the date of birth</td>
        <td>2020-11-05</td>
        <td>voL1qX3Jy6T</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Pza resistant</td>
        <td>Set the status of resistance to Pza based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>VoVIBsA0S8g</td>
      </tr>
      <tr>
        <td>Lab: Truenat result - hide specimen and date unless Truenat has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>vp0HTD0vJ3V</td>
      </tr>
      <tr>
        <td>Treatment: Assign "No value" to delay in days</td>
        <td>Assign no value to delay in days</td>
        <td>2020-11-05</td>
        <td>VQDCodU4MmB</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Delamanid</td>
        <td>Hide Delamanid from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>VrjlyAUs98C</td>
      </tr>
      <tr>
        <td>Classification: DR</td>
        <td>Classify as DR case</td>
        <td>2020-11-05</td>
        <td>VtrRY1oITQU</td>
      </tr>
      <tr>
        <td>HIV: hide HIV Status Date if HIV Status is Unknown</td>
        <td>Hide HIV STATUS Date if HIV Status is Unknown</td>
        <td>2020-11-05</td>
        <td>vXXtfTOIL9L</td>
      </tr>
      <tr>
        <td>Lab: Hide Status Section</td>
        <td></td>
        <td>2020-11-05</td>
        <td>W1OWf6FhL0F</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Subsequent DST in LM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Subsequent DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>W3cmfpuTbzf</td>
      </tr>
      <tr>
        <td>Lab: set classification to lab confirmed if positive lab results are available</td>
        <td>Set the confirmation method to bacteriologically confirmed if a positive lab result has been recorded.</td>
        <td>2020-11-05</td>
        <td>WGPZYj6KTFX</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in LM - Ethambutol</td>
        <td>Hide Ethambutol from list of drugs used for Initial DST in liquid media if not used</td>
        <td>2020-11-05</td>
        <td>wmXda1OfAYF</td>
      </tr>
      <tr>
        <td>Treatment : set treatment start date</td>
        <td>Assign treatment start date when treatment regimen has been selected and there was no previous regimen, or if a new regimen is selected AND the previous treatment start date is different from the current.</td>
        <td>2020-11-05</td>
        <td>WqIL99ateGS</td>
      </tr>
      <tr>
        <td>LAB: Hide "TB-LAMP" fields</td>
        <td>Hide "TB-LAMP" fields unless "TB-LAMP" is selected</td>
        <td>2020-11-05</td>
        <td>WTYaaBwu9Q5</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide LF-LAM Test</td>
        <td>Hide LF-LAM Test</td>
        <td>2020-11-05</td>
        <td>wtyHmh5igwP</td>
      </tr>
      <tr>
        <td>Display current treatment regimen</td>
        <td></td>
        <td>2020-11-05</td>
        <td>WY94qMK6Ysi</td>
      </tr>
      <tr>
        <td>Date validation: Date for TB-Truenat lab results must be on or after date of sample collection</td>
        <td>The date for TB-Truenat lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>WyowVFQNnrl</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Initial DST in SM - Isoniazid CB</td>
        <td>Hide Isoniazid CB from list of drugs used for Initial DST in solid media if not used</td>
        <td>2020-11-05</td>
        <td>x56WrfsLnAY</td>
      </tr>
      <tr>
        <td>Date validation: Date of death cannot be before treatment initiation date</td>
        <td>Date of death cannot be before treatment initiation date</td>
        <td>2020-11-05</td>
        <td>x6l9nunkDAb</td>
      </tr>
      <tr>
        <td>LAB: Hide "Subsequent DST in Liquid Media (Mgit)" fields</td>
        <td>Hide "Subsequent DST in Liquid Media (Mgit)" fields unless "Subsequent DST in Liquid Media (Mgit)" is selected</td>
        <td>2020-11-05</td>
        <td>X6oqKohK2Vr</td>
      </tr>
      <tr>
        <td>Classification: show resistance classification</td>
        <td>Show case classification (DS, DR, RR, MDR, XDR)</td>
        <td>2020-11-05</td>
        <td>XbtNbRu3WcV</td>
      </tr>
      <tr>
        <td>Manually Assign Resistance Classification MDR</td>
        <td>Manually Assign Resistance Classification MDR</td>
        <td>2020-11-05</td>
        <td>XeAxrOpyLWj</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Dlm resistant</td>
        <td>Set the status of resistance to Dlm based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>XGryKiY6YEK</td>
      </tr>
      <tr>
        <td>Display 1-line Treatment Outcome definition "Cured"</td>
        <td>Display 1-line Treatment Outcome definition "Cured"</td>
        <td>2020-11-05</td>
        <td>XNcUSlpVK6h</td>
      </tr>
      <tr>
        <td>LAB: Hide "Xpert RIF" field</td>
        <td>Hide "Xpert RIF" field unless MTB is detected</td>
        <td>2020-11-05</td>
        <td>XnQYppAjm0T</td>
      </tr>
      <tr>
        <td>Treatment: drug resistance not detected, but case is registered on second-line</td>
        <td>Drug resistance not detected, but case is registered on second-line</td>
        <td>2020-11-05</td>
        <td>xoCMDMzuGhJ</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Rif not resistant</td>
        <td>Set the status of resistance to Rif based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>XQBX8unnFOd</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Mfx CC not resistant</td>
        <td>Set the status of resistance to Mfx based on current event and previous status</td>
        <td>2020-11-05</td>
        <td>XTbXgY6T5Rj</td>
      </tr>
      <tr>
        <td>Date validation: Date for Initial DST LM lab results must be on or after date of sample collection</td>
        <td>The date for Initial DST LM lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>XtxkST1l7KD</td>
      </tr>
      <tr>
        <td>Display Definition "Patient with unknown previous TB treatment history" in Treatment History</td>
        <td>Display Definition "Patient with unknown previous TB treatment history" in Treatment History</td>
        <td>2020-11-05</td>
        <td>xvvOxjyFsCV</td>
      </tr>
      <tr>
        <td>Display current age ( < 2) in the top bar</td>
        <td>Display Age ( <2) in the top bar</td>
        <td>2020-11-05</td>
        <td>xy71ub4TsF5</td>
      </tr>
      <tr>
        <td>CONSTANT - Hide Sputum Smear Microscopy Test</td>
        <td>Hide Sputum Smear Microscopy Test</td>
        <td>2020-11-05</td>
        <td>y06VcSAi2Zp</td>
      </tr>
      <tr>
        <td>Lab: Assign date Rif resistance detected (DST SUB LM)</td>
        <td>Lab: Assign date Rif resistance detected (DST SUB LM) if Rif resistance is detected, a date has been entered and the date is preceding the current Rif resistance date</td>
        <td>2020-12-09</td>
        <td>Y0qj2MgL7ZA</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Amk/Cap not resistant</td>
        <td>Set the status of resistance to Amk/Cap based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>y3UoIrkDYO9</td>
      </tr>
      <tr>
        <td>Registration: display reminder to retest HIV</td>
        <td>Display reminder to retest patient for HIV if the HIV Status date is +6 months</td>
        <td>2020-11-05</td>
        <td>Y8WFkcBC4lf</td>
      </tr>
      <tr>
        <td>Outcome: hide denotification if outcome selected</td>
        <td>If and outcome is selected, hide the "denotification" field</td>
        <td>2020-11-05</td>
        <td>yIjGxwB8kq9</td>
      </tr>
      <tr>
        <td>Treatment: specify other drug</td>
        <td>Show field for specifying other drug</td>
        <td>2020-11-05</td>
        <td>ZE6qhEb63P0</td>
      </tr>
      <tr>
        <td>Make mandatory: "RIF result" field for Xpert</td>
        <td>
          Make "RIF result" field mandatory if MTB is detected</td>
        <td>2020-11-05</td>
        <td>ZeZZJsP2XxE</td>
      </tr>
      <tr>
        <td>Date validation: Date for GeneXpert lab results must be on or after date of sample collection</td>
        <td>The date for GeneXpert lab results must be on or after date of sample collection</td>
        <td>2020-11-05</td>
        <td>Zij8h3ds7xy</td>
      </tr>
      <tr>
        <td>Lab: Liquid culture result - hide specimen and date unless culture has been entered</td>
        <td></td>
        <td>2020-11-05</td>
        <td>ZJOYEMNAtzb</td>
      </tr>
      <tr>
        <td>Assign clinically diagnosed RR/MDR TB to Resistance Classification</td>
        <td>Assign Temporary Resistance Classification RR/MDR for clinically diagnosed cases starting on second-line treatment</td>
        <td>2020-11-05</td>
        <td>ZlfHtHE6tXe</td>
      </tr>
      <tr>
        <td>Outcome - Hide Outcome Dropdown Option Failed - second-line treatment</td>
        <td>Hide Outcome dropdown option Failed - if Outcome is recorded within first 5 months of second-line treatment</td>
        <td>2020-11-05</td>
        <td>ZNtO2PbgDaw</td>
      </tr>
      <tr>
        <td>Hide "Not TB case" (Explanation)</td>
        <td>Hide Not TB case (Explanation) unless "De-notify" is selected</td>
        <td>2020-11-05</td>
        <td>Zp8zZcUhGud</td>
      </tr>
      <tr>
        <td>Lab: assign status of resistance - Inh CB not resistant</td>
        <td>Set the status of resistance to Inh CB based on current event and previous status</td>
        <td>2020-12-09</td>
        <td>zpYoI6g5ZMN</td>
      </tr>
      <tr>
        <td>Treatment: Hide first line regimen option if first line regimen in previous event</td>
        <td></td>
        <td>2020-11-05</td>
        <td>zsIzPyV43qb</td>
      </tr>
      <tr>
        <td>Outcome: outcome due date - second line-treatment</td>
        <td>Calculate an outcome due date for second-line treatment from date of diagnosis (24 months)</td>
        <td>2020-11-05</td>
        <td>ZTFfcEfFjxS</td>
      </tr>
    </table>
    <h4>Program Tracked Entity Attributes</h4>
    <table>
      <tr>
        <th>Tracked Entity Attribute Name</th>
        <th>Last updated</th>
        <th>Program Tracked Entity Attribute UID</th>
        <th>Tracked Entity Attribute UID</th>
      </tr>
      <tr>
        <td>National ID</td>
        <td>2020-08-04</td>
        <td>WGAYdyLvlHd</td>
        <td>Ewi7FUfcHAD</td>
      </tr>
      <tr>
        <td>TB Registration Number</td>
        <td>2020-08-04</td>
        <td>ngmTjpcWtTZ</td>
        <td>ntelZthDPpR</td>
      </tr>
      <tr>
        <td>Family name</td>
        <td>2020-08-04</td>
        <td>aQ9uwwF98rj</td>
        <td>aW66s2QSosT</td>
      </tr>
      <tr>
        <td>Given name</td>
        <td>2020-08-04</td>
        <td>RGggZsUAgKg</td>
        <td>TfdH5KvFmMy</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2020-08-04</td>
        <td>NL0A0PV9OKc</td>
        <td>CklPZdOd6H1</td>
      </tr>
      <tr>
        <td>Date of birth is estimated</td>
        <td>2020-08-04</td>
        <td>UL8nsHjf333</td>
        <td>Z1rLc1rVHK8</td>
      </tr>
      <tr>
        <td>Date of birth (age)</td>
        <td>2020-08-04</td>
        <td>EcXmoNn84AM</td>
        <td>mAWcalQYYyk</td>
      </tr>
      <tr>
        <td>Foreign-born</td>
        <td>2020-08-04</td>
        <td>JYZMYTu5OwS</td>
        <td>xdRQzKcARGt</td>
      </tr>
      <tr>
        <td>Administrative area of residence</td>
        <td>2020-08-04</td>
        <td>KwYTprVNXJP</td>
        <td>ljHL8NnSEAD</td>
      </tr>
      <tr>
        <td>Address (current)</td>
        <td>2020-08-04</td>
        <td>bMYK8keEjLZ</td>
        <td>VCtm2pySeEV</td>
      </tr>
      <tr>
        <td>Mobile phone number</td>
        <td>2020-08-04</td>
        <td>tFv8IsTNRIV</td>
        <td>ciCR6BBvIT4</td>
      </tr>
    </table>
    <h2 id="constants">Constants</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Amikacin</td>
        <td>Subsequent DST LM - Amk</td>
        <td>2020-11-12</td>
        <td>a4PpEfSutcV</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Pyrazinamide</td>
        <td>Initial DST SM - Pza</td>
        <td>2020-11-12</td>
        <td>aCaNdqUIDZl</td>
      </tr>
      <tr>
        <td>TB-Drugs: LPA (Fq/2Li) - Ethambutol</td>
        <td>LPA (Fq/2LI) - Emb</td>
        <td>2020-11-06</td>
        <td>AiyTLOJHMkl</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Isoniazid (CB)</td>
        <td>Initial DST SM - Inh (CB)</td>
        <td>2020-11-12</td>
        <td>anpSc1tmlft</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Linezolid</td>
        <td>Initial DST LM - Lzd</td>
        <td>2020-11-12</td>
        <td>aZq11UuXPP6</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Levofloxacin</td>
        <td>Subsequent DST LM - Lfx</td>
        <td>2020-11-12</td>
        <td>b1KgVOel21P</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Pyrazinamide</td>
        <td>Subsequent DST SM - Pza</td>
        <td>2020-11-12</td>
        <td>bHPYGfrFNV2</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Delamanid</td>
        <td>Initial DST LM - Dlm</td>
        <td>2020-11-12</td>
        <td>BJTzi3WWjhT</td>
      </tr>
      <tr>
        <td>TB-Lab: Subsequent Phenotypic DST in Solid Media (eg. LJ)</td>
        <td>Subsequent DST SM</td>
        <td>2020-12-09</td>
        <td>BpRfvWQcvTo</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Clofazimine</td>
        <td>Subsequent DST SM - Cfz</td>
        <td>2020-11-12</td>
        <td>bywBn5DxVdi</td>
      </tr>
      <tr>
        <td>TB-Lab: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>2020-12-09</td>
        <td>cFoFDkXKcXC</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Isoniazid (CC)</td>
        <td>Initial DST LM - Inh (CC)</td>
        <td>2020-11-12</td>
        <td>cRldkiBh5xv</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Linezolid</td>
        <td>Initial DST SM - Lzd</td>
        <td>2020-11-12</td>
        <td>CVQR2ZtZWxk</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Moxifloxacin (CC)</td>
        <td>Subsequent DST SM - Mfx (CC)</td>
        <td>2020-11-12</td>
        <td>Czx5FuOqF9i</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Isoniazid (CC)</td>
        <td>Initial DST SM - Inh (CC)</td>
        <td>2020-11-12</td>
        <td>dAPAScvFPfX</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Moxifloxacin (CC)</td>
        <td>Initial DST LM - Mfx (CC)</td>
        <td>2020-11-12</td>
        <td>dgjpdQO2Iva</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Amikacin</td>
        <td>Subsequent DST SM - Amk</td>
        <td>2020-11-12</td>
        <td>dTwKm1u2VhY</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Isoniazid (CC)</td>
        <td>Subsequent DST SM - Inh (CC)</td>
        <td>2020-11-12</td>
        <td>eM3UfUO7W8O</td>
      </tr>
      <tr>
        <td>TB-Lab: LPA (Rif/Inh)</td>
        <td>LPA (Rif/Inh)</td>
        <td>2020-12-09</td>
        <td>ESUffSPwmju</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Isoniazid (CB)</td>
        <td>Subsequent DST LM - Inh (CB)</td>
        <td>2020-11-12</td>
        <td>F9DTb5zl8rS</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Pyrazinamide</td>
        <td>Initial DST LM - Pza</td>
        <td>2020-11-12</td>
        <td>FDtk4otxDse</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Levofloxacin</td>
        <td>Subsequent DST SM - Lfx</td>
        <td>2020-11-12</td>
        <td>Fw8wOlTETPt</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Clofazimine</td>
        <td>Initial DST LM - Cfz</td>
        <td>2020-11-12</td>
        <td>GL5JTtBvbEC</td>
      </tr>
      <tr>
        <td>TB-Lab: LPA (Fq/2LI)</td>
        <td>LPA (Fq/2LI)</td>
        <td>2020-12-09</td>
        <td>govArZqiFzY</td>
      </tr>
      <tr>
        <td>TB-Treatment: Lists of First-line and Second-line drugs</td>
        <td>First-line and Second-line drugs</td>
        <td>2020-12-09</td>
        <td>GxOlFoUKbHB</td>
      </tr>
      <tr>
        <td>TB-Lab: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF</td>
        <td>2020-12-09</td>
        <td>H4ObQDbhnTA</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Moxifloxacin (CC)</td>
        <td>Subsequent DST LM - Mfx (CC)</td>
        <td>2020-11-12</td>
        <td>HhKitGif8RV</td>
      </tr>
      <tr>
        <td>TB-Lab: Initial Phenotypic DST in Solid Media (eg. LJ)</td>
        <td>Initial DST SM</td>
        <td>2020-12-09</td>
        <td>HjN2Bgnusyy</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Ethambutol</td>
        <td>Subsequent DST LM - Emb</td>
        <td>2020-11-12</td>
        <td>Ic5asMdbpH8</td>
      </tr>
      <tr>
        <td>TB-Lab: Culture in Solid Media (e.g. LJ)</td>
        <td>Culture SM</td>
        <td>2020-12-09</td>
        <td>iSKEqcuVAui</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Linezolid</td>
        <td>Subsequent DST SM - Lzd</td>
        <td>2020-11-12</td>
        <td>KIeI2d8xalG</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Bedaquiline</td>
        <td>Initial DST LM - Bdq</td>
        <td>2020-11-12</td>
        <td>KjvwSybuWJU</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Rifampicin</td>
        <td>Subsequent DST LM - Rif</td>
        <td>2020-11-12</td>
        <td>lelJEADYpeI</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Isoniazid (CB)</td>
        <td>Initial DST LM - Inh (CB)</td>
        <td>2020-11-12</td>
        <td>lqaf0KfpHGd</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Moxifloxacin (CB)</td>
        <td>Initial DST SM - Mfx (CB)</td>
        <td>2020-11-12</td>
        <td>m4c79OHEKCG</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Linezolid</td>
        <td>Subsequent DST LM - Lzd</td>
        <td>2020-11-12</td>
        <td>mU5iEABeF2K</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Ethambutol</td>
        <td>Initial DST LM - Emb</td>
        <td>2020-11-12</td>
        <td>n9zOOsLO0QP</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Clofazimine</td>
        <td>Subsequent DST LM - Cfz</td>
        <td>2020-11-12</td>
        <td>Nb6oHqjCCZq</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Levofloxacin</td>
        <td>Initial DST SM - Lfx</td>
        <td>2020-11-12</td>
        <td>NlOX3oV4gWe</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Moxifloxacin (CB)</td>
        <td>Subsequent DST SM - Mfx (CB)</td>
        <td>2020-11-12</td>
        <td>NvA1K4hFJbc</td>
      </tr>
      <tr>
        <td>TB-Lab: Initial Phenotypic DST in Liquid Media (eg. MGIT)</td>
        <td>Initial DST LM</td>
        <td>2020-12-09</td>
        <td>OQxeAIyQUeB</td>
      </tr>
      <tr>
        <td>TB-Lab: Sputum Smear Microscopy</td>
        <td>Microscopy</td>
        <td>2020-12-09</td>
        <td>q1ah12sKfG3</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Rifampicin</td>
        <td>Initial DST SM - Rif</td>
        <td>2020-11-12</td>
        <td>Q67DDsupq7v</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Bedaquiline</td>
        <td>Subsequent DST LM - Bdq</td>
        <td>2020-11-12</td>
        <td>QaioqMbO0TX</td>
      </tr>
      <tr>
        <td>TB-Lab: Culture in Liquid Media (e.g. MGIT)</td>
        <td>Culture LM</td>
        <td>2020-12-09</td>
        <td>qpAseG5vJyS</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Bedaquiline</td>
        <td>Subsequent DST SM - Bdq</td>
        <td>2020-11-12</td>
        <td>r70ONQRhaHY</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Delamanid</td>
        <td>Subsequent DST SM - Dlm</td>
        <td>2020-11-12</td>
        <td>RFqmLP5W5di</td>
      </tr>
      <tr>
        <td>TB-Lab: LF-LAM</td>
        <td>LF-LAM</td>
        <td>2020-12-09</td>
        <td>riDIK5mvDzW</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Moxifloxacin (CC)</td>
        <td>Initial DST SM - Mfx (CC)</td>
        <td>2020-11-12</td>
        <td>RJNE1o9cw7Y</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Isoniazid (CB)</td>
        <td>Subsequent DST SM - Inh (CB)</td>
        <td>2020-11-12</td>
        <td>s8WPR943gGS</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Levofloxacin</td>
        <td>Initial DST LM - Lfx</td>
        <td>2020-11-12</td>
        <td>t7Okdm8VgDV</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Moxifloxacin (CB)</td>
        <td>Initial DST LM - Mfx (CB)</td>
        <td>2020-11-12</td>
        <td>UL61U78GWCg</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Rifampicin</td>
        <td>Initial DST LM - Rif</td>
        <td>2020-11-12</td>
        <td>uOJYEwV7XfN</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Bedaquiline</td>
        <td>Initial DST SM - Bdq</td>
        <td>2020-11-12</td>
        <td>UxcTzMRQsfa</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Delamanid</td>
        <td>Initial DST SM - Dlm</td>
        <td>2020-11-12</td>
        <td>VUlsMrm4D8k</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Pyrazinamide</td>
        <td>Subsequent DST LM - Pza</td>
        <td>2020-11-12</td>
        <td>VY15auehssY</td>
      </tr>
      <tr>
        <td>TB-Lab: Subsequent Phenotypic DST in Liquid Media (eg. MGIT)</td>
        <td>Subsequent DST LM</td>
        <td>2020-12-09</td>
        <td>W8Fm1pJuJPL</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Ethambutol</td>
        <td>Subsequent DST SM - Emb</td>
        <td>2020-11-12</td>
        <td>wNxsAieLWYc</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Liquid Media - Amikacin</td>
        <td>Initial DST LM - Amk</td>
        <td>2020-11-12</td>
        <td>x6v8O6EZo0U</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Moxifloxacin (CB)</td>
        <td>Subsequent DST LM - Mfx (CB)</td>
        <td>2020-11-12</td>
        <td>xfltmyqC3p0</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Amikacin</td>
        <td>Initial DST SM - Amk</td>
        <td>2020-11-12</td>
        <td>XO1V9o5C95J</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Delamanid</td>
        <td>Subsequent DST LM - Dlm</td>
        <td>2020-11-12</td>
        <td>Xt5GU9kBD7q</td>
      </tr>
      <tr>
        <td>TB-Lab: TB-LAMP</td>
        <td>TB-LAMP</td>
        <td>2020-12-09</td>
        <td>yF0xR5nDSXa</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Ethambutol</td>
        <td>Initial DST SM - Emb</td>
        <td>2020-11-12</td>
        <td>yxPHZFwMTN6</td>
      </tr>
      <tr>
        <td>TB-Lab: Truenat</td>
        <td>Truenat</td>
        <td>2020-12-09</td>
        <td>zBicQdPbHfj</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Liquid Media - Isoniazid (CC)</td>
        <td>Subsequent DST LM - Inh (CC)</td>
        <td>2020-11-12</td>
        <td>ZBpqH7xJLBO</td>
      </tr>
      <tr>
        <td>TB-Drugs: Initial Phenotypic DST in Solid Media - Clofazimine</td>
        <td>Initial DST SM - Cfz</td>
        <td>2020-11-12</td>
        <td>ZDpLleSK08x</td>
      </tr>
      <tr>
        <td>TB-Drugs: Subsequent Phenotypic DST in Solid Media - Rifampicin</td>
        <td>Subsequent DST SM - Rif</td>
        <td>2020-11-12</td>
        <td>zJoEjvstp2d</td>
      </tr>
    </table>
    <h2 id="dataElements">Data Elements</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Categorycombo</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh)</td>
        <td>LPA (Rif/Inh)</td>
        <td></td>
        <td>LPA (Rif/Inh)</td>
        <td>default</td>
        <td>2020-11-06</td>
        <td>a2I7mdEL028</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
        <td>Subsequent DST SM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>A2iF5Ix8pAf</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
        <td>Subsequent DST LM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>agZKnJWKdQK</td>
      </tr>
      <tr>
        <td>TB Lab: TB-LAMP</td>
        <td>TB-LAMP</td>
        <td></td>
        <td>TB-LAMP Test</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>aQxta3CjJ0o</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
        <td>Subsequent DST LM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - critical concentration (Mfx CC), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>ASr2gFadIie</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Pza</td>
        <td>Treatment Second-line - Pza</td>
        <td></td>
        <td>Pyrazinamide (Pza)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>Au1qHXm7z9n</td>
      </tr>
      <tr>
        <td>TB: Treatment Outcome delay (weeks)</td>
        <td>Treatment outcome delay</td>
        <td></td>
        <td>Number of weeks between due Treatment outcome date and the factual outcome</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>AycLmJbEv9M</td>
      </tr>
      <tr>
        <td>TB Lab: TB-LAMP specimen number</td>
        <td>TB-LAMP specimen number</td>
        <td></td>
        <td>TB-LAMP specimen number</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>b32VVMA8FEV</td>
      </tr>
      <tr>
        <td>TB: Treatment Initiation delay (days)</td>
        <td>Treatment initiation delay</td>
        <td></td>
        <td>Number of days between date of diagnosis and treatment initiation date</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>B7uqbrRKr2T</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Dlm</td>
        <td>Treatment Second-line - Dlm</td>
        <td></td>
        <td>Delamanid (Dlm)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>b89yFC4FHtF</td>
      </tr>
      <tr>
        <td>TB Lab: TB-LAMP Date</td>
        <td>TB-LAMP Date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>BMBQRUWGC96</td>
      </tr>
      <tr>
        <td>TB Lab: TB-LAMP MTB</td>
        <td>TB-LAMP MTB</td>
        <td></td>
        <td>TB-LAMP MTB</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>bNGqfxvPbPo</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
        <td>Subsequent DST SM</td>
        <td></td>
        <td>Subsequent DST in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>BNkkWpCKgLR</td>
      </tr>
      <tr>
        <td>TB Lab: Date of initial DST results (solid media)</td>
        <td>Date of initial DST SM results</td>
        <td></td>
        <td>Date of final initial DST results (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>bXaGYMAnfNH</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
        <td>LPA (Fq/2LI) - Amk/Cap</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Amikacin/Capreomycin</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>C2owWE9gaoe</td>
      </tr>
      <tr>
        <td>TB Lab: Solid culture specimen test result</td>
        <td>Solid Culture result</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>CiyzVihv21K</td>
      </tr>
      <tr>
        <td>TB: Reassign Resistance Classification</td>
        <td>Reassign Resistance Classification</td>
        <td></td>
        <td>Reassign Resistance Classification manually</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>cMiU42qZMbL</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert Result Date</td>
        <td>Xpert lab result date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>cQUTagw2Jtw</td>
      </tr>
      <tr>
        <td>TB Registration: Previous treatment history</td>
        <td>Previous treatment history</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>cv1d5PIjzGb</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert results - MTB</td>
        <td>Xpert MTB</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>CxjSGmVSIrD</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert Ultra results - RIF</td>
        <td>Xpert Ultra - RIF</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>d2nso3iTDyC</td>
      </tr>
      <tr>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
        <td>Date of LPA (Rif/Inh)</td>
        <td></td>
        <td>Date of LPA (Rif/Inh)</td>
        <td>default</td>
        <td>2020-11-06</td>
        <td>D4z4o6JR9M0</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Other</td>
        <td>Treatment Second-line - Other</td>
        <td></td>
        <td>Other</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>dBjZPN1aEnN</td>
      </tr>
      <tr>
        <td>TB Lab: Sputum smear microscopy</td>
        <td>Sputum smear microscopy</td>
        <td></td>
        <td>Sputum smear microscopy</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Dd95Kl4aXZf</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Ipm</td>
        <td>Treatment Second-line - Ipm</td>
        <td></td>
        <td>Imipenem-cilastatin (Ipm-Cln)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>DEUPlcvyWlY</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
        <td>Initial DST LM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>DjVjz7PNXJA</td>
      </tr>
      <tr>
        <td>Treatment First-line - Rif</td>
        <td>Treatment First-line - Rif</td>
        <td></td>
        <td>Rifampicin (Rif)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>dUeTqbQ4mEz</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
        <td>Subsequent DST SM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>DVEEyF5cpjB</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
        <td>Subsequent DST SM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>dwi6P6D2iFg</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
        <td>Initial DST SM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>dyqHwVB1oij</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
        <td>LPA (Fq/2LI) - Fq</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Fluoroquinolones</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>E61DoZgoPH2</td>
      </tr>
      <tr>
        <td>TB: risk factor - diabetes</td>
        <td>Risk factor diabetes</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>ea5ktuqF6xc</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST Specimen Number (solid media)</td>
        <td>Sub DST SM specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>Ec6plSlaIU2</td>
      </tr>
      <tr>
        <td>HIV Infection</td>
        <td>HIV Infection</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>ehtg3U5qmuI</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
        <td>Subsequent DST LM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Ei5mffgPCHN</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
        <td>Initial DST LM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>ema8JjkIDTz</td>
      </tr>
      <tr>
        <td>TB Outcome - Reason for case denotification</td>
        <td>Denotification Reason</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>eMNDiZHLDaq</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Mpm</td>
        <td>Treatment Second-line - Mpm</td>
        <td></td>
        <td>Meropenem (Mpm)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>EQVtpmthuAH</td>
      </tr>
      <tr>
        <td>TB Outcome - Not TB case (Explanation)</td>
        <td>Not TB Case (Explanation)</td>
        <td></td>
        <td>Provide reasons for denotification</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>eU9zyTHI4oq</td>
      </tr>
      <tr>
        <td>Treatment First-line - Emb</td>
        <td>Treatment First-line - Emb</td>
        <td></td>
        <td>Ethambutol (Emb)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>Ey5hCmNIHtp</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
        <td>Initial DST LM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin CB (Mfx CB), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>F4fNZ8htdHP</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert results - RIF</td>
        <td>Xpert - RIF</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>F6kH0qcMT7Z</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
        <td>Subsequent DST SM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>FjsunwwqBMk</td>
      </tr>
      <tr>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
        <td>LPA (Fq/2LI) - Specimen type</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>FKxBceeFNuR</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
        <td>LPA (Rif/Inh) - Rif</td>
        <td></td>
        <td>Final LPA (Rif/Inh) result for Rifampicin</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Gey1agRf0Kh</td>
      </tr>
      <tr>
        <td>TB Lab: Smear specimen number</td>
        <td>Smear specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>GKCCcIyrJmn</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
        <td>Subsequent DST SM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>GZ5Vqh8wdI1</td>
      </tr>
      <tr>
        <td>Treatment First-line - Pza</td>
        <td>Treatment First-line - Pza</td>
        <td></td>
        <td>Pyrazinamide (Pza)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>Hap7vcfxJkB</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
        <td>Initial DST SM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>HCLjG26CmTS</td>
      </tr>
      <tr>
        <td>TB Lab: Truenat</td>
        <td>Truenat</td>
        <td></td>
        <td>Truenat</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>HjZ2k3ZvpRU</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
        <td>Initial DST LM</td>
        <td></td>
        <td>Initial phenotypic DST in liquid media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>HkZ1hGWBqlZ</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Emb</td>
        <td>Treatment Second-line - Emb</td>
        <td></td>
        <td>Ethambutol (Emb)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>hm58z5YMj4V</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Cfz</td>
        <td>Treatment Second-line - Cfz</td>
        <td></td>
        <td>Clofazimine (Cfz)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>hRFRpjD1nem</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
        <td>Subsequent DST LM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>IBqX2HMQV4T</td>
      </tr>
      <tr>
        <td>TB Lab: Liquid culture specimen test result</td>
        <td>Liquid Culture result</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>iD9wKzRYCLc</td>
      </tr>
      <tr>
        <td>TB Registration: Second-line drugs</td>
        <td>History: second-line drugs</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>IEQdNOn4TMd</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert specimen number</td>
        <td>Xpert specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>ig6R6PnpsHv</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
        <td>Subsequent DST SM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - clinical breakpoint (Mfx CB), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>iGcMnwWVhKh</td>
      </tr>
      <tr>
        <td>TB Lab: LF-LAM</td>
        <td>LF-LAM</td>
        <td></td>
        <td>LF-LAM Test</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>iiVMeXUBuyF</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Other drug - specify</td>
        <td>Treatment Second-line - Other drug - specify</td>
        <td></td>
        <td>Other drug - specify</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>il1wc9qGoUE</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Amk</td>
        <td>Treatment Second-line - Amk</td>
        <td></td>
        <td>Amikacin (Amk)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>iqhIJDJd1AT</td>
      </tr>
      <tr>
        <td>TB Resistance Classification</td>
        <td>Resistance Classification</td>
        <td></td>
        <td>Resistance Classification</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>IqWm68GM8iC</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST Liquid Media Specimen Number</td>
        <td>Init DST LM specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>IsndMvNPutD</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
        <td>Subsequent DST SM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>J0DefR0gJZV</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
        <td>Subsequent DST SM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>jC2yaMqEOPb</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
        <td>Initial DST SM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>jD5CwNpVmb3</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
        <td>Initial DST SM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - critical concentration (Mfx CC), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Jps4U0wxlyI</td>
      </tr>
      <tr>
        <td>Treatment First-line - Inh</td>
        <td>Treatment First-line - Inh</td>
        <td></td>
        <td>Isoniazid (Inh)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>jVBbPLaiuVD</td>
      </tr>
      <tr>
        <td>TB: second-line treatment start date</td>
        <td>Second-line treatment start date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>KbBzirlv7BU</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
        <td>Subsequent DST LM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>KJ55m8WkSCO</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Lzd</td>
        <td>Treatment Second-line - Lzd</td>
        <td></td>
        <td>Linezolid (Lzd)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>kK2Y5O5urC0</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
        <td>Initial DST LM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>KWijdprKE8o</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert Ultra specimen number</td>
        <td>Xpert Ultra specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>Lf02pJ3jScn</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
        <td>Initial DST SM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - clinical breakpoint (Mfx CB), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>LgnTOBA3Fuk</td>
      </tr>
      <tr>
        <td>TB Outcome - Case denotification</td>
        <td>Not TB</td>
        <td></td>
        <td>Cases that are enrolled in the TB programme, but later determined not to be TB cases.</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>Lj1yD6S1Qio</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert Ultra results - MTB</td>
        <td>Xpert Ultra MTB</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>lmXKhJA5nk1</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Cap</td>
        <td>Treatment Second-line - Cap</td>
        <td></td>
        <td>Capreomycin (Cap)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>LOo4b0NvlQx</td>
      </tr>
      <tr>
        <td>TB Lab: LF-LAM MTB</td>
        <td>LF-LAM MTB</td>
        <td></td>
        <td>LF-LAM MTB</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>Lr8yX1aTLf4</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
        <td>Initial DST SM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>LRfRdS1tsMK</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
        <td>Initial DST SM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>m1qdvx91gZz</td>
      </tr>
      <tr>
        <td>TB Lab: LPA FQ/2LI Specimen Number</td>
        <td>LPA FQ 2LI specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>M3tqCBDxR4a</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
        <td>Xpert MTB/RIF Ultra</td>
        <td></td>
        <td>Xpert MTB/RIF Ultra</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>MAItgXvlO5L</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert Ultra Result Date</td>
        <td>Xpert Ultra lab result date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>mFCcHXpopRD</td>
      </tr>
      <tr>
        <td>TB Lab: LF-LAM specimen number</td>
        <td>LF-LAM specimen number</td>
        <td></td>
        <td>LF-LAM specimen number</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>MFfdhf9yuYD</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Cs</td>
        <td>Treatment Second-line - Cs</td>
        <td></td>
        <td>Cycloserine (Cs)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>mVw0FXMqDK8</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
        <td>Initial DST SM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Na38GSfYww7</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
        <td>Subsequent DST SM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>nBVHqtynKKg</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
        <td>Initial DST LM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>nG3H0zGCpXg</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
        <td>Subsequent DST SM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>NIiZmSVFoFD</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Bdq</td>
        <td>Treatment Second-line - Bdq</td>
        <td></td>
        <td>Bedaquiline (Bdq)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>nnUlbhRUewx</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
        <td>Initial DST LM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>nulxcFUqHFK</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
        <td>Initial DST LM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>oKdArKmQaar</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Amx/Clv</td>
        <td>Treatment Second-line - Amx/Clv</td>
        <td></td>
        <td>Amoxicillin clavulanic acid (Amx/Clv)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>OlsWZhqz8ff</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
        <td>Subsequent DST LM - Emb</td>
        <td></td>
        <td>Drug susceptibility testing for Ethambutol (Emb), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>oVK7axGLOks</td>
      </tr>
      <tr>
        <td>TB Lab: Liquid culture specimen number</td>
        <td>Liquid culture specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-11-05</td>
        <td>oXBlG5tNThH</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
        <td>Initial DST LM - Inh CC</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - critical concentration (Inh CC), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>OXN8xMgpVvC</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
        <td>Initial DST SM</td>
        <td></td>
        <td>Initial phenotypic DST in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>OZV3tzf7bux</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
        <td>Subsequent DST LM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>P282EjwlnqS</td>
      </tr>
      <tr>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
        <td>LPA (Rif/Inh) - Specimen type</td>
        <td></td>
        <td>What specimen type was used for LPA?</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>p3L4HYkzU4o</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
        <td>Initial DST SM - Amk</td>
        <td></td>
        <td>Drug susceptibility testing for Amikacin (Amk), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>peAahjwkqNX</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
        <td>Subsequent DST LM - Lzd </td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Ps4JPDTACGB</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
        <td>Initial DST SM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>pTRWioGFFod</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
        <td>Initial DST LM - Pza</td>
        <td></td>
        <td>Drug susceptibility testing for Pyrazinamide (Pza), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Pvok4dVDC9n</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
        <td>Subsequent DST LM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>pXViXBpKM6Y</td>
      </tr>
      <tr>
        <td>TB Lab: Date RIF resistance first detected</td>
        <td>Date first RIF resistance</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>QDa04y5c0Bf</td>
      </tr>
      <tr>
        <td>TB Lab: LF-LAM Date</td>
        <td>LF-LAM Date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>qhbOlKrEPzT</td>
      </tr>
      <tr>
        <td>Treatment Second-line - PAS</td>
        <td>Treatment Second-line - PAS</td>
        <td></td>
        <td>p-aminosalicylic acid (PAS)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>qL9526SBPRh</td>
      </tr>
      <tr>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
        <td>Culture SM</td>
        <td></td>
        <td>Culture in solid media (e.g. LJ)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>QQEolquguCi</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
        <td>LPA (Fq/2LI) - Kan</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Kanamycin</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>qt2LpZN8Hb3</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
        <td>Subsequent DST SM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>R25K2kAAG4g</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
        <td>Initial DST LM - Lzd</td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>R4Lknzhufeh</td>
      </tr>
      <tr>
        <td>TB outcome due date</td>
        <td>TB outcome due</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>R9DL4SaAImg</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
        <td>Initial DST SM - Rif</td>
        <td></td>
        <td>Drug susceptibility testing for Rifampicin (Rif), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>RAtv78ZXQec</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
        <td>Subsequent DST LM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>rjMeZmOEivb</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Kan</td>
        <td>Treatment Second-line - Kan</td>
        <td></td>
        <td>Kanamycin (Kan)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>RL1d3jJf16t</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Lfx</td>
        <td>Treatment Second-line - Lfx</td>
        <td></td>
        <td>Levofloxacin (Lfx)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>ruxlza6qoxK</td>
      </tr>
      <tr>
        <td>Treatment regimen</td>
        <td>Regimen</td>
        <td></td>
        <td>Treatment regimen</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>s84QVMsGP0W</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI)</td>
        <td>LPA (Fq/2LI)</td>
        <td></td>
        <td>LPA (Fq/2LI)</td>
        <td>default</td>
        <td>2020-11-06</td>
        <td>Sd91IsXISjp</td>
      </tr>
      <tr>
        <td>TB: risk factor - smoking</td>
        <td>Risk factor smoking</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>T1KNskHm0zg</td>
      </tr>
      <tr>
        <td>TB Manually Assigned Resistance Classification</td>
        <td>Manual Resistance Classification</td>
        <td></td>
        <td>Manually Assigned Resistance Classification</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>T9YJ0gs7n3n</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Stm</td>
        <td>Treatment Second-line - Stm</td>
        <td></td>
        <td>Streptomycin (Stm)</td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>TgqKqIBTJ6U</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
        <td>Subsequent DST LM - Mfx CB</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - clinical breakpoint (Mfx CB), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>TJLwFGwpGFU</td>
      </tr>
      <tr>
        <td>TB Lab: Truenat MTB</td>
        <td>Truenat MTB</td>
        <td></td>
        <td>Truenat MTB</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>TPeXlGuQWUQ</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Eto</td>
        <td>Treatment Second-line - Eto</td>
        <td></td>
        <td>Ethionamide (Eto)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>tqSvdlcVdWn</td>
      </tr>
      <tr>
        <td>TB: risk factor - undernourishment</td>
        <td>Risk factor undernourishment</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>trTuuZ9xWgs</td>
      </tr>
      <tr>
        <td>TB Lab: Truenat Result Date</td>
        <td>Truenat Result Date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>TX30Ikr7clr</td>
      </tr>
      <tr>
        <td>TB Lab: Truenat specimen number</td>
        <td>Truenat specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>u1y2NS6qoIL</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>Subsequent DST LM</td>
        <td></td>
        <td>Subsequent DST in liquid media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>uaewAATQgBJ</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST Specimen Number (liquid nedia) </td>
        <td>Sub DST LM specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-12-09</td>
        <td>UAlFUPZp8Kt</td>
      </tr>
      <tr>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
        <td>Date of subsequent DST SM results</td>
        <td></td>
        <td>Date of final subsequent DST results (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>uEV8flIOeYI</td>
      </tr>
      <tr>
        <td>TB Lab: Solid culture lab result date</td>
        <td>Solid Culture lab result date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>uFkaH9jzpcp</td>
      </tr>
      <tr>
        <td>TB Lab: Solid culture specimen number</td>
        <td>Solid Culture specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>ug1acEAsTfd</td>
      </tr>
      <tr>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
        <td>Culture LM</td>
        <td></td>
        <td>Culture in liquid media (e.g. MGIT)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>uI7p5xLE1C8</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
        <td>LPA (Rif/Inh) - Inh</td>
        <td></td>
        <td>Final LPA (Rif/Inh) result for Isoniazid</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>UIzR3p4nlMI</td>
      </tr>
      <tr>
        <td>TB Lab: Date RIF resistance detected</td>
        <td>Date RIF resistance</td>
        <td> </td>
        <td>Date RIF resistance is detected. This is used to calculate the date that RIF resistance is FIRST detected, which is a separate data element.</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>UJ7JPl1LB9y</td>
      </tr>
      <tr>
        <td>TB: ART Patient ID</td>
        <td>ART ID</td>
        <td></td>
        <td>ART Number</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>ujCxCam6D0L</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
        <td>Subsequent DST LM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>un8hXdOPwzh</td>
      </tr>
      <tr>
        <td>TB Outcome - Duplicate's record number</td>
        <td>Duplicate's record number</td>
        <td></td>
        <td>Provide duplicate's record number</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>USgo6lDw8By</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Trd</td>
        <td>Treatment Second-line - Trd</td>
        <td></td>
        <td>Terizidone (Trd)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>V2Iyaaznzs5</td>
      </tr>
      <tr>
        <td>HIV status date</td>
        <td>HIV date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>V6RVBzCr3Kl</td>
      </tr>
      <tr>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
        <td>Date of LPA (Fq/2LI)</td>
        <td></td>
        <td>Date of LPA (Fq/2LI)</td>
        <td>default</td>
        <td>2020-11-06</td>
        <td>vezbpFOckNI</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Mfx</td>
        <td>Treatment Second-line - Mfx</td>
        <td></td>
        <td>Moxifloxacin (Mfx)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>vKSjnMPHR6F</td>
      </tr>
      <tr>
        <td>TB Lab: LPA RIF/INH Specimen Number</td>
        <td>LPA RIF INH specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>VpFIxl7ZX7n</td>
      </tr>
      <tr>
        <td>TB Lab: Xpert MTB/RIF</td>
        <td>Xpert MTB/RIF</td>
        <td></td>
        <td>Xpert MTB/RIF</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>VSuQ1rwL2nA</td>
      </tr>
      <tr>
        <td>TB Lab: Truenat RIF</td>
        <td>Truenat RIF</td>
        <td></td>
        <td>Truenat RIF</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>vVLgOXwlIVj</td>
      </tr>
      <tr>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
        <td>Date of initial DST LM results</td>
        <td></td>
        <td>Date of final initial DST results (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Wg7Df5kgpaF</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
        <td>Initial DST SM - Inh CB</td>
        <td></td>
        <td>Drug susceptibility testing for Isoniazid - clinical breakpoint (Inh CB), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>wgEYFWwfv7z</td>
      </tr>
      <tr>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
        <td>Date of subsequent DST LM results</td>
        <td></td>
        <td>Date of final subsequent DST results (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>wi4NRarMSuv</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
        <td>LPA (Fq/2LI) - Emb</td>
        <td></td>
        <td>Final LPA (Fq/2LI) result for Ethambutol</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>WLaOsGs9ujA</td>
      </tr>
      <tr>
        <td>ART start date</td>
        <td>ART start date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>WrG6slZ7nlG</td>
      </tr>
      <tr>
        <td>TB: Treatment outcome</td>
        <td>Treatment outcome</td>
        <td></td>
        <td>Treatment Outcome</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>wtZuz8Im69G</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
        <td>Initial DST LM - Dlm</td>
        <td></td>
        <td>Drug susceptibility testing for Delamanid (Dlm), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>wzPWimo6vO3</td>
      </tr>
      <tr>
        <td>Current Address - Coordinates</td>
        <td>Current Address</td>
        <td></td>
        <td>Current address coordinates</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>x8RVc1REj1q</td>
      </tr>
      <tr>
        <td>TB Lab: Liquid culture lab result date</td>
        <td>Liquid Culture lab result date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>xagezRGPgQo</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST Solid Media Specimen Number</td>
        <td>Init DST SM specimen number</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>XcVFoGVN5Bu</td>
      </tr>
      <tr>
        <td>TB: Site of disease</td>
        <td>Site of disease</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>XfqbpoBl2VS</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
        <td>Initial DST SM - Lzd</td>
        <td></td>
        <td>Drug susceptibility testing for Linezolid (Lzd), initial DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>xP5C3zmYXde</td>
      </tr>
      <tr>
        <td>TB Lab: Date of microscopy</td>
        <td>Date of microscopy result</td>
        <td></td>
        <td>Date of microscopy</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>xyczZvsuaWr</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
        <td>Subsequent DST SM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin - critical concentration (Mfx CC), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>xZfTs7RfeIU</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
        <td>Subsequent DST SM - Lfx</td>
        <td></td>
        <td>Drug susceptibility testing for Levofloxacin (Lfx), subsequent DST (solid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>Y1VpjCBrpEc</td>
      </tr>
      <tr>
        <td>TB: ART started</td>
        <td>ART started</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>Y4W9L0ROIts</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
        <td>Initial DST LM - Mfx CC</td>
        <td></td>
        <td>Drug susceptibility testing for Moxifloxacin CC (Mfx CC), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>yiGr4JTFLv3</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Pa</td>
        <td>Treatment Second-line - Pa</td>
        <td></td>
        <td>Pretomanid (Pa)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>yIyB5VNxh1O</td>
      </tr>
      <tr>
        <td>Treatment Second-line - Pto</td>
        <td>Treatment Second-line - Pto</td>
        <td></td>
        <td>Prothionamide (Pto)</td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>yQzILNttTKR</td>
      </tr>
      <tr>
        <td>TB: risk factor - alcohol</td>
        <td>Risk factor alcohol</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>Yt8rEcU2HKC</td>
      </tr>
      <tr>
        <td>TB first-line treatment start date</td>
        <td>First-line treatment start date</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>yxz1b5sB5sg</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
        <td>LPA (Fq/2LI) - MTB</td>
        <td></td>
        <td>LPA (Fq/2LI) - MTB</td>
        <td>default</td>
        <td>2020-11-06</td>
        <td>z0j1fZQHoSB</td>
      </tr>
      <tr>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
        <td>Subsequent DST LM - Bdq</td>
        <td></td>
        <td>Drug susceptibility testing for Bedaquiline (Bdq), subsequent DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>zcmsN575vwZ</td>
      </tr>
      <tr>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
        <td>LPA (Rif/Inh) - MTB</td>
        <td></td>
        <td>LPA (Rif/Inh) - MTB</td>
        <td>default</td>
        <td>2020-11-06</td>
        <td>Zd7703kfnOC</td>
      </tr>
      <tr>
        <td>TB Lab: Smear specimen result</td>
        <td>Microscopy result</td>
        <td></td>
        <td></td>
        <td>default</td>
        <td>2020-10-16</td>
        <td>Zos365qSyj0</td>
      </tr>
      <tr>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
        <td>Initial DST LM - Cfz</td>
        <td></td>
        <td>Drug susceptibility testing for Clofazimine (Cfz), initial DST (liquid media)</td>
        <td>default</td>
        <td>2020-11-16</td>
        <td>ZSL9PI7Kbsa</td>
      </tr>
    </table>
    <h2>Data Element Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Case Surveillance</td>
        <td>2020-10-16</td>
        <td>K97n4JS39z9</td>
      </tr>
    </table>
    <h3>Data Element Groups - Data Elements</h3>
    <table>
      <tr>
        <th>Data Element Group</th>
        <th>Data Element</th>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: TB-LAMP</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Pza</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: Treatment Outcome delay (weeks)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: TB-LAMP specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: Treatment Initiation delay (days)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Dlm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: TB-LAMP Date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: TB-LAMP MTB</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date of initial DST results (solid media)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Fq/2LI) - Amk/Cap</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Solid culture specimen test result</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: Reassign Resistance Classification</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert Result Date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Registration: Previous treatment history</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert results - MTB</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert Ultra results - RIF</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date of LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Other</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Sputum smear microscopy</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Ipm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media)- Amk</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment First-line - Rif</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Lzd </td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Fq/2LI) - Fq</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: risk factor - diabetes</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST Specimen Number (solid media)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>HIV Infection</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Outcome - Reason for case denotification</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Mpm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Outcome - Not TB case (Explanation)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment First-line - Emb</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert results - RIF</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Specimen type used for LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Rif/Inh) - Rif</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Smear specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment First-line - Pza</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Truenat</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Emb</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Cfz</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Amk</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Liquid culture specimen test result</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Registration: Second-line drugs</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LF-LAM</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Other drug - specify</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Amk</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Resistance Classification</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST Liquid Media Specimen Number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment First-line - Inh</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: second-line treatment start date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Lzd</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert Ultra specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Outcome - Case denotification</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert Ultra results - MTB</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Cap</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LF-LAM MTB</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Pza</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Emb</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA FQ/2LI Specimen Number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert MTB/RIF Ultra</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert Ultra Result Date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LF-LAM specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Cs</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Cfz</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Bdq</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Amx/Clv</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Emb</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Liquid culture specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Inh (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Cfz</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Specimen type used for LPA (Rif/Inh)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Amk</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lzd</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Pza</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Rif</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date RIF resistance first detected</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LF-LAM Date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - PAS</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Culture in solid media (e.g. LJ)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Fq/2LI) - Kan</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Lzd </td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB outcome due date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Rif</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Kan</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Lfx</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment regimen</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: risk factor - smoking</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Manually Assigned Resistance Classification</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Stm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Mfx (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Truenat MTB</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Eto</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: risk factor - undernourishment</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Truenat Result Date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Truenat specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST Specimen Number (liquid nedia) </td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date of subsequent DST results (solid media)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Solid culture lab result date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Solid culture specimen number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Culture in liquid media (e.g. MGIT)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Rif/Inh) - Inh</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date RIF resistance detected</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: ART Patient ID</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Outcome - Duplicate's record number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Trd</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>HIV status date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date of LPA (Fq/2LI)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Mfx</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA RIF/INH Specimen Number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Xpert MTB/RIF</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Truenat RIF</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date of initial DST results (liquid media)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Inh (CB)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date of subsequent DST results (liquid media)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Fq/2LI) - Emb</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>ART start date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: Treatment outcome</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Dlm</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Current Address - Coordinates</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Liquid culture lab result date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST Solid Media Specimen Number</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: Site of disease</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (solid media) - Lzd</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Date of microscopy</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (solid media) - Lfx</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: ART started</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Mfx (CC)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Pa</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>Treatment Second-line - Pto</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB: risk factor - alcohol</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB first-line treatment start date</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Fq/2LI) - MTB</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Subsequent DST (liquid media) - Bdq</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: LPA (Rif/Inh) - MTB</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Smear specimen result</td>
      </tr>
      <tr>
        <td>TB Case Surveillance</td>
        <td>TB Lab: Initial DST (liquid media) - Cfz</td>
      </tr>
    </table>
    <h2 id="categoryCombos">Category Combinations</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Categories</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-11-05</td>
        <td>bjDvmb4bfuf</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categories">Data Element Categories</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Category options</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-12-09</td>
        <td>GLevLNI9wkl</td>
        <td>default</td>
      </tr>
    </table>
    <h2 id="categoryOptions">Data Element Category Options</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-11-05</td>
        <td>xYerKDKCefk</td>
      </tr>
    </table>
    <h2 id="categoryOptionCombos">Category Option Combination</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>default</td>
        <td>2020-11-05</td>
        <td>HllvX50cXC0</td>
      </tr>
    </table>
    <h2 id="optionSets">Option Sets</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
        <th>Options</th>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>2020-08-04</td>
        <td>bLA3AqDKdwx</td>
        <td>Yes; No; Unknown</td>
      </tr>
      <tr>
        <td>TB treatment history</td>
        <td>2020-10-16</td>
        <td>cEiPBSWUO5S</td>
        <td>New; Relapse; Treatment after failure; Treatment after lost to follow-up; Other previously treated; Unknown</td>
      </tr>
      <tr>
        <td>TB treatment category</td>
        <td>2020-10-16</td>
        <td>dT4kJgZc1lj</td>
        <td>First-line Treatment; Second-line Treatment</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>2020-10-16</td>
        <td>ekhfzhURD44</td>
        <td>Susceptible; Resistant; Contaminated; Indeterminate</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>2020-11-16</td>
        <td>eUBlAbh0g2h</td>
        <td>Detected; Not detected; Error; Invalid; No result</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>2020-09-02</td>
        <td>hiQ3QFheQ3O</td>
        <td>Male; Female</td>
      </tr>
      <tr>
        <td>TB treatment outcome</td>
        <td>2020-08-04</td>
        <td>ITvFkEpEsfp</td>
        <td>Cured; Completed; Failed; Died; Lost to follow-up; Not evaluated</td>
      </tr>
      <tr>
        <td>TB site of disease</td>
        <td>2020-10-16</td>
        <td>jcuKftMQQaa</td>
        <td>Pulmonary; Extra-pulmonary; Pulmonary and extra-pulmonary</td>
      </tr>
      <tr>
        <td>TB Resistance Classification</td>
        <td>2020-10-16</td>
        <td>kWeUuhzCjD6</td>
        <td>DS (drug-susceptible TB); RR (rifampicin resistant TB); MDR (multidrug resistant TB); XDR (extensive drug resistant TB)</td>
      </tr>
      <tr>
        <td>TB - Denotification reasons</td>
        <td>2020-10-16</td>
        <td>nJY9CwyaYij</td>
        <td>Not a TB Case; Duplicate</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>2020-08-04</td>
        <td>oKESbY0JpLt</td>
        <td>Sputum samples or sediments; MTB culture isolates</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>2020-10-16</td>
        <td>q75AsvLUWVp</td>
        <td>Susceptible; Resistant; Indeterminate</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>2020-10-16</td>
        <td>rB88xT5ggFg</td>
        <td>MTB; NTM; No growth; Contaminated</td>
      </tr>
      <tr>
        <td>Positive/Negative</td>
        <td>2020-10-16</td>
        <td>WaV48ymJu9V</td>
        <td>Positive; Negative</td>
      </tr>
    </table>
    <h2 id="options">Options</h2>
    <table>
      <tr>
        <th>Option Set Name</th>
        <th>Name</th>
        <th>Code</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Detected</td>
        <td>DETECTED</td>
        <td>2020-10-16</td>
        <td>aIKhwpm3xjg</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Female</td>
        <td>FEMALE</td>
        <td>2020-08-04</td>
        <td>AZK4rjJCss5</td>
      </tr>
      <tr>
        <td>TB Resistance Classification</td>
        <td>MDR (multidrug resistant TB)</td>
        <td>MDR</td>
        <td>2020-10-16</td>
        <td>bMHKsYkUzLA</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Indeterminate</td>
        <td>INDETERMINATE</td>
        <td>2020-10-16</td>
        <td>bOnWRnVw30P</td>
      </tr>
      <tr>
        <td>TB - Denotification reasons</td>
        <td>Not a TB Case</td>
        <td>NOT_TB</td>
        <td>2020-10-16</td>
        <td>brTCJsqltgu</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Indeterminate</td>
        <td>INDETERMINATE</td>
        <td>2020-10-16</td>
        <td>cqyKiKWzg1m</td>
      </tr>
      <tr>
        <td>TB treatment outcome</td>
        <td>Died</td>
        <td>DIED</td>
        <td>2020-06-29</td>
        <td>Cr4yBYTVQKe</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Yes</td>
        <td>YES</td>
        <td>2020-08-04</td>
        <td>CvivP1rh4ii</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Contaminated</td>
        <td>CONTAMINATED</td>
        <td>2020-08-04</td>
        <td>eeiCaPcf3ZX</td>
      </tr>
      <tr>
        <td>TB treatment outcome</td>
        <td>Not evaluated</td>
        <td>NOT_EVALUATED</td>
        <td>2020-06-29</td>
        <td>F5HHfyhxEVb</td>
      </tr>
      <tr>
        <td>TB treatment outcome</td>
        <td>Failed</td>
        <td>FAILURE</td>
        <td>2020-06-29</td>
        <td>fBzrcckMN32</td>
      </tr>
      <tr>
        <td>TB - Denotification reasons</td>
        <td>Duplicate</td>
        <td>DUPLICATE</td>
        <td>2020-10-16</td>
        <td>Fk9C13dup31</td>
      </tr>
      <tr>
        <td>TB site of disease</td>
        <td>Pulmonary and extra-pulmonary</td>
        <td>SITE_BOTH</td>
        <td>2020-10-16</td>
        <td>FPR377Jsqiu</td>
      </tr>
      <tr>
        <td>TB treatment outcome</td>
        <td>Lost to follow-up</td>
        <td>LOST_TO_FOLLOW_UP</td>
        <td>2020-06-29</td>
        <td>HabQuRUu60c</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Error</td>
        <td>ERROR</td>
        <td>2020-11-16</td>
        <td>Hv5WIheOqCR</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>Sputum samples or sediments</td>
        <td>SPUTUM_SAMPLES_OR_SEDIMENTS</td>
        <td>2020-08-04</td>
        <td>io6qvQDAP8r</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>No growth</td>
        <td>NO_GROWTH</td>
        <td>2020-11-05</td>
        <td>iRIdWqmsuhn</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>Contaminated</td>
        <td>CONTAMINATED</td>
        <td>2020-08-04</td>
        <td>Ix8MPUuGZXD</td>
      </tr>
      <tr>
        <td>TB treatment category</td>
        <td>First-line Treatment</td>
        <td>FIRST_LINE_TREATMENT</td>
        <td>2020-10-16</td>
        <td>jASklx0TkjA</td>
      </tr>
      <tr>
        <td>TB Resistance Classification</td>
        <td>XDR (extensive drug resistant TB)</td>
        <td>XDR</td>
        <td>2020-10-16</td>
        <td>JSnowcsawur</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2020-06-29</td>
        <td>jwk0lGLsonq</td>
      </tr>
      <tr>
        <td>Positive/Negative</td>
        <td>Negative</td>
        <td>NEGATIVE</td>
        <td>2020-06-29</td>
        <td>K2uAuIFc3Ym</td>
      </tr>
      <tr>
        <td>TB treatment history</td>
        <td>Other previously treated</td>
        <td>HISTORY_OTHER_PREV</td>
        <td>2020-10-16</td>
        <td>KZEdgNfplu0</td>
      </tr>
      <tr>
        <td>TB site of disease</td>
        <td>Extra-pulmonary</td>
        <td>SITE_EXTRA_PULMONARY</td>
        <td>2020-10-16</td>
        <td>La2NLASuNEI</td>
      </tr>
      <tr>
        <td>TB Resistance Classification</td>
        <td>DS (drug-susceptible TB)</td>
        <td>DS</td>
        <td>2020-10-16</td>
        <td>nnWDmxPRacc</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2020-11-05</td>
        <td>O9zjp4LJUeu</td>
      </tr>
      <tr>
        <td>TB site of disease</td>
        <td>Pulmonary</td>
        <td>SITE_PULMONARY</td>
        <td>2020-10-16</td>
        <td>oLTrGldDO1u</td>
      </tr>
      <tr>
        <td>Susceptible/Resistant/Indeterminate</td>
        <td>Susceptible</td>
        <td>SUSCEPTIBLE</td>
        <td>2020-11-05</td>
        <td>p3SXa0Go6cJ</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>No</td>
        <td>NO</td>
        <td>2020-11-05</td>
        <td>PLlPgcfbL1D</td>
      </tr>
      <tr>
        <td>TB treatment category</td>
        <td>Second-line Treatment</td>
        <td>SECOND_LINE_TREATMENT</td>
        <td>2020-10-16</td>
        <td>PtV4QCiCFTh</td>
      </tr>
      <tr>
        <td>TB treatment history</td>
        <td>Treatment after lost to follow-up</td>
        <td>HISTORY_LOST_TO_FOLLOWUP</td>
        <td>2020-10-16</td>
        <td>QAujTw5GXFt</td>
      </tr>
      <tr>
        <td>TB treatment history</td>
        <td>Relapse</td>
        <td>HISTORY_RELAPSE</td>
        <td>2020-10-16</td>
        <td>QhTtV5VMRpn</td>
      </tr>
      <tr>
        <td>TB treatment history</td>
        <td>Treatment after failure</td>
        <td>HISTORY_FAILED</td>
        <td>2020-10-10</td>
        <td>qpIqHMGtCw6</td>
      </tr>
      <tr>
        <td>TB treatment history</td>
        <td>Unknown</td>
        <td>HISTORY_UNKNOWN</td>
        <td>2020-06-28</td>
        <td>RGG610pGTQf</td>
      </tr>
      <tr>
        <td>TB DST result</td>
        <td>Resistant</td>
        <td>RESISTANT</td>
        <td>2020-11-05</td>
        <td>RrdcLAuvPke</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Invalid</td>
        <td>INVALID</td>
        <td>2020-11-16</td>
        <td>rw8mrcHxfHg</td>
      </tr>
      <tr>
        <td>Yes/No/Unknown</td>
        <td>Unknown</td>
        <td>UNKNOWN</td>
        <td>2020-08-04</td>
        <td>TKD1XJ4ZhMO</td>
      </tr>
      <tr>
        <td>TB Resistance Classification</td>
        <td>RR (rifampicin resistant TB)</td>
        <td>RR</td>
        <td>2020-10-16</td>
        <td>tN7FVrN8pXn</td>
      </tr>
      <tr>
        <td>TB treatment outcome</td>
        <td>Cured</td>
        <td>CURED</td>
        <td>2020-06-29</td>
        <td>ua2ffBFlL04</td>
      </tr>
      <tr>
        <td>Sex</td>
        <td>Male</td>
        <td>MALE</td>
        <td>2020-08-04</td>
        <td>UrUdMteQzlT</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>MTB</td>
        <td>MTB</td>
        <td>2020-08-13</td>
        <td>UsugTEaeBhi</td>
      </tr>
      <tr>
        <td>TB treatment history</td>
        <td>New</td>
        <td>HISTORY_NEW</td>
        <td>2020-10-16</td>
        <td>XTd3y2UBFbU</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>Not detected</td>
        <td>NOT_DETECTED</td>
        <td>2020-10-16</td>
        <td>YMFMcGchVjk</td>
      </tr>
      <tr>
        <td>TB Final Culture Result</td>
        <td>NTM</td>
        <td>NTM</td>
        <td>2020-08-13</td>
        <td>YoZDgCMUpJy</td>
      </tr>
      <tr>
        <td>TB treatment outcome</td>
        <td>Completed</td>
        <td>COMPLETED</td>
        <td>2020-06-29</td>
        <td>Yrl4wFxjfpp</td>
      </tr>
      <tr>
        <td>TB DRS LPA Specimen</td>
        <td>MTB culture isolates</td>
        <td>MTB_CULTURE_ISOLATES</td>
        <td>2020-08-04</td>
        <td>zAH62QSxRYh</td>
      </tr>
      <tr>
        <td>Positive/Negative</td>
        <td>Positive</td>
        <td>POSITIVE</td>
        <td>2020-06-29</td>
        <td>zdSmHv0Gc9x</td>
      </tr>
      <tr>
        <td>TB MTB test result</td>
        <td>No result</td>
        <td>NO_RESULT</td>
        <td>2020-11-16</td>
        <td>znxRpLrCUNj</td>
      </tr>
    </table>
    <h2 id="indicatorGroups">Indicator Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td></td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
    </table>
    <h3>Indicator Groups - Indicators</h3>
    <table>
      <tr>
        <th>Indicator Group</th>
        <th>Indicator</th>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td>TB - Completed (New and relapse DS-TB) (%)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td>TB - Lost to follow-up (New and relapse DS-TB) (%)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td>TB - Died (New and relapse DS-TB) (%)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td>TB - Failed (New and relapse DS-TB) (%)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td>TB - Treatment success rate for new and relapse DS-TB (%)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td>TB - Cured (New and relapse DS-TB) (%)</td>
      </tr>
      <tr>
        <td>TB Case Surveillance (Tracker)</td>
        <td>TB - Not evaluated (New and relapse DS-TB) (%)</td>
      </tr>
    </table>
    <h2 id="indicators">Indicators</h2>
    <table>
      <tr>
        <th>UID</th>
        <th>Name</th>
        <th>Shortname</th>
        <th>Code</th>
        <th>Description</th>
        <th>Numerator</th>
        <th>Denominator</th>
        <th>Type</th>
        <th>Last updated</th>
        <th>Indicator group UID</th>
      </tr>
      <tr>
        <td>bQNk7XfCVaT</td>
        <td>TB - Completed (New and relapse DS-TB) (%)</td>
        <td>Completed (New and relapse DS-TB) (%)</td>
        <td></td>
        <td></td>
        <td>Completed (DS-TB)</td>
        <td>Total new and relapse registered</td>
        <td>Percentage</td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
      <tr>
        <td>COt9AAFSa8i</td>
        <td>TB - Lost to follow-up (New and relapse DS-TB) (%)</td>
        <td>Lost-to-follow-up (New and relapse DS-TB) (%)</td>
        <td></td>
        <td></td>
        <td>Lost to follow-up (DS-TB)</td>
        <td>Total new and relapse registered</td>
        <td>Percentage</td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
      <tr>
        <td>hRnrxBIhyDF</td>
        <td>TB - Died (New and relapse DS-TB) (%)</td>
        <td>Died (New and relapse DS-TB) (%)</td>
        <td></td>
        <td></td>
        <td>Died (DS-TB)</td>
        <td>Total new and relapse registered</td>
        <td>Percentage</td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
      <tr>
        <td>RFHqjdWbiF0</td>
        <td>TB - Failed (New and relapse DS-TB) (%)</td>
        <td>Failed (New and relapse DS-TB) (%)</td>
        <td></td>
        <td></td>
        <td>Failed (DS-TB)</td>
        <td>Total new and relapse registered</td>
        <td>Percentage</td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
      <tr>
        <td>VsOw9l8nTib</td>
        <td>TB - Treatment success rate for new and relapse DS-TB (%)</td>
        <td>Cured/completed DS-TB (%)</td>
        <td></td>
        <td></td>
        <td>New and relapse DS-TB: cured and completed</td>
        <td>New and relapse cases registered</td>
        <td>Percentage</td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
      <tr>
        <td>Vx27NM3lvXP</td>
        <td>TB - Cured (New and relapse DS-TB) (%)</td>
        <td>Cured (New and relapse DS-TB) (%)</td>
        <td></td>
        <td></td>
        <td>Cured (DS-TB)</td>
        <td>Total new and relapse registered</td>
        <td>Percentage</td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
      <tr>
        <td>yomoDu4G8da</td>
        <td>TB - Not evaluated (New and relapse DS-TB) (%)</td>
        <td>Not evaluated (New and relapse DS-TB) (%)</td>
        <td></td>
        <td></td>
        <td>Not evaluated (DS-TB)</td>
        <td>Total new and relapse registered</td>
        <td>Percentage</td>
        <td>2020-10-16</td>
        <td>tAKC8OODCJl</td>
      </tr>
    </table>
    <h2 id="indicatorTypes">Indicator types</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Factor</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Percentage</td>
        <td>100</td>
        <td>2020-11-05</td>
        <td>e1jRVY5Mcq0</td>
      </tr>
    </table>
    <h2 id="programIndicatorGroups">Program Indicator Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Shortname</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB (For Aggregate Reporting)</td>
        <td></td>
        <td>2020-10-16</td>
        <td>ByComvoqyPP</td>
      </tr>
      <tr>
        <td>TB Case Surveillance (core)</td>
        <td></td>
        <td>2020-10-16</td>
        <td>GKaacrZF7iJ</td>
      </tr>
      <tr>
        <td>TB Case Surveillance - GTB Report</td>
        <td></td>
        <td>2020-10-16</td>
        <td>rfOllbK3gIL</td>
      </tr>
    </table>
    <h3>Program Indicator Groups - Program Indicators</h3>
    <table>
      <tr>
        <th>Prog.Ind. UID</th>
        <th>Program Indicator Group</th>
        <th>Program Indicator</th>
        <th>Program Indicator UID</th>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: not evaluated - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>AMBYD2z0chD</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: lost to follow-up - confirmed XDR cases on second line regimen</td>
        <td>aRIhTkvSCDu</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Previously treated (excluding relapses) pulmonary TB cases, bacteriologically confirmed</td>
        <td>aSliDbjlhox</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Unknown treatment history patients tested for susceptibility to rifampicin</td>
        <td>azNkWe4xzP6</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Unknown treatment history extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>B9OaviyjiPC</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Unknown treatment history pulmonary TB cases, clinically diagnosed</td>
        <td>bxCmHHPPzDQ</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: not evaluated - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>cQKLW4zJWY7</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: not evaluated - previously treated (excluding relapse) cases</td>
        <td>cuS1pT1wWAn</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome - previously treated (excluding relapse) cases registered (cohort)</td>
        <td>czdztQdLtvp</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 45-54 years female</td>
        <td>D3eZeSgzOhV</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 5-14 years male</td>
        <td>D6fmWXsg4pM</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: not evaluated - TB/HIV new and relapse cases</td>
        <td>Eb9Gd37H6aO</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment failed - clinically diagnosed new and relapse cases</td>
        <td>eJbF4wquzx4</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: lost to follow-up - TB/HIV new and relapse cases</td>
        <td>eLkTBRFURvg</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment completed - TB/HIV new and relapse cases</td>
        <td>FMqTHEACG9S</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New patients tested for susceptibility to rifampicin</td>
        <td>FZwrly5hxUk</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New pulmonary TB cases, clinically diagnosed</td>
        <td>G3g4XfQKemC</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: not evaluated - bacteriologically confirmed new and relapse cases</td>
        <td>GH7d54KUSXT</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Relapse pulmonary TB cases, clinically diagnosed</td>
        <td>gS5n5YA7pDZ</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome - clinically diagnosed new and relapse cases registered (cohort)</td>
        <td>GYEaZfyLm4T</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>Tested for RR-TB</td>
        <td>HMxJoOFyaC6</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - TB/HIV - HIV status positive</td>
        <td>iQS9zGYpokL</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Relapse pulmonary TB cases, bacteriologically confirmed</td>
        <td>J5dqOCSj047</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: death - bacteriologically confirmed new and relapse cases</td>
        <td>JrUWL08Ddnv</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: cured - bacteriologically confirmed new and relapse cases</td>
        <td>jSEquR6y8Fx</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Unknown treatment history pulmonary TB cases, bacteriologically confirmed</td>
        <td>jvbwDQuzrcA</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 15-24 years female</td>
        <td>jwKEkp66bbi</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: lost to follow-up - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>KgPvXVYytRH</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 55-64 years male</td>
        <td>kmDgwo2xyPG</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment completed - clinically diagnosed new and relapse cases</td>
        <td>kQp74SERV3T</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 65+ years female</td>
        <td>kvIrnIoJAYR</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: death - TB/HIV new and relapse cases</td>
        <td>LichImvUvB6</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 25-34 years female</td>
        <td>lmlfITJdHAw</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Patients with presumptive TB with positive bacteriological examination results</td>
        <td>lv098ob7lcD</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: death - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>lXNyCenjXnr</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: lost to follow-up - clinically diagnosed new and relapse cases</td>
        <td>mvlf2nQYvV9</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 35-44 years male</td>
        <td>mweuNzij888</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: cured - previously treated (excluding relapse) cases</td>
        <td>MyOZiGalvsI</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment failed - previously treated (excluding relapse) cases</td>
        <td>Ndssi9W1fix</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Relapse extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>NfgFScH9jCr</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: death - confirmed XDR cases on second line regimen</td>
        <td>NRdnhrWhU5x</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: not evaluated - clinically diagnosed new and relapse cases</td>
        <td>NRHSfORo0MH</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Previously treated extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>Nrit96cdaRl</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: cured - confirmed XDR cases on second line regimen</td>
        <td>oPnDPdsC9Ic</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 45-54 years male</td>
        <td>oSaoqqQ2MSt</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed</td>
        <td>oVD0Omx832C</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 35-44 years female</td>
        <td>OwzSNSMtcgA</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment completed - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>oYKZO6PawO4</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 0-4 years male</td>
        <td>p37LM8QH1y5</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Laboratory-confirmed RR-TB or MDR-TB cases</td>
        <td>pkN8Etipkfm</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 5-14 years female</td>
        <td>PQhiQM94UYf</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 25-34 years male</td>
        <td>QbplzyMJIHI</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment failed - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>QC5QxnAGu9D</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Previously treated pulmonary TB cases, clinically diagnosed</td>
        <td>rCh3rLTcUpi</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment completed - bacteriologically confirmed new and relapse cases</td>
        <td>rMDJ40j7Gdz</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Laboratory confirmed MDR-TB cases (excluding XDR)</td>
        <td>rp8sBCRlPXK</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment failed - bacteriologically confirmed new and relapse cases</td>
        <td>RQ3sKIsE5TJ</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: cured - TB/HIV new and relapse cases</td>
        <td>rrtwzWk80lS</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - TB/HIV - HIV positive on ART</td>
        <td>Rz1R6RuKUwJ</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment failed - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>S1QUkIjBtRh</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment failed - TB/HIV new and relapse cases</td>
        <td>SaXYEOgPoae</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 65+ years male</td>
        <td>SgOZ40SAyBF</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: death - clinically diagnosed new and relapse cases</td>
        <td>szVjaIR5Y0w</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: lost to follow-up - previously treated (excluding relapse) cases</td>
        <td>TKh36q9byZ2</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment failed - confirmed XDR cases on second line regimen</td>
        <td>tKlafE4iYmF</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Previously treated patients tested for susceptibility to rifampicin</td>
        <td>TO5t4GynFmy</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: death - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>tRlRFI5clem</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Not laboratory-confirmed RR and MDR cases who started treatment for MDR-TB</td>
        <td>ubKa6QPpGPU</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome - TB/HIV new and relapse cases registered (cohort)</td>
        <td>usOS0aEFimg</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Patients with presumptive TB undergoing bacteriological examination</td>
        <td>uxRQkvPX3O0</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - TB/HIV - New and relapse TB cases, tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis</td>
        <td>uyJRjx7Kg62</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 15-24 years male</td>
        <td>V14skZKSqwe</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Patients (laboratory-confirmed RR-TB or MDR-TB) who started treatment for MDR-TB</td>
        <td>vlzsn2ahiPt</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome - bacteriologically confirmed new and relapse cases registered (cohort)</td>
        <td>Vq2QZrz5t7e</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment completed - confirmed XDR cases on second line regimen</td>
        <td>vuG9jUefhvX</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 55-64 years female</td>
        <td>wGetVr8DIzX</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New and relapse TB cases - 0-4 years female</td>
        <td>wHpLgrq0RhX</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: lost to follow-up - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>WR5MkUOzYQx</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR) (cohort)</td>
        <td>WXGJbirp6DL</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment completed - previously treated (excluding relapse) cases</td>
        <td>XvDSvGx9euM</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: death - previously treated (excluding relapse) cases</td>
        <td>Y4IC1OjAdf3</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: lost to follow-up - bacteriologically confirmed new and relapse cases</td>
        <td>Y8wvwRgGcUS</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: not evaluated - confirmed XDR cases on second line regimen</td>
        <td>YsxMI4Dv7s7</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR) (cohort)</td>
        <td>yVo8pfW8opl</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: cured - confirmed RR and MDR cases on second-line treatment regimen (excluding XDR)</td>
        <td>Z7r9H312QOu</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: cured - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>ZeSCOQzujFZ</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome - confirmed XDR cases on second line regimen (cohort)</td>
        <td>zgjfcJiBlED</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - Outcome: treatment completed - confirmed RR and MDR HIV-positive cases on second-line treatment regimen (excluding XDR)</td>
        <td>ZkenguAQ0U6</td>
      </tr>
      <tr>
        <td>ByComvoqyPP</td>
        <td>TB (For Aggregate Reporting)</td>
        <td>TB_AGG - New pulmonary TB cases, bacteriologically confirmed</td>
        <td>zUjUpQKcgc9</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB smear negative cases confirmed by Xpert/Xpert Ultra</td>
        <td>A6QW5Se4bN1</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB patients with no outcome record</td>
        <td>C77Z0rBR6tf</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>Previously treated cases (all TB forms)</td>
        <td>fv2mi0z837P</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB smear positive cases confirmed by Xpert/Xpert Ultra</td>
        <td>fW00N22cQKu</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB - Cases that have not started on treatment</td>
        <td>GNgsosCnVv3</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse DS-TB cases registered in the previous year - Failed</td>
        <td>gXdZvVlriyU</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>Days from RIF resistance detected to start of second-line treatment</td>
        <td>HdGEwlnAt84</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New cases (all TB forms)</td>
        <td>HhHwJurxok6</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>Tested for RR-TB</td>
        <td>HMxJoOFyaC6</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB cases confirmed by Sputum Smear Microscopy</td>
        <td>IanRArM3Oyg</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB cases with valid test result for rifampicin</td>
        <td>j40qQvDbCZU</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB confirmed RR cases (excluding MDR and XDR)</td>
        <td>jqPP4x1pJP0</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse DS-TB cases registered in the previous year - Cured</td>
        <td>kI4SUMqwaSK</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB rifampicin resistance detected by Xpert/Xpert Ultra</td>
        <td>m6o3AGQzaOZ</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB previously treated cases confirmed by Xpert/Xpert Ultra</td>
        <td>m7hXZQve8sf</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse DS-TB cases registered in the previous year - Completed</td>
        <td>MarJBwWbuX8</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB/HIV - positive</td>
        <td>MjW9Kd1tdR6</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>Lab-confirmed RR/MDR-TB started MDR treatment</td>
        <td>NhdSPPqMQ6G</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB rifampicin resistance detected by Xpert/Xpert Ultra in previously treated cases (excluding relapse)</td>
        <td>o3V2cL9Sclf</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB patients that have not started treatment</td>
        <td>OrvVU0I9wTT</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB case - previously treated - pulmonary, bacteriologically confirmed</td>
        <td>pL6Kh1R46EQ</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB lab confirmed cases</td>
        <td>RIuJAIU6Ke9</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB rifampicin resistance detected by Xpert/Xpert Ultra in new cases</td>
        <td>RjZ6QHK4SdB</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse cases registered in the previous year</td>
        <td>RTVZ6viHiST</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB new cases confirmed by Xpert/Xpert Ultra</td>
        <td>Ry81r5wNOhd</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse DS-TB cases registered in the previous year - Died</td>
        <td>St3jDtJRslC</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB cases notified (total)</td>
        <td>svi5rSf4zNR</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB/HIV - tested</td>
        <td>SzBkyKHWux0</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>Previously treated (including relapse) TB patients diagnosed without using a WHO recommended rapid diagnostic test</td>
        <td>TnSBORHgIL2</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>Lab-confirmed RR/MDR-TB</td>
        <td>TsGkTLQxLYN</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse cases (all TB forms)</td>
        <td>UG8KMWTNHTA</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB cases confirmed by Xpert/Xpert Ultra</td>
        <td>wIWezCzFIWx</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>TB - Patient's age</td>
        <td>WlgSirxU9bG</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse DS-TB cases registered in the previous year - Cured or treatment completed</td>
        <td>wQWTOm3n7RC</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse DS-TB cases registered in the previous year - Lost to follow-up</td>
        <td>yGFpCtuXgQj</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td>New and relapse DS-TB cases registered in the previous year - Not evaluated</td>
        <td>z1J7ACEYJgy</td>
      </tr>
      <tr>
        <td>GKaacrZF7iJ</td>
        <td>TB Case Surveillance (core)</td>
        <td> TB/HIV on ART</td>
        <td>z6ynKOp9PMS</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.05(iii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - New</td>
        <td>a2ISgtLxvUD</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.29.05(b) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - HIV unknown</td>
        <td>A3jU0towQsO</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.11(vi) - TB test - Pulmonary TB cases, bacteriologically confirmed, MDR - New</td>
        <td>AQUPGk2RiyX</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.07 - TB case - New and relapse TB cases - 15-19 years male</td>
        <td>BBMZo6tzlLw</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.05(i) - TB case - Pulmonary TB cases, bacteriologically confirmed - New</td>
        <td>bEelTQKUhQg</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.43.03 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Treatment failed</td>
        <td>bLPtxJ52Xjw</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.14 - TB Detection - Laboratory confirmed RR-TB or MDR-TB cases (excluding XDR cases)</td>
        <td>bS1ZVLaujxF</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.43.05 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Lost to follow-up</td>
        <td>bxca3bJItoQ</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.40.04 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Died</td>
        <td>CchM3mn5FuB</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.01(i) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - New</td>
        <td>ckraG6QcAal</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.43.06 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Not evaluated</td>
        <td>clCbQFGkMYA</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.39.03 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Treatment failed</td>
        <td>cpDl0MWCsbB</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.29.05(b) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - HIV negative</td>
        <td>DLohQ8ka4tM</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.44.04 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Died</td>
        <td>DVc4NJAGzGB</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.29.01(a) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - HIV positive</td>
        <td>Dy0ypgU2HJb</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.13 - TB case - New and relapse TB cases - 35-44 years male</td>
        <td>E2fky3dIsN0</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.31(ii) - TB test - Pulmonary RR/MDR TB cases, bacteriologically confirmed - resistant to any fluoroquinolone</td>
        <td>e9tXCLfhv63</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.04 - TB case - Previously treated patients, excluding relapse cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed)</td>
        <td>eeyV1nNafyJ</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.15 - TB Detection - Laboratory confirmed MDR-TB cases (excluding XDR cases)</td>
        <td>efyDakQPlNV</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.02(i) - TB case - Pulmonary TB cases, clinically diagnosed - New, or previous treatment history unknown</td>
        <td>EWUiMYjHPAq</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.05(ii) - TB case - Pulmonary TB cases, bacteriologically confirmed - Previously treated (including relapses)</td>
        <td>ExcvvS28nkb</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.04(ii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - RR - Previously treated (including relapses)</td>
        <td>FIWaUqszG5L</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.38.02 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>Fwm1w3NeBCK</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.19 - TB case - New and relapse TB cases - 65+ years male</td>
        <td>G28nlIwPd5U</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.11 - TB case - New and relapse TB cases - 25-34 years male</td>
        <td>g9E46OVm80h</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.29.03(a) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - HIV unknown</td>
        <td>Ga3wBXN0Mtd</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.02(i) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Previously treated (including relapses)</td>
        <td>gc1pSRqXnSY</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.29.02(a) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - HIV negative</td>
        <td>goRIAhBdWI8</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.01(ii) - TB case - Pulmonary TB cases, bacteriologically confirmed - Relapse</td>
        <td>GuxCHZwaRwr</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.07(iv) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - resistant to H - New</td>
        <td>GvtxMLDy4r2</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.03 - TB case - New and relapse TB cases - 5-9 years male</td>
        <td>GY8498BoEGB</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.30.01(a) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - Age(0-14)</td>
        <td>GZYHbHjsf12</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.06 - TB case - New and relapse TB cases - 10-14 years female</td>
        <td>HcJ57ScuWYc</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.15 - TB case - New and relapse TB cases - 45-54 years male</td>
        <td>HGmabhFtFVi</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.03(ii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - RR - New</td>
        <td>iePYwzgp7ol</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.05(iii) - TB case - Pulmonary TB cases, bacteriologically confirmed - Previous treatment history unknown</td>
        <td>Iid3xCxad9o</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.32(i) - TB test - Pulmonary MDR TB cases, bacteriologically confirmed with test results for any fluoroquinolone (FQ) and any second-line injectable agent (2LI)</td>
        <td>IjDJnGx9ltW</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.40.02 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>ijSGiogUaCX</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.34 - TB/HIV - New and relapse TB cases, tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis</td>
        <td>IPULEreCaHJ</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.35 - TB/HIV - New and relapse TB cases, HIV positive</td>
        <td>iPZPx2aOz2T</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.01(i) - TB case - Pulmonary TB cases, bacteriologically confirmed - New, or previous treatment history unknown</td>
        <td>j9ERFbo5Km8</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.38.03 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Treatment failed</td>
        <td>JlVDhjChVAx</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.04 - TB case - New and relapse TB cases - 5-9 years female</td>
        <td>JwXFsl4krgP</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.43.01 - TB Detection - RR-TB/ MDR-TB cases on second-line TB treatment (2 years prior to reporting period) (cohort)</td>
        <td>K9xltx7wXIb</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.12 - TB case - New and relapse TB cases - 25-34 years female</td>
        <td>KJoROII5Ynw</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.38.01 - TB Case - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>koVBk2KCseJ</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.39.05 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Lost to follow up</td>
        <td>kVHCjqlEC61</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.10 - TB case - New and relapse TB cases - 20-24 years female</td>
        <td>L34ycD00LSG</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.03(ii) - TB case - Extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed - Relapse</td>
        <td>LmLuG771h1g</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.43.02 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Cured or treatment completed</td>
        <td>loeESUTz5DN</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.16 - TB Detection - Laboratory confirmed XDR-TB cases (including MDR-TB cases from previous years)</td>
        <td>lva8WWCgm6I</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.29.04(b) - TB/HIV - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - HIV positive</td>
        <td>M832SsV7XlM</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.20 - TB case - New and relapse TB cases - 65+ years female</td>
        <td>MeRodi5qCj1</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.39.01 - TB Case - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>mRKV7yWZoQy</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.30.04(b) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - Age (15+)</td>
        <td>MtVmvly5X0J</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.17 - TB Treatment - Not laboratory-confirmed RR and MDR cases who started treatment for MDR-TB</td>
        <td>MwZSCg7C9DU</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.09 - TB case - New and relapse TB cases - 20-24 years male</td>
        <td>mYnHzn6wWdh</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.10(v) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - Resistant to R - Previously treated (including relapses)</td>
        <td>n0fN5DOHRsj</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.08 - TB case - New and relapse TB cases - 15-19 years female</td>
        <td>n5E1PHDcShv</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.40.01 - TB Case - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>n5xUcQS5Lim</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.40.05 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Lost to followup</td>
        <td>n6V3gvdRppU</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.39.06 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Not evaluated</td>
        <td>nA35a1OteGT</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.44.05 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Lost to follow-up</td>
        <td>nAos1lanETk</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.08(iv) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - Resistant to H - Previously treated (including relapses)</td>
        <td>nOoCupuvVyG</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.30.02(a) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Resistant to rifampicin - Age(15+)</td>
        <td>nRbutMsw93F</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.18 - TB Treatment - laboratory-confirmed RR-TB or MDR-TB patients who started treatment for MDR-TB</td>
        <td>o8aunPo6Lek</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.09(v) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - resistant to R - New</td>
        <td>obUamd4MrWm</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.06 - TB case - Total number of TB cases reported among foreign-born individuals</td>
        <td>OkpGxKo3KV0</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.19 - TB Treatment - RR and MDR cases (Age <15) who started treatment for MDR-TB</td>
        <td>oNynyr6rNtl</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.44.06 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Not evaluated</td>
        <td>p3VRjjM3ZM7</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.42.02 - TB Outcome - New and relapse TB cases registered in the previous year, 0-14 years, (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>pFhfF6xssTm</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.42.01 - TB Case - New and relapse TB cases registered in the previous year , 0-14 years, (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) (cohort)</td>
        <td>PhMxH0ohHIe</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.38.06 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Not evaluated</td>
        <td>q1AOyVwCjMh</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.19b - TB Treatment - RR and MDR cases (Age <15) who started treatment for MDR-TB - (Offset 1 year)</td>
        <td>QeY8kipz7E2</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.02(ii) - TB case - Pulmonary TB cases, clinically diagnosed - Relapse</td>
        <td>QXMznIjvAOV</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.03(i) - TB case - Extrapulmonary TB cases, bacteriologically confirmed or clinically diagnosed - New, or previous treatment history unknown</td>
        <td>QXUPxRVUrRS</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.44.01 - TB Detection - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period (cohort)</td>
        <td>rEH6P6rDI70</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.36 - TB/HIV - New and relapse TB cases - HIV positive - started or continued on antiretroviral therapy (ART)</td>
        <td>rmjYUeBHgxR</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.01 - TB case - New and relapse TB cases - 0-4 years male</td>
        <td>ROZvV7ifMzP</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.02 - TB case - New and relapse TB cases - 0-4 years female</td>
        <td>sFqDZGHXcO1</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.32(ii) - TB test - Pulmonary XDR TB cases, bacteriologically confirmed</td>
        <td>sRMkfFBN5C9</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.17 - TB case - New and relapse TB cases - 55-64 years male</td>
        <td>suOzy2QXSMK</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.39.02 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Cured or treatment completed</td>
        <td>TFsioIbdHo6</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.31(i) - TB test - Pulmonary RR/MDR TB cases, bacteriologically confirmed with test results for any fluoroquinolone</td>
        <td>TrGi5iJmFFm</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.20 - TB Treatment - laboratory-confirmed XDR-TB patients who started treatment for XDR-TB</td>
        <td>tsCchEKn7Br</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.43.04 - TB Outcome - Laboratory confirmed RR/MDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Died</td>
        <td>TylI5dxJdUl</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>GTB - TB Treatment - Patients who started treatment for MDR-TB</td>
        <td>UC5A1tourVG</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.16 - TB case - New and relapse TB cases - 45-54 years female</td>
        <td>UVyRsJoYkoL</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.44.03 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Treatment failed</td>
        <td>uyVkItSis8Z</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.38.05 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Lost to followup</td>
        <td>VdTczAataUy</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.30.03(b) - TB/Age - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin - Susceptible to rifampicin - Age (0-14)</td>
        <td>Vg8Pecklo8m</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.18 - TB case - New and relapse TB cases - 55-64 years female</td>
        <td>vjbnO9EU7e5</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.11 - TB Test - New and relapse cases tested using a WHO-recommended rapid diagnostic</td>
        <td>vU3ODjQ6JzS</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.12(vi) - TB test - Pulmonary TB cases, bacteriologically confirmed - MDR - Previously treated (including relapses)</td>
        <td>WcF7wOPcINj</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.05 - TB case - New and relapse TB cases - 10-14 years male</td>
        <td>wyrybOcxzcd</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.39.04 - TB Outcome - Previously treated TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Died</td>
        <td>xClehUT1Wz1</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.40.03 - TB Outcome - Previously treated HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Treatment failed</td>
        <td>xDCf04DhseZ</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.09.14 - TB case - New and relapse TB cases - 35-44 years female</td>
        <td>XE5DnJncyFA</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.38.04 - TB Outcome - New and relapse TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Died</td>
        <td>XH7TFzwdcNo</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.28.06(iii) - TB test - Pulmonary TB cases, bacteriologically confirmed with test results for rifampicin and isoniazid - Previously treated (including relapses)</td>
        <td>YzSvXLoUYoy</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.40.06 - TB Outcome - New and relapse HIV-positive TB cases registered in the previous year (bacteriologically confirmed or clinically diagnosed, pulmonary or extrapulmonary) - Not evaluated</td>
        <td>z7eXLnunj8d</td>
      </tr>
      <tr>
        <td>rfOllbK3gIL</td>
        <td>TB Case Surveillance - GTB Report</td>
        <td>2.44.02 - TB Outcome - Laboratory confirmed XDR-TB cases started on second-line TB treatment 2 years prior to reporting period - Cured or treatment completed</td>
        <td>z8pnOFkWAYl</td>
      </tr>
    </table>
    <h2 id="dashboards">Dashboards</h2>
    <h3>TB Reports</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>TB Reports</td>
        <td>2020-07-29</td>
        <td>SZyUynAiGgM</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td>bd1eqZ3DeA4</td>
        <td>Event report</td>
        <td>Delays in TB Treatment initiation</td>
        <td>Fl5vtUKBEJT</td>
        <td>2020-07-29</td>
        <td>SZyUynAiGgM</td>
      </tr>
      <tr>
        <td>q4HUtieyl1s</td>
        <td>Event report</td>
        <td>TB patients with unknown HIV status</td>
        <td>v9Jx3HNqpmi</td>
        <td>2020-07-29</td>
        <td>SZyUynAiGgM</td>
      </tr>
      <tr>
        <td>qmuoJ2ROwUb</td>
        <td>Event report</td>
        <td>List of patients with no treatment initiation date</td>
        <td>cCtA7jBYlk8</td>
        <td>2020-07-29</td>
        <td>SZyUynAiGgM</td>
      </tr>
      <tr>
        <td>bTvGzCZecxK</td>
        <td>Event report</td>
        <td>List of patients with no outcome</td>
        <td>wbASm5U5KZc</td>
        <td>2020-07-29</td>
        <td>SZyUynAiGgM</td>
      </tr>
      <tr>
        <td>wWwqzbkVF5G</td>
        <td>Event report</td>
        <td>Overview of all patients - current year</td>
        <td>bW2PsggnaGu</td>
        <td>2020-07-29</td>
        <td>SZyUynAiGgM</td>
      </tr>
    </table>
    <h3>TB core indicators</h3>
    <table>
      <tr>
        <td>Name</td>
        <td>Last updated</td>
        <td>UID</td>
      </tr>
      <tr>
        <td>TB core indicators</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
    </table>
    <h4>Dashboard items</h4>
    <table>
      <tr>
        <th>Content UID</th>
        <th>Content/item type</th>
        <th>Content name</th>
        <th>Dashboard Item UID</th>
        <th>Last updated</th>
        <th>Dashboard UID</th>
      </tr>
      <tr>
        <td></td>
        <td>TEXT</td>
        <td></td>
        <td>OdakKlBGlcC</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
      <tr>
        <td>N6MAiuCeFF0</td>
        <td>Map</td>
        <td>TB Case notifications by facility (all cases, all forms)</td>
        <td>ojNG3Cbdqxj</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
      <tr>
        <td>bZ3BsrJ1lXH</td>
        <td>Chart</td>
        <td>Treatment outcomes for DS-TB new and relapse (%)</td>
        <td>LGv7gNyRqZf</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
      <tr>
        <td>Z9P1vqpyOQC</td>
        <td>Chart</td>
        <td>Treatment success rate for new and relapse DS-TB (%)</td>
        <td>l4cePGpOtMs</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
      <tr>
        <td>wvZJ7I88BQf</td>
        <td>Chart</td>
        <td>Cascade of care for RR/MDR-TB</td>
        <td>Yym4lPBxgV3</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
      <tr>
        <td>lYgjQOu3G2e</td>
        <td>Chart</td>
        <td>TB/HIV cascade of care</td>
        <td>yDxYB4UabGH</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
      <tr>
        <td>ruHUaT9geGr</td>
        <td>Chart</td>
        <td>TB case notifications (all cases, all forms)</td>
        <td>WTGWZmCX1Wx</td>
        <td>2020-11-04</td>
        <td>TFr3hdGobbN</td>
      </tr>
    </table>
    <h2 id="charts">Charts</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Treatment outcomes for DS-TB new and relapse (%)</td>
        <td>Treatment outcomes for DS-TB new and relapse (%) - current quarter</td>
        <td>2020-10-16</td>
        <td>bZ3BsrJ1lXH</td>
      </tr>
      <tr>
        <td>TB/HIV cascade of care</td>
        <td>TB/HIV cascade of care - current quarter</td>
        <td>2020-10-16</td>
        <td>lYgjQOu3G2e</td>
      </tr>
      <tr>
        <td>TB case notifications (all cases, all forms)</td>
        <td>TB case notifications (all cases, all forms) - current quarter</td>
        <td>2020-10-16</td>
        <td>ruHUaT9geGr</td>
      </tr>
      <tr>
        <td>Cascade of care for RR/MDR-TB</td>
        <td>Cascade of care for RR/MDR-TB - current quarter</td>
        <td>2020-10-16</td>
        <td>wvZJ7I88BQf</td>
      </tr>
      <tr>
        <td>Treatment success rate for new and relapse DS-TB (%)</td>
        <td>Treatment success rate for new and relapse DS-TB (%)</td>
        <td>2020-10-16</td>
        <td>Z9P1vqpyOQC</td>
      </tr>
    </table>
    <h2 id="maps">Maps</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB Case notifications by facility (all cases, all forms)</td>
        <td> </td>
        <td>2020-12-07</td>
        <td>N6MAiuCeFF0</td>
      </tr>
    </table>
    <h2 id="eventReports">Event reports</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Description</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>Delays in TB Treatment initiation</td>
        <td>Delays in TB Treatment initiation - this year, last five years</td>
        <td>2020-10-16</td>
        <td>bd1eqZ3DeA4</td>
      </tr>
      <tr>
        <td>List of patients with no outcome</td>
        <td>List of patients with no outcome</td>
        <td>2020-10-16</td>
        <td>bTvGzCZecxK</td>
      </tr>
      <tr>
        <td>TB patients with unknown HIV status</td>
        <td>This is a list of all TB patients whose HIV infection status is unknown. Please review these patients and consider testing them for HIV or enter the data if the status is known.</td>
        <td>2020-10-16</td>
        <td>q4HUtieyl1s</td>
      </tr>
      <tr>
        <td>List of patients with no treatment initiation date</td>
        <td>List of patients with no treatment initiation date</td>
        <td>2020-10-16</td>
        <td>qmuoJ2ROwUb</td>
      </tr>
      <tr>
        <td>Overview of all patients - current year</td>
        <td>Overview of all patients - current year</td>
        <td>2020-10-16</td>
        <td>wWwqzbkVF5G</td>
      </tr>
    </table>
    <h2 id="trackedEntityInstanceFilters">Tracked Entity Instance Filters</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>All current TB patients</td>
        <td>2020-06-15</td>
        <td>DDYEZxtXUoJ</td>
      </tr>
      <tr>
        <td>Outcome record missing</td>
        <td>2020-06-15</td>
        <td>mrhsMwDhxfc</td>
      </tr>
      <tr>
        <td>Enrollment completion pending</td>
        <td>2020-12-07</td>
        <td>Q8v3oAYr09t</td>
      </tr>
      <tr>
        <td>Treatment initiation pending</td>
        <td>2020-06-15</td>
        <td>xOeDy8UoNoL</td>
      </tr>
    </table>
    <h2 id="userGroups">User Groups</h2>
    <table>
      <tr>
        <th>Name</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>TB access</td>
        <td>2020-12-10</td>
        <td>pyu2ZlNKbzQ</td>
      </tr>
      <tr>
        <td>TB admin</td>
        <td>2020-12-02</td>
        <td>Ubzlyfqm1gO</td>
      </tr>
      <tr>
        <td>TB data capture</td>
        <td>2020-12-02</td>
        <td>UKWx4jJcrKt</td>
      </tr>
      <tr>
        <td>TB lab data capture</td>
        <td>2020-12-02</td>
        <td>zBZXkRW0PJy</td>
      </tr>
    </table>
    <h2>Users</h2>
    <table>
      <tr>
        <th>Username</th>
        <th>Last updated</th>
        <th>UID</th>
      </tr>
      <tr>
        <td>who</td>
        <td>2020-07-07</td>
        <td>vUeLeQMSwhN</td>
      </tr>
    </table>
  </body>

</html>